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 1HistoRy of liveR tRansplantation
The first successful human liver transplantation was performed in 1967 by Thomas 
Starzl and colleagues (1). This life-saving treatment has evolved tremendously over 
the years and has become the golden standard for patients with end-stage liver 
disease (ESLD) and/or hepatocellular carcinoma (HCC). From the beginning, most 
liver transplantations in the Western world have been performed with grafts from 
deceased donors (2). Unfortunately, there has always been a significant disbalance 
between the number of patients in need of a liver transplant and the availability of 
donor organs, increasing the length of the waiting list and resulting in patients dying 
before an organ becomes available (3).
expanding the donor pool
World-wide, most grafts retrieved from deceased donors come from heart beating 
or ‘donation after brain death’ (DBD) donors. The worsening organ shortage has led 
to several strategies to expand the donor pool. In the nineties marginal or ‘extended 
criteria donor’ (ECD) grafts were introduced, including grafts from older donors and 
steatotic grafts (4). Quickly thereafter, grafts from non-heart beating or ‘donation 
after circulatory death’ (DCD) donors were assumed to have a large potential to 
further increase the donor supply. The initial results with DCD grafts were promising 
and these organs have been a regular source of organs since the early years of this 
century in several countries, including the United States (US) and United Kingdom 
(UK), and across the European mainland (5–7). However, DCD donation involves an 
extra period of warm ischemia before the organs can be retrieved, potentially impair-
ing organ quality. Consequently, the use of DCD grafts for liver transplantation has 
been associated with an increased incidence of postoperative complications, such as 
primary non function (PNF), acute kidney injury (AKI) and ischemic-type biliary lesions 
(ITBL) (8–10). These DCD-specific complications lead to inferior graft and patient 
survival rates, compared to when DBD grafts are used (11,12). However, more recent 
studies report satisfactory patient and graft outcomes in case of strict donor and 
recipient selection criteria (13,14).
the liver transplantation recipient
Liver transplantation should be suggested for every patient suffering from ESLD, 
cirrhosis with HCC or acute liver failure in whom the liver transplant would extend life 
expectancy or improve the quality of life, as advised by the ‘Clinical practice guide-
lines for liver transplantation’ from the European Association Study of the Liver (15). 
The disbalance in the equilibrium between available donors and patients in need of 
Chapter 1
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a liver transplant is an accumulative burden for the waiting list. To limit the waitlist 
mortality, many countries introduced a ‘sickest first’ policy for the allocation of liver 
grafts, following the Model for End-stage Liver Disease (MELD) score (16,17). The 
MELD-model is based on the dysfunction of the bilirubin metabolism, coagulopathy 
and renal failure in end stage liver disease, using the serum bilirubin, international 
normalized ratio (INR) and serum creatinine levels to predict 90-day mortality. Con-
sequently, less patients died while awaiting a liver transplant, but the sickest patients 
were selected for transplant, including patients with severe renal failure (18).
balance of Risk
The increased use of DCD and other marginal grafts and prioritization of the sickest 
patients on the liver transplantation waiting list is a potential “disastrous” combina-
tion. Therefore, it is pivotal to identify the specific marginal aspect of each graft and 
comprehend its grade of marginality. With this in mind, each graft can be allocated 
to the appropriate recipient. For example, a patient with a HCC that might quickly 
cross the Milan-criteria and would be excluded from liver transplantation could be 
evaluated for transplantation with a DCD graft, as it is likely that such a marginal 
graft is more quickly available than a standard graft. The additional risk of PNF, bili-
ary and renal complications should be considered, but the DCD transplant can be 
the only option to cure the patient from his malignant disease (19–21). In contrast, 
a patient who is critically ill with a high MELD-score and admitted on ICU due to 
decompensated ESLD could be too sick to receive a marginal graft. As complications 
are more likely to occur with marginal grafts, a very sick recipient may not have the 
reserve to recover from this event. Therefore, DCD grafts and other marginal grafts 
are in general not considered for patients with high MELD-scores in countries, such 
as the UK and the Netherlands (22). Dutkowski and colleagues presented a new score 
system to evaluate the balance of risk (BAR-score) to detect and avoid unfavourable 
combinations of donor and recipient factors and this score has also proven to be 
useful in the acceptance for liver grafts in patients with higher MELD-scores (>30 
points) (23,24).
the kidneys at risk in liver transplantation
The ‘renal’ risk for liver transplantation recipients increased significantly over the 
last years due to (I) the pre-transplant renal impairment and (II) the increased use of 
marginal grafts. These grafts are more susceptible for hepatic ischemia/reperfusion 
injury (IRI) and this not only impacts on the initial function of the liver graft, but also 
has a negative effects on other organs, including the kidney (25). This phenomenon, 
caused by the release of tissue debris, pro-inflammatory cytokines and chemokines 
11
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 1after a period of organ ischemia, leads to a systemic inflammatory response similar 
as seen in sepsis and multi-organ failure (26–29). This response is considered to play 
an important role in the pathogenesis renal dysfunction after liver transplantation 
(30–32). Previous studies have shown that not only DCD grafts, but also marginal 
DBD grafts, are associated with an increased risk of post-transplant AKI (10,33). 
There is a wide variety in the severity of AKI in the early postoperative phase and 
not all patients require renal replacement therapy (RRT). Also, most patients recover 
quickly from this initial hit, but some have a slow recovery or will remain dialysis-
dependent. The multifactorial origin of AKI and its deleterious effects on various 
short- and long-term outcomes make it essential to identify the patients at risk for 
AKI after liver transplantation.
aims and outline of tHis tHesis
The aim of this thesis is to evaluate emerging risk factors for potential postoperative 
complications with the recent developments in liver transplantation practice. The 
focus lies on two important pillars: the evolving use of DCD grafts over the last two 
decades and the implications of graft quality on renal issues in liver transplantation. 
The two intertwine as the strategy to use DCD grafts to overcome the donor organ 
shortage is associated with specific complications, such as AKI.
The use of DCD grafts in liver transplantation is discussed in part i of this thesis. 
chapter 2 serves as a synopsis of the introduction and development of DCD grafts 
in liver transplantation. This chapter includes the current knowledge about the chal-
lenges with the use of this type of grafts and strategies that have been developed 
worldwide to improve the outcomes of these grafts. In chapter 3 we present a com-
parison study about the short and long-term outcomes after liver transplantation of 
DCD and DBD grafts using the novel Comprehensive Complication Index. chapter 
4 follows as a more in-depth analysis of the impact of the donor warm ischemia time 
(WIT) in DCD grafts with a focus on the course of hemodynamic parameters after 
the donor withdrawal of treatment (WoT). A new risk score to define futility in DCD 
liver transplantation is presented in chapter 5. The UK DCD Risk Score stratifies the 
risk for graft loss using three risk groups to improve the decision making process of 
matching DCD grafts and recipients.
In part ii the risks factors for renal complications after liver transplantation are 
assessed. An overview of AKI and renal dysfunction on the long-term is given in 
Chapter 1
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chapter 6. It summarizes previous studies about AKI and chronic kidney disease 
(CKD) and discusses the multifactorial origin of kidney problems in liver transplanta-
tion candidates and recipients. Graft quality and IRI are an upcoming issue and the 
postreperfusion syndrome is the first presentation of severe IRI after reperfusion of 
the new graft. Therefore, we have evaluated the relation between the postreper-
fusion syndrome and post-transplant AKI in chapter 7. The severity of IRI is also 
determined by the length of ischemic periods during preservation of the liver graft. 
In chapter 8 the impact of all the consecutive warm ischemia times of DCD grafts 
on the development of AKI is discussed. We present a new prediction model for 
postoperative AKI in chapter 9. The AKI Prediction Score comprehends the graft, 
recipient and surgical risk factors into one model to identify the patients at risk for 
severe AKI directly after liver transplantation. chapter 10 focusses on the relation 
between the use of marginal grafts and long-term renal dysfunction. The results of 
this thesis are summarised and discussed with recommendations for future research 
in chapter 11.
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PREDICTING OUTCOME IN DCD 
LIVER TRANSPLANTATION
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tHe intRoduction of dcd gRafts
DCD (or at that time so-called non-heart beating donation) has been explored since 
the start of human organ transplantation. In fact, the first human heart, lung, kidney 
and liver transplants were performed with DCD grafts (1–4). However, since the Har-
vard consensus report to determine brain death in 1968, liver transplantation with 
organs retrieved from brain death donor became the golden standard (5). Due to 
the rapid developing organ shortage, donation after circulatory death was revived in 
the Western world during the early 1980s, with a pioneering role for the Netherlands 
using DCD kidneys for transplantation (6). Due to the complexity of the surgical 
procedure, the immediate life-saving concept and potential lethal complications, it 
took a bit more time for transplant surgeons to engage in DCD liver transplantation, 
but DCD grafts are part of the liver transplantation practice since the early 2000s in 
North America and many European countries.
classification of dcd donation
Starzl and colleagues reported in 1995 their first series of thirteen DCD grafts used 
for transplantation (7). They used two types of grafts:
§ Uncontrolled DCD grafts: a patient that is (in the process of being) pronounced 
brain death, with a sudden, unexpected cardiac arrest. Thereafter, cardiopulmo-
nary resuscitation CPR is started and the patient is transported to theatre for the 
organ donation procedure.
§ Controlled DCD grafts: a patient has irreversible neurological damage, but either 
do not fulfil the brain death criteria or the family requests withdrawal of life sup-
port before organ donation. In these cases, the life support is withdrawn and 
the organ procurement procedure starts after a certain period (variable between 
countries) after circulatory arrest.
As expected, the actual transplantation rate of livers from potential donors was higher 
in the controlled group (86% vs. 60%). The results of the uncontrolled DCD grafts were 
disappointing, with half of the patients requiring immediate retransplantation due to 
PNF and inadequate portal flow and two other patients lost their grafts later due 
to other causes. All the grafts after controlled DCD donation functioned well (n=6) 
and after two years three patients were alive with functioning grafts. In the following 
years, the option of DCD grafts was explored in other countries. The widely used 
‘Maastricht Classification’ (table 1) for DCD donation were introduced by Kootstra 
and colleagues in 1995, stratifying the potential DCD donors into four (and later five) 
groups (8–10). This classification is more specific about the location and unexpected 
Chapter 2
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aspect of the DCD donation. The most common used categories are II (uncontrolled) 
and III (controlled). Liver transplantation with type II DCD donors has been common 
practice Spain and has later been explored in Italy and France (11–13). Due to the 
unpredictable warm ischemia times in type II DCD liver grafts, the outcomes of liver 
transplantation with these grafts are capricious with higher rates of PNF and biliary 
complications, with initial one-year graft survival rates of only 50% (14,15). The Span-
ish law allows for premortal cannulation of the donors and therefore, the clinicians 
quickly engaged in the use of perfusion techniques with cardiopulmonary bypass of 
the donor, to limit the warm ischemia times and to optimize organ quality. Although 
initially only a small percentage of the potential grafts were used for transplantation, 
the results of this normothermic regional perfusion with type II grafts were improving 
and therefore it is now common practice in this country (16,17).
type iii dcd organ donation
All the following chapters in this thesis will concern liver transplantation with type III 
controlled DCD grafts. Type III DCD organs have been the preferred option from the 
beginning in the US, Canada, and several European countries, including the Nether-
lands, Belgium and the UK (18). Regularly, a type III DCD donor is admitted on ICU 
and there is a controlled WoT. This can either be either in ICU, anaesthetic room or 
table 1 – Modified Maastricht classification for donors after circulatory death
Adapted from Thuong et al, Transplant International, 2016 (10).
category i Found dead out of hospital
Uncontrolled IA. Cardiocirculatory death outside hospital with no witness. Totally 
uncontrolled.
 IB. Cardiocirculatory death outside hospital with rapid resuscitation attempt.
category ii Unsuccessful resuscitation
Uncontrolled IIA. Unexpected cardiocirculatory death in ICU
 IIB. Unexpected cardiocirculatory death in hospital with rapid resuscitation
category iii Awaiting cardiac arrest
Controlled IIIA. Expected cardiocirculatory death in ICU
 IIIB. Expected cardiocirculatory death in OR (withdrawal phase >30 min)
 IIIC. Expected cardiocirculatory death in OR (withdrawal phase <30 min)
category iv Cardiac arrest while brain death
Uncontrolled IVA. Unexpected cardiocirculatory arrest in a brain dead donor (in ICU)
Controlled IVB. Expected cardiocirculatory arrest in a brain dead donor (in OR or ICU)
category v Euthanasia
Controlled VA. Medically assisted cardiocirculatory death in ICU or ward.
Uncontrolled VB. Medically assisted cardiocirculatory death in OR.
23
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operation theatre. After circulatory arrest, there is an obligatory waiting time before 
death can be declared. This time is 5 minutes by law in the Netherlands, but varies 
between 5 and 20 minutes in Europe (10). Because the general practice for WoT in 
the Netherlands is on ICU, there is an additional transport time of the donor to the 
operation theatre, which extends the period of donor warm ischemia time (DWIT) 
(19). The aim of the organ procurement in DCD donation is to safely retrieve the 
organs as quickly as possible. The principle of the super-rapid technique consists of 
coordinated surgical steps including a rapid thoraco-laparotomy, cannulation of the 
abdominal aorta for cold perfusion, venous exsanguination and cross-clamping of the 
thoracic aorta and followed by separate resection of all organs (20). An overview of 
organ donation by graft type in the Netherlands during the last years is displayed in 
figure 1, showing a steady increase of controlled DCD donation from the year 2000 
(21). After the start of the DCD program in 1999, due to a part of the donors that do 
not proceed to donation and a number of liver grafts discarded before implantation, 
the number of liver transplants performed with DCD grafts grew at a slower pace 
(figure 2), with 45 DCD transplants in 2014.
figure 1 – Number of deceased organ donors in the Netherlands
From Leiden et al, Netherlands Journal of Medicine, 2016 (21).
figure 2 – Liver transplantation by graft type in the Netherlands since 2000
From Leiden et al, Netherlands Journal of Medicine, 2016 (21).
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Donor warm ischemia time
The obligatory DWIT in DCD donation is responsible for the additional period of 
warm ischemia and aggravation of hepatic IRI (22). figure 3 shows an overview of the 
separate period between the WoT until the start of cold perfusion. At this moment, 
there is no consensus about the actual definition of DWIT and various definitions 
are used (10). Overall, DWIT can be divided into two periods: the agonal phase 
(from WoT until circulatory arrest) and the asystolic phase (from circulatory arrest until 
the start of cold perfusion). For the graft to be considered for liver transplantation, 
the length of the full period of DWIT cannot extend one hour in most countries, 
including the UK and the Netherlands (23,24). On average, the time for a potential 
DCD donor to die is 36 minutes (25). However, DWIT is a dynamic period and some 
donors have a much longer period of hypoxia or hypotension during the agonal 
phase, with a potential major impact on the severity of hepatic IRI. The impact of 
DWIT on postoperative outcomes after DCD liver transplantation has been studied 
before, but different definitions of DWIT were used and consequently, the length of 
an acceptable DWIT in these studies ranges from 10 to 35 minutes (26–30). A com-
mon way to assess DWIT is with the functional DWIT. This period is a combination 
of agonal phase starting with the drop in saturation (SpO2 <80%) or blood pressure 
(MAP or SBP <50 mm Hg), until the start of cold perfusion. In many countries, the 
cut-off for discarding a DCD liver is 30 minutes of functional DWIT.
Withdrawal of 
treatment
Saturation
<80%
Circulatory
arrest
Agonal phase Asystolic phase
SBP            
<50 mm Hg
Circulatory
arrest
Start cold
perfusion
Asystolic phase
Asystolic phase
Total DWIT
Phases of donor warm ischemia time
Hypoxic agonal phase
Hypotensive agonal phase
Hypoxic functional DWIT
Hypotensive functional DWIT
figure 3 – Overview of the separate periods of donor warm ischemia time
The potential of expanding the donor pool
Even after more than 20 years of liver transplantation with DCD grafts, there are no 
exact numbers on what the real contribution of DCD grafts is to the patients waiting 
for a liver. Transplantation with DCD grafts comes with a certain risk of PNF or other 
complications and some patients will even die before a second organ becomes avail-
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able. Therefore, the actual benefit and perspective for the patient on the waiting list 
is more complicated to estimate. In an early nationwide comparative study from US 
(2006) of DCD and DBD grafts, an increased relative risk (RR 1.85) for graft failure was 
reported with the use of DCD grafts (31). However, a following study in 2014 with US 
United Network for Organ Sharing (UNOS) data confirmed the inferior graft survival 
rates with DCD grafts, but the patient survival on the long-term was comparable with 
DBD grafts, implicating these patients are relisted an retransplanted timely (32).
Survival outcomes in comparison with DBD grafts
Since the start of DCD liver transplantation, multiple groups from all over the world 
have reported their experience with these grafts, some of them also comparing the 
results with DBD grafts. The first report from the University of Wisconsin with 19 DCD 
grafts in 1999, already reported an increased incidence of PNF leading to more graft 
loss in this group, but comparable patient survival with recipients of DBD grafts (33). 
In the following years, more centres reported their experience with mixed results 
(34,35). National data from US arrived in 2003, summarizing the centre experiences, 
with increased retransplantation rates and inferior survival with the use of DCD grafts 
(36). The first results from Europe (King’s College, UK) were promising, with satis-
factory results with grafts of selected DCD donors (37). Results of the Dutch DCD 
program (2010) were similar, with satisfactory survival rates, despite a higher risk for 
biliary strictures (38). Importantly, duration of DWIT and cold ischemia time were 
both identified as risk factors in DCD liver transplantation and should be minimized. 
Additional donor risk factors for DCD graft failure that are identified are older donors 
and high donor weight (graft steatosis). Older recipients, those with high MELD-
scores (>35) and life-support prior to transplantation are also at increased risk for 
graft failure (28).
With the additional risk of DCD grafts in mind, many have adapted the strategy to 
allocate these grafts to recipients with lower MELD-scores, such as patients with HCC 
at risk for exceeding Milan-criteria (39,40). This leads to differences between DCD 
and DBD liver transplantation in donor, graft and recipient risk factors, compromising 
the analysis of outcome. Therefore, several groups have published their data using 
propensity score matching, a method to equalize study groups in non-randomised 
studies, by matching the cases of the intervention group (DCD) to certain cases from 
the control group (DBD) by preselected characteristics (41). The studies from the 
early years in DCD liver transplantation and those performed without matching dem-
onstrate mixed positive and negative results. Interestingly, the general sentiment of 
the five studies using propensity score matching display significant inferior results 
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with DCD grafts: PNF and ITBL were more frequently observed in recipients of DCD 
grafts that were matched to a DBD counterpart, leading to inferior graft and overall 
survival rates (30,42–45). The overall negative results of these studies with matched 
cases shows the ‘real’ additional risk of DCD donation in comparison to brain-death 
donors. It also suggest that balancing the risk between donor and recipient in a 
combined DCD & DBD donor pool is essential to optimize the results of the popula-
tion on the liver transplant waiting list.
The trends from studies published in the last three years is that the known complica-
tions of using DCD grafts are still a serious issue and these patients have an in-
creased risk for graft loss (29,44). However, due to the early identification of patients 
with serious complications, they can be relisted earlier and receive optimal bridging 
treatment towards retransplantation, leading to comparable patient survival on the 
long-term (29). The Birmingham group from the UK has used more marginal DCD 
grafts over the last years, with comparable survival rates with DBD grafts, by select-
ing the right patient to receive a DCD graft (44). More recently, they have shown that 
DCD grafts from older donors are not associated with poorer outcomes, provided 
that other risk factors are eliminated (46). Historically, transplant surgeons in the US 
have been more cautious with the use of DCD grafts, displayed by the low rate of 
DCD liver transplantation nationally (only 6% of total deceased donor transplants in 
2016 (47). However, recently voices arise in the US to approach DCD grafts with a 
different strategy to limit the duration of cold ischemia time and only select patients 
with relatively low MELD-scores (48).
specific postoperative complications
Primary non-function
Due to the additional warm ischemic period during DCD donation, there is a signifi-
cant depletion of intracellular energy reserves leading to more severe hepatic IRI (49). 
Prolonged duration of DWIT has been linked to non-viability of DCD grafts in pigs 
and the first studies in humans already showed higher incidence of PNF (7,33,36,50). 
Incidence rates up to 12% of have been reported over the years, but this was not 
always significantly more compared to DBD grafts (30,35,36,51,52). Furthermore, 
some have described their DCD experience without any cases of PNF (53–55). Ad-
ditional to a long DWIT, donor age, graft steatosis and prolonged cold ischemia are 
thought to increase the risk for PNF (56).
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Ischemic-type biliary lesions
Biliary complications are considered the Achilles heel of DCD liver transplantation. Es-
pecially strictures not related to the biliary anastomosis created during the transplant, 
the so-called non-anastomotic strictures, ischemic cholangiopathy or ischemic-type 
biliary lesions (ITBL) are more frequently observed when DCD grafts are used. ITBL 
are defined as symptomatic strictures of the intrahepatic or hilar bile ducts after liver 
transplantation, in the presence of a patent hepatic artery (57). Every graft prepared 
for liver transplantation experiences a certain period of warm and cold preserva-
tion, leading to significant injury to the luminal biliary epithelium, but this does not 
necessarily lead to ITBL. Although the exact pathogenesis of ITBL remains unknown, 
recent literature proposes that injury to specific components of the bile duct, i.e. the 
peribiliary glands and vascular plexus during preservation is associated with develop-
figure 4 – Macroscopic, radiological and histological appearance of ITBL after liver transplantation.
From Deltenre et al, Seminars in liver disease, 2008 (62).
Biliary casts. (A) Typical appearance on endoscopic retrograde cholangiopancreatography in a pa-
tient with ischemic cholangiopathy following liver transplantation. Filling defects (white arrow) can 
be seen in dilated bile ducts, with mildly irregular margins. (B) Gross appearance at sectioning in 
an excised liver. Solid brown material can be seen within large bile ducts (white arrows). (C) Micro-
scopic appearance of a large bile duct. Biliary epithelium is lacking in some areas (gray arrow) and 
is reserved in other areas (white arrow). Solid, bile-stained material is observed within the lumen 
(black arrow). (Courtesy of Dr. Annie Sibert, Service de Radiologie, and Dr. Vale´ rie Paradis, Service 
d’Anatomie et de Cytologie pathologiques, Hôpital Beaujon, Clichy, France.)
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ment of ITBL (58,59). This suggests that adequate preservation of these structures 
is essential for a timely regeneration of the biliary epithelium. Additional damage 
of bile salts after transplantation and subsequent influx of immune cells leading to 
inflammation and fibrosis can result in ITBL (60). The extra period of warm ischemia 
during DWIT potentially leads to the additional injury of the vital structures of the 
biliary tree, increasing the risk for development of ITBL with DCD grafts. Patients can 
develop the strictures within months after liver transplantation (figure 4), regularly 
requiring endoscopic and surgical interventions, but often retransplantation cannot 
be avoided (61).
In the largest meta-analysis (2011) about ITBL after DCD liver transplantation com-
prehending 11 studies by Jay et al, ITBL was observed in 16% of the recipients 
receiving a DCD graft and they had an 10.8x increased odds of developing ITBL, 
compared to DBD recipients (63). As a result, DCD recipients also had a 2.6-fold 
increased odds of retransplantation. A more recent meta-analysis from 2014 showed 
similar results with ITBL occurring in 16% and 3% after liver transplantation with DCD 
and DBD grafts, respectively (64). ITBL has a multifactorial origin and a wide variety 
of ITBL-rates have been observed between single-centre experiences and ranges 
from 3% to 38% (40,42,44,64–71). An evaluation of the IDOL-consortium involving 
10 centres across the US, ITBL was present in 12%, ranging from 6% to 26% in the 
individual centres (72). Identified risk factors for ITBL are prolonged duration of warm 
and cold ischemia and specifically the length of donor warm ischemia. There is no 
consensus about the impact of donor age and development of ITBL and these grafts 
should not be avoided for age per se (45,46,66,73,74).
Acute kidney injury
AKI is a common issue after liver transplantation and is the result of donor, surgi-
cal and recipient risk factors. The kidney is a known organ to suffer from hepatic 
IRI, due to the release of pro-inflammatory cytokines and reactive oxygen species, 
acting like a systemic inflammatory response syndrome (75). With the evolving use 
of marginal grafts, including DCD grafts, graft quality takes more part in the develop-
ment of post-transplant AKI (76). The Birmingham group was the first to describe 
an increased frequency of AKI with the use of DCD grafts and was observed in 53% 
of the recipients, compared to 32% of the DBD recipients (figure 5) (77). These 
findings were later confirmed by others (54). The increased incidence of AKI did 
not lead to more CKD in the Birmingham cohort. However, an indirect relationship 
between DCD liver transplantation and end-stage renal disease on the long-term 
was observed in a nationwide-US registry study (78).
29
Literature Review on DCD Liver Transplantation
C
ha
pt
er
 2
Pa
rt 
I
Cost-Effectiveness & Quality of Life
The use of DCD grafts is also associated with higher costs after transplantation, 
due to the development of complications requiring multiple interventions, hospital 
admissions and even retransplantation, such as ITBL (79). This has been shown in 
several cost-effectiveness studies from US and the Netherlands (80,81). Due to the 
long-term problems with intensive and multidisciplinary treatments, ITBL has a sig-
nificant impact on the quality of life of the patients as well (82). Recipients of DCD 
grafts have a significant better quality of life on the long-term, when compared to 
recipients who remained waiting on the waiting list for a DBD liver transplant (83).
Although DCD liver transplantation is not without risk, it has expanded the donor 
pool significantly over the last years. Avoiding the DCD-specific complications and 
preventing the need for retransplantation are the most important issues to solve in 
the near future to improve outcomes and quality of life and reduce costs. Machine 
perfusion techniques have the potential to improve outcomes of marginal grafts, 
such as DCD grafts and assessment of the risk factors for graft failure in DCD liver 
transplantation is pivotal to identify these grafts that have the most benefit of these 
new preservation techniques (84).
figure 5 – Comparison of acute kidney injury after liver transplantation using DCD or DBD grafts.
From Leithead et al, American Journal of Transplantation, 2012 (77).
Stacked bar graph demonstrating the proportion of DCD liver transplant recipients and DBD recipi-
ents who developed acute renal dysfunction during the immediate postoperative period.
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summaRy
Liver transplantation is complex surgery and the increasing use of marginal grafts is 
pressurizing current postoperative outcomes. DCD grafts in particular are associated 
with PNF and ITBL with subsequent impaired graft survival rates. The aim of this study 
was to test the total burden of complications in the early postoperative period after 
liver transplantation between DCD and DBD grafts with the novel Comprehensive 
Complication Index (CCI). We performed a retrospective single-centre study of all 
liver transplantations performed since the start of DCD program (2001-2015). CCI (at 
hospital discharge and six months) was the result of ALL complications weighted by 
their Clavien-Dindo grade. A multiple logistic regression model was used to identify 
factors associated with a complex postoperative course (CCI at six months >60). In 
total, 441 cases were included: 115 DCD and 326 DBD grafts. Median in-hospital CCI 
was comparable for both groups (DCD 38.2; DBD 36.7; p=0.429). Six-months post-
operative median CCI was signifi cantly higher for DCD grafts (53.4 vs 47.2; p=0.041). 
Also, more DCD recipients underwent retransplantation for ITBL in this period (4% vs 
1%; p=0.031). Logistic regression identifi ed recipient BMI (p=0.046), recipient WIT 
(OR 1.032; 95%CI 1.008-1.056; p=0.008), and DCD graft (OR 3.913; 95%CI 1.200-
12.767; p=0.024) as risk factors for a CCI >60. In conclusion, this analysis shows a 
comparable complication rate during the index hospital stay for DCD and DBD LT, 
but the CCI increases signifi cantly for DCD recipients in six months after transplanta-
tion. Reduction of biliary complications, especially ITBL, is needed to improve the 
outcomes for DCD grafts.
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intRoduction
DCD grafts are increasingly used to overcome the organ shortage in liver transplan-
tation (1,2). The use of these marginal grafts is associated with several complications, 
such as PNF, AKI and ITBL, resulting in inferior graft and recipient survival (3–6). 
However, recent studies show that with careful selection of DCD grafts and recipients 
the survival rates can reach a level comparable DBD liver transplantation (7–10). Fur-
thermore, DCD grafts have shown to be a useful source of organs for patients waiting 
for a transplant with an HCC. Their time on the waitlist can be shortened before they 
cross Milan criteria and they are more likely to tolerate an extended criteria organ, 
due to their relatively low biological MELD-score (11–13).
The complexity of the surgical procedure, the severe disease of the patient and the mar-
ginal graft puts patients receiving a DCD graft more at risk for postoperative complica-
tions. However, the diversity of complications makes it difficult to compare postoperative 
outcomes and solid endpoints, like early postoperative mortality, have become rare due 
to successful retransplantation. The Comprehensive Complication Index (CCI) is a novel 
tool to combine all complications into one number that comprehends the entire burden 
of postoperative morbidity (14). It has shown its efficacy in gastro-intestinal surgery to 
serve as a primary outcome measure and compare treatment groups (15,16). In the early 
postoperative period after liver transplantation vascular complications, infections, acute 
rejection, EAD and kidney injury are the most common problems, while chronic rejec-
tion, recurrence of liver disease and biliary complications develop several months after 
transplant (17). These later (biliary) complications require often interventional therapy as 
well, such as endoscopic treatment, surgery or even retransplantation (18).
The aim of this study was to compare all postoperative morbidity with the novel CCI 
between DCD and DBD grafts up to six months after liver transplantation.
metHods
This retrospective study was performed with approval of the Erasmus MC Institutional 
Review Board (MEC-2014-670). All consecutive patients who underwent deceased 
donor liver transplantation with age ≥18 years in our center from the start of the DCD 
program were included (10/2001 - 08/2015). Exclusion criteria were retransplanta-
tion, split-liver transplantation, combined liver kidney transplantation and transplant 
for acute hepatic failure.
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table 1 - donor, recipient and surgical characteristics of DCD and DBD liver transplantation
donor dbd (n=326) dcd (n=115) total (n=441) p-value
Age (years) 54 (44-63) 47 (38-56) 51 (43-61) <0.001
Male gender (%) 164 (50) 64 (56) 228 (52) 0.324
Body mass index 24.5 (22.7-26.9) 22.7 (21.6-25.4) 24.2 (22.6-26.6) 0.017
Cause of death (%)
Trauma 57 (18) 29 (25) 86 (20)
Anoxia 12 (4) 24 (21) 36 (8)
Cerebrovascular accident 251 (77) 57 (50) 308 (70)
Other 6 (2) 5 (4) 11 (3) <0.001
Location (%)
Local 26 (8) 15 (13) 41 (9)
National 244 (75) 97 (84) 341 (77)
International 56 (17) 3 (3) 59 (13) <0.001
Donor risk index
Official 2.0 (0.4) 2.5 (0.5) 2.1 (0.5) <0.001
Excluding DCD status 2.0 (0.4) 1.7 (0.3) 1.9 (0.4) <0.001
Donor warm ischemia time (min)
Asystolic (n=112) . 16.8 (4.8) . .
Ischemic agonal phase (n=88) . 13.0 (7.0) . .
Recipient
Age (years) 53 (43-60) 55 (48-62) 53 (44-60) 0.016
Male gender (%) 213 (65) 79 (69) 292 (66) 0.513
Body mass index 25.2 (22.7-28.4) 25.3 (23.2-29.1) 25.2 (22.9-28.6) 0.655
Type of liver disease (%)
Hepatitis B 30 (9) 9 (8) 39 (9)
Hepatitis C 44 (14) 23 (20) 67 (15)
Biliary cirrhosis 111 (34) 27 (24) 138 (31)
Alcohol related cirrhosis 55 (17) 22 (19) 77 (18)
Other 86 (26) 34 (30) 120 (27) 0.188
Hepatocellular carcinoma (%) 75 (23) 36 (31) 111 (25) 0.078
Child Pugh score 8 (6-10) 8 (7-10) 8 (6-10) 0.572
MELD score 14 (9-20) 15 (9-20) 14 (9-20) 0.409
Sodium (mmol/L) 138 (135-140) 138 (134-140) 138 (135-140) 0.323
Medical history( %)
Diabetes Mellitus 70 (22) 29 (25) 99 (22) 0.408
Coronary artery disease 11 (3) 3 (3) 14 (3) 0.687
Hypertension 17 (5) 6 (5) 23 (5) 0.999
surgical
Operation time (hours) 7.5 (6.7-8.7) 7.6 (6.9-8.4) 7.5 (6.8-8.7) 0.551
Cold ischemia time (hours) 6.9 (5.6-8.3) 6.5 (5.8-7.4) 6.7 (5.7-8.0) 0.338
Recipient warm ischemia time (min) 28 (24-34) 28 (24-35) 28 (24-35) 0.850
Blood loss (L) 3.8 (2.4-6.5) 4.5 (3.2-6.8) 4.0 (2.5-6.5) 0.067
RBC transfusion (units) 3 (1-6) 3 (1-6) 4 (3-7) 0.734
FFP transfusion (units) 4 (0-8) 4 (0-8) 3 (1-6) 0.687
Platelet transfusion (units) 1 (0-2) 1 (0-2) 4 (0-8) 0.188
Peak postoperative serum AST (U/L) 856 (555-1699) 2657 (1311-4905) 1061 (630-244) <0.001
AST, aspartate transaminase; DBD, donation after brain death; DCD, donation after circulatory death; FFP, 
fresh frozen plasma; MELD, model for end stage liver disease; RBC, red blood cells.
Continuous variables are presented in median and interquartile range.
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All collected donor and recipient characteristics are displayed in table 1. This data 
was used to calculate the donor risk index (DRI), MELD and Child-Pugh score as well 
(19,20). Graft allocation in the Netherlands is based on the MELD-principle. WoT of 
DCD donors is on the ICU and there is an obligatory 5-minute waiting time after cir-
culatory arrest. The super-rapid retrieval technique is used to minimize the asystolic 
phase of DWIT (21). Exclusion criteria for DCD donors included age >60 years, body 
mass index (BMI) >28, aspartate transaminase (AST) >120 U/L and serum sodium > 
160 mmol/L. The vascular and biliary flush is performed with University-of-Wisconsin 
preservation fluid. Prior to 2013 histidine-tryptophan-ketoglutarate was used as well. 
Standard surgical technique included piggyback cavo-caval anastomosis with only 
incidental use of a portocaval shunt. Operation time, cold ischemia time, and recipi-
ent WIT, intraoperative blood loss with subsequent transfusion requirements were 
all recorded. The peak serum AST level in the first 72 hours was used as a surrogate 
marker for hepatic IRI, a known marker for EAD (22). The standard immunosuppres-
sion regime changed during the study period. Until 2012 the regimen consisted 
of tacrolimus from day 0 and prednisolone (for 3 months). In 2012 mycophenolate 
mophetil (MMF) (from day 0) and basiliximab (day 0 and 4) were added and introduc-
tion of tacrolimus was postponed for kidney protection until day 5.
Duration of hospital and ICU admission, recipient and graft survival were all docu-
mented. The CCI was calculated using the original algorithm with all complications 
that occurred during hospital admission and up to six months after transplantation 
using the Clavien-Dindo classification (14,23). The range of the CCI is 0-100, with 100 
equaling death. In case of retransplantation, a grade 4A complication was scored and 
thereafter follow up was terminated to prevent progression of CCI points for the first 
graft that were actually a complication from the re-transplant graft. ITBL was defined 
as postoperative symptomatic strictures and associated dilatation of the intrahepatic 
or hilar bile duct(s). These symptoms were (1) confirmed by endoscopic retrograde 
cholangiopancreatography, magnetic resonance cholangiopancreatography or 
percutaneous transhepatic cholangiography, (2) in the presence of a patent hepatic 
artery confirmed by ultrasound and (3) required biliary endoscopic or percutaneous 
intervention or retransplantation.
Statistical analysis
Data were analyzed with IBM SPSS Statistics V24 (IBM Corporation, Armonk, NY, USA). 
The student’s t-test was used to compare normally distributed continuous variables. 
Nonparametric continuous variables were compared using the Mann-Whitney-U test. 
To compare categorical variables the Chi-square test or Fisher’s exact test were used. 
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P-values <0.05 were considered statistically significant. A multiple logistic regres-
sion model with all relevant donor, recipient and surgical characteristics was used to 
identify factors associated with a complicated course after liver transplantation (CCI 
>60 at six months after transplant). Long-term survival rates were estimated using 
Kaplan-Meier methods. The median follow up period was 6.9 years.
Results
During the study period 634 liver transplants were performed at our center: 120 DCD 
and 504 DBD grafts. The following transplants were excluded: 85 retransplantations, 
10 split-livers, 16 combined liver-kidney transplants and 77 transplants for acute 
hepatic failure. Two cases were excluded because of missing data and 3 recipients 
who died within 24 hours after transplant (all DBD grafts). This lead to an inclusion of 
441 liver transplants: 115 DCD and 363 DBD liver transplants.
baseline characteristics
Baseline characteristics are displayed in table 1. Median donor age was 51 years 
and DCD donors were significantly younger (47 vs. 54 years; p<0.001). Median BMI 
was lower in the DCD donors as well (22.7 vs. 24.5; p=0.017). After correction for 
DCD transplantation the DRI was significantly lower in the DCD group (1.7 vs. 2.0; 
p<0.001). Median age of the recipients was 53 years and significantly higher in those 
who received a DCD graft (55 vs. 53 years; p=0.016). Both Child-Pugh and MELD-
score prior to transplant were comparable in both groups. The cold ischemia time 
was 6.9h in the DBD group, compared to 6.5h in the DCD group (p=0.338). Recipient 
WIT was 28 minutes in both groups. The transfusion requirement was comparable for 
both groups as well. Postoperative peak serum AST was significantly higher in DCD 
recipients (2657 vs. 856 U/L; p<0.001).
postoperative outcomes and the comprehensive complication index
Postoperative outcome parameters in the first six months after liver transplantation are 
shown in table 2. All in-hospital outcome parameters were comparable for DCD and 
DBD grafts. After six months the mortality rate was 11% in the DCD group, compared 
to 7% in the DBD group (p=0.152). The retransplantation rate was higher in DCD 
recipients (15% vs. 5%; p=0.001). A tendency towards more biliary complications was 
observed in the DCD group (34% vs. 26%; p=0.081). Furthermore, the incidence of 
ITBL in this period was significantly higher in this group (11% vs. 3%; p<0.001). More 
DCD recipients received a retransplant for ITBL as well (4% vs. 1%: p=0.031).
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The CCI at hospital discharge and six months after transplant is displayed in figure 
1. The median CCI at hospital discharge was 37.1 and comparable for DCD and DBD 
grafts (38.2 vs. 36.7; p=0.434). On the contrary, six months after transplant recipients 
in the DCD group had a significantly higher CCI (53.4 vs 47.2; p=0.041). To assess the 
origin of the overall difference at six months, all complications were divided into four 
categories: surgical (including hepatic artery thrombosis (HAT), rebleed, perforation), 
medical (PNF, kidney injury, rejection, diabetes mellitus (DM), myocardial infarction, 
stroke, etc.), biliary complications (including ITBL and anastomotic strictures) and 
infections. There were no significant differences in these subgroups for DCD and 
DBD grafts after six months, but a trend was observed for a higher CCI in the DCD 
groups for biliary (p=0.071) and medical (p=0.051) complications.
table 2 - postoperative outcome parameters after liver transplantation with DCD and DBD grafts
in-hospital dcd (n=115) dbd (n=326) total (n=441) p-value
≥1 severe complication (CD grade 3B) (%) 39 (34) 113 (35) 152 (35) 0.884
Postoperative ventilation days 0 (0-1) 0 (0-1) 0 (0-1) 0.117
Length of stay ICU (days) 3 (2-4) 3 (2-4) 3 (2-4) 0.557
Length of stay entire admission (days) 20 (15-28) 19 (15-29) 19 (15-29) 0.825
Retransplantation (%) 7 (6) 11 (3) 18 (4) 0.206
Death (%) 11 (10) 20 (6) 31 (7) 0.216
Within six months
Readmission (%) 54 (47) 142 (44) 196 (44) 0.528
Death (%) 13 (11) 23 (7) 36 (8) 0.152
Biliary complications
All biliary complications* (%) 39 (34) 83 (26) 122 (28) 0.081
Anastomotic biliary complications** (%) 21 (18) 59 (18) 80 (18) 0.969
Ischemic type biliary lesions (%) 13 (11) 9 (3) 22 (5) <0.001
Retransplantation (%)
Total 17 (15) 17 (5) 34 (8) 0.001
Hepatic artery thrombosis 5 (4) 9 (3) 14 (3) 0.372
Portal vein thrombosis 3 (3) 1 (1) 4 (1) 0.056
Primary non function 4 (3) 1 (1) 5 (1) 0.018
Ischemic type biliary lesions 5 (4) 3 (1) 8 (2) 0.031
Other 0 3 (1) 3 (1) 0.403
CD, Clavien Dindo; DBD, donation after brain death; DCD, donation after circulatory death; ICU, 
intensive care unit.
Continuous variables are presented in median and interquartile range.
* Include all biliary complications: ischemic type biliary lesions, anastomotic complications and 
treatment for incidental cholangitis without diagnosed underlying disease.
** Requiring at least endoscopic or percutaneous treatment.
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Factors associated with a high Comprehensive Complication Index after six months
A multiple logistic regression model (table 3) was used to identify donor, recipi-
ent and surgical factors associated with a complicated postoperative course (CCI 
>60 after six months). For example, one re-operation for bleeding (grade 3B) and 
re-admittance at ICU for respiratory sepsis (grade 4B) during hospital admittance 
and one endoscopic treatment for ITBL (grade 3A) and one course of antibiotics for 
a pneumonia after discharge (grade 2) lead to a CCI of 63.7 at six months. Three 
factors were associated with a CCI >60: Recipient BMI (OR 1.052; p=0.046), duration 
of recipient WIT (OR 1.032; p=0.008) and use of a DCD graft (OR 3.913; p=0.024).
Long term survival
The five-year estimated graft (71%) and patient (81%) survival are displayed in figure 
2. Recipients who received a DCD graft had a significantly lower five-year estimated 
graft survival (60% vs.75%; p=0.002). However, there was no significant difference 
observed in the estimated patient survival (DCD 75%; DBD 82%; p=0.090).
discussion
Our results show with use of the CCI that outcome of DCD and DBD liver transplanta-
tion is comparable during the index hospital stay, but that DCD recipients experience 
more complications in the long run. This study thus confirms the outcomes of other 
publications, reporting both similar and detrimental outcome in DCD liver transplan-
tation and shows the dynamic increase of total burden of complications, depending 
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figure 1 – CCI for recipients of DCD and DBD grafts at hospital discharge and six months after 
liver transplantation
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figure 2 - Five year graft (A) and patient (B) survival after DCD and DBD liver transplantation
table 3 - multiple logistic regression model to identify factors associated with a CCI >60 six 
months after liver transplantation
Recipient odds ratio 95% ci p-value
Age 1.007 0.998-1.027 0.481
Gender 1.255 0.792-1.990 0.334
Body mass index 1.052 1.001-1.105 0.046
MELD score 1.018 0.992-1.045 0.168
Indication for transplant
Biliary cirrhosis 1.000 . 0.231
Viral hepatitis 0.744 0.401-1.380 0.348
Alcohol related cirrhosis 0.944 0.488-1.825 0.863
Other 1.379 0.800-2.376 0.247
donor      
Age 1.003 0.988-1.018 0.692
Gender 1.123 0.735-1.718 0.591
Body mass index 1.005 0.948-1.065 0.869
DCD graft 3.913 1.200-12.767 0.024
surgical      
Cold ischemia time 1.091 0.983-1.211 0.102
Recipient warm ischemia time 1.032 1.008-1.056 0.008
>5 units RBC transfusion 1.440 0.896-2.313 0.132
CI, confidence interval; DCD, donation after circulatory death; MELD, model for end stage liver 
disease; RBC, red blood cells.
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on the time frame that is analyzed (3,5,7,24,25). The novelty of our study lies in the 
method of comparing outcomes between DCD and DBD grafts. With the new CCI 
as a continuous variable, we can actually show the extent of difference in morbidity 
between the grafts and how the burden of complications increases over time.
The potential complications after DCD liver transplantation require a delicate selec-
tion of grafts and matching recipients. Known factors that impair outcomes of DCD 
grafts are both recipient and donor age and BMI, MELD-score, and prolonged cold 
and warm ischemic times (26,27). Our DCD and DBD cohorts show similar recipient 
characteristics with comparable MELD and Child-Pugh scores, previous medical his-
tory and even a higher recipient age in DCD recipients. The donor age limit of 60 
years in DCD transplantation led to a lower donor age. Also, according to a protocol 
cut-off level of 28 for BMI in DCD donors to minimalize severely steatotic liver grafts, 
BMI was significantly lower in the DCD group. Importantly, cold and recipient warm 
ischemia times were comparable for DCD and DBD grafts.
The recently developed CCI is based on a formula used in the economic world, which 
incorporates multiple factors influencing the globalization of a corporation decision. 
With this formula all complications, weighted by severity, are integrated in a linear 
scale from 0 to 100. It facilitates reporting not only of the in-hospital morbidity, but 
also at various postoperative follow up moments, e.g. the six-months morbidity. In 
this study, the CCI proves again its easy applicability to longitudinal assessment of 
complications over time, as illustrated in the analysis of the six-months follow up. 
Also, the CCI correlates well with more traditional complication parameters, such as 
length of stay, grade 3 and higher complications and graft survival, which adds clini-
cal relevance to this new global marker of morbidity. The major benefit of the CCI is 
that although the incidence of particular complications may be low, the accumulation 
of all complications and their severity is accounted for in the value of the CCI.
Our regression model identified DCD grafts as the main factor associated with a CCI 
of >60 after six months. We chose this cut-off because of the clinical example given 
in the results. Furthermore, Schlegel et al recently showed in a risk assessment of 
high MELD recipients that the median CCI for recipients with MELD >30 was 56 after 
one year (28). The CCI in this study correlated well with several preoperative risk 
scores for graft survival after liver transplantation as well. Other significant factors in 
our model included recipient BMI and prolonged recipient WIT. Obesity is a known 
factor in surgery for infectious complications and long-term outcomes, but results in 
liver transplantation are not conclusive and malnutrition is here an important factor 
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as well (29–31). Recipient WIT aggravates hepatic IRI, but recent studies focus more 
on the impact of the obligatory DWIT in DCD liver transplantation (32,33). DWIT is 
per definition not present in DBD donors, but this period is indirectly represented 
through the DCD graft factor in our multivariable model.
Parallel to the classical outcomes, the CCI showed no differences between DBD and 
DCD recipients during the index in-hospital stay, probably reflecting effective donor-
recipient matching to balance the risks intrinsic to the use of a DCD graft. However, 
after six months more recipients in the DCD group developed biliary complications 
and required a retransplant. The progression of the CCI showed a similar picture: 
during the initial hospital admittance values were equal, but after six months the CCI 
was significantly higher for DCD graft recipients. The calculation of the CCI for the 
subgroups showed that mainly biliary and medical complications were more common 
and required more treatment in the DCD group within the first six months. Because 
only 22 recipients developed ITBL in this period, we did not create subgroup to 
evaluate the CCI for ITBL alone. The higher retransplantation rate at six months after 
DCD liver transplantation was predictive for a worse long-term outcome in our cohort 
and DCD recipients had a lower 5-year estimated graft survival. Earlier studies on this 
subject are not conclusive and several studies have reported impaired long-term 
graft survival for DCD grafts as well, while others showed results comparable with 
DBD grafts (8,34–36). The discrepancies between these studies is likely the result 
of variation in the selection of DCD donors and recipients between countries and 
transplant centers. The five-year patient survival was not inferior for DCD grafts in 
this study, probably due to our liberal retransplantation policy for patients with a 
failing graft due to ITBL. If ITBL as a late effect of the use of DCD liver grafts can be 
prevented, the outcome of DCD liver grafts can become truly comparable to that 
of DBD liver grafts. Hypothermic oxygenated and normothermic machine perfusion 
are currently under study to improve graft quality and show promising results in 
expanding the viable organ donor pool and decrease ITBL requiring retransplanta-
tion (37,38).
This study has several limitations. Data was collected retrospectively, but performed 
by only one individual, leading to a consistent interpretation and registration of com-
plications. Our DCD and DBD cohorts are comparable for most of the pretransplant 
characteristics, but inherent to the use of high-risk grafts, some donor and recipient 
characteristics were significantly different, as described above. This reflects however 
the actual clinical situation in many institutions using DCD grafts, because of stricter 
donor and recipient selection criteria when DCD grafts are used. Therefore, we de-
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cided not to balance the groups using propensity matching in this cohort. Recipients 
requiring retransplantation form a unique group: a 4A complication was scored for 
retransplantation and we terminated follow up after retransplantation, because we 
encountered a case with a retransplant for PNF and the recipient developed ITBL af-
ter retransplantation. Also, the CCI is originally developed for surgical complications, 
while in liver transplantation postoperative infections and medical complications are 
common as well.
In conclusion, with the use of the CCI this study provides a new view on postoperative 
complications and graft usage in liver transplantation. Patients receiving a DCD graft 
have a similar course during the postoperative hospital stay, but more complications 
occur thereafter in the first six months. Biliary complications such as ITBL, are major 
contributors to the morbidity of DCD liver transplantation. The following graft sur-
vival is impaired for DCD grafts as well. The novel graft persevering techniques, such 
as machine perfusion, are essential to improve the overall outcomes of DCD grafts.
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summaRy
The aim of this study was to investigate the impact of hypoxia and hypotension dur-
ing agonal phase of DWIT on hepatic IRI and complications in DCD liver transplanta-
tion. A retrospective single-centre study of 93 DCD liver transplants (Maastricht type 
III) was performed. DWIT was divided into two periods: agonal phase (from WoT 
until circulatory arrest) and asystolic phase (circulatory arrest until cold perfusion). 
During agonal phase, a drop to <80% in SpO2 was considered as the start of hypoxia 
(SpO2-Agonal) and a drop to <50 mmHg as the start of hypotension (SBP-Agonal). 
Peak postoperative AST level >3000 U/L was considered as severe hepatic IRI. SpO2 
dropped within 2 minutes after WoT <80%, while the SBP dropped to <50 mmHg 
after 9 minutes, resulting in a longer SpO2-Agonal (13 minutes) than SBP-Agonal (6 
minutes). In multiple logistic regression analysis, only duration of SpO2-Agonal was 
associated with severe hepatic IRI (p=0.006) and not SBP-Agonal (p=0.32). Also, re-
cipients with long SpO2-Agonal (>13 minutes) had more complications with a higher 
CCI during hospital admission (43.0 vs 32.0; p=0.002) and 90-day graft loss (26% 
vs. 6%; p=0.01), compared to recipients with a short SpO2-Agonal (≤13 minutes). 
Furthermore, Cox proportional hazard modelling identifi ed a long SpO2-Agonal as a 
risk factor for long-term graft loss (HR 3.30; 95% CI 1.15-9.48; p=0.03). In conclusion, 
the onset of hypoxia during agonal phase is related to severity of hepatic IRI and 
postoperative complications. Therefore, SpO2 <80% should be considered as the 
start of functional DWIT in DCD liver transplantation.
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intRoduction
DCD grafts are increasingly being used in liver transplantation and in some European 
countries more than one third of the deceased donor liver transplants are performed 
with DCD grafts (1–3). Nonetheless, the use of these marginal grafts is associated 
with various biliary and renal complications, resulting in inferior survival rates, com-
pared to DBD grafts (4–11).
The inferior results are likely the consequence of the obligatory DWIT. This extra 
period of warm ischemia in DCD grafts is thought to aggravate hepatic IRI (12,13). 
In previous studies duration of DWIT has been linked to biliary complications and 
impaired graft survival (9–13). In general, DWIT consists of two periods (figure 3 – 
chapter 2): the agonal phase (from WoT until circulatory arrest) and asystolic phase 
(from circulatory arrest until cold perfusion). However, multiple definitions for DWIT 
are currently being used (14). The trajectory of agonal phase differs widely between 
donors and the exact moment of onset of hepatic tissue injury is still unknown. 
Furthermore, the lack of an uniform definition for the onset of DWIT compromises 
evaluation of its impact on recipient outcomes. Earlier studies, primarily focusing 
on the blood pressure during agonal phase, yielded varying results on its relation 
to postoperative complications (15–18). Abt et al showed that a slow decline in 
SBP during agonal phase is correlated with long term graft loss. Therefore, SBP 
is frequently used to mark the beginning of functional DWIT. However, from our 
clinical experience we have noticed that the peripheral oxygen saturation (SpO2) 
drops much quicker than SBP during the agonal phase. We therefore hypothesize 
that ischemic hepatic injury is more closely related to the onset of hypoxia, rather 
than hypotension during the agonal phase.
The aim of this study is first, to explore the relation between vital parameters during 
agonal phase and hepatic IRI and observe potential cut-off points for the start of 
functional DWIT. Secondly, we will explore the relation between the agonal phase 
and recipient outcome in DCD liver transplantation.
metHods
This retrospective study was performed with approval of the Erasmus University 
Medical Centre Institutional Review Board (registration number: MEC-2014-670). All 
consecutive adult patients who underwent DCD liver transplantation in our centre 
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from July 2008 until March 2016 were included. All DCD grafts were retrieved from 
Maastricht type III donors. Exclusion criteria were retransplantation and liver trans-
plantation for acute liver failure. None of the grafts were machine perfused. In the 
Netherlands, DCD donors older than 60 years of age or with a BMI >28 are regularly 
not considered for liver donation. Also, we allocate DCD livers preferably to recipi-
ents with HCC and/or a relatively low biological MELD-score of <20. The DRI was 
calculated to express graft quality (19). The amount of graft steatosis was assessed 
in biopsies taken after reperfusion. Data following duration and structure of different 
phases of DWIT were retrieved from the Eurotransplant database. An overview of 
DWIT is displayed in Figure 1A. The cut-off time points during agonal phase were 
considered at <80% for SpO2 (SpO2-Agonal) and <50 mmHg for SBP (SBP-Agonal). 
DCD grafts used in this study come from donors in the Netherlands only and are of-
fered through the Eurotransplant waitlist, based on MELD status. In the Netherlands, 
WoT of the donor is on the ICU. After circulatory arrest, there is an obligatory 5 
minutes waiting time, where after the donor is declared deceased and transported 
to the operation theatre (5-10 minutes) for organ procurement, using the super-rapid 
retrieval technique (20). The first flush (6-8 L) is performed with UW (University of 
Wisconsin) preservation fluid under a pressure of 200 mmHg via the aorta. The portal 
vein, hepatic artery and biliary tract are additionally flushed at the back-table with UW 
as well. Standard surgical technique included piggyback cavo-caval anastomosis with 
only incidental use of a portocaval shunt and the graft was routinely reperfused via 
portal vein. Duration of the surgical procedure, cold ischemia time, and recipient WIT, 
intraoperative blood loss with subsequent transfusion of red blood cell concentrates 
(RBC), and fresh frozen plasma (FFP) and end of surgery requirement of vasopressors 
were all recorded. The postreperfusion syndrome (PRS) was defined as a >30% drop 
in mean arterial pressure (MAP) in the 5 minutes after reperfusion, lasting at least 
1 minute (21). The peak AST level in the first 72 postoperative hours was used as 
a marker for severity of hepatic IRI, a known marker for early allograft dysfunction 
(EAD) as well (22). The standard immunosuppression regime in our centre is based 
on the triple therapy strategy: prednisolone and MMF from day 0, basiliximab at 
day 0 and day 4 and introduction of tacrolimus on postoperative day 5. Duration of 
hospital and ICU admission, recipient and graft survival were all documented to as-
sess postoperative morbidity and mortality. All major postoperative complications in 
the first year were documented. Major postoperative complications were defined as 
grade ≥ 3b by the Clavien-Dindo classification and the CCI was calculated at hospital 
discharge, 6 months and 12 months after transplantation (23,24).
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statistical analysis
Data were analysed with IBM SPSS Statistics version 24 (IBM Corporation, Armonk, 
NY, USA). The student’s t test was used to compare normally distributed continuous 
variables. Nonparametric continuous variables were compared using the Mann-
Whitney U test. To compare categorical variables the Chi-square test or Fisher’s exact 
test were used. P-values <0.05 were considered statistically significant. Continuous 
variables were expressed as mean with standard deviation (SD) or median and inter-
quartile range (IQR), where appropriate. A multiple logistic regression analysis was 
used to identify donor, DWIT and surgical risk factors associated with severe hepatic 
IRI (peak serum AST >3000 U/L). Two years graft and patient survival rates were 
estimated using Kaplan-Meier methods. A Cox proportional hazard model was used 
to identify donor, surgical and recipient factors associated with graft loss within the 
first two years after transplantation.
Results
During the study period, 105 patients underwent DCD liver transplantation of whom 
93 were included. Two cases were excluded because of re-transplantation and one 
recipient was transplanted for acute liver failure. In eight cases the duration of DWIT 
and donor’s hemodynamic profile data was missing. In one case intraoperative data 
was not complete.
baseline characteristics
Baseline characteristics are displayed in table 1. Median recipient age was 57 years 
and 70% of the recipients were male. Viral hepatitis was the most common diagnosis 
of liver disease (27%), followed by alcohol-related cirrhosis (22%), and biliary cirrhosis 
(17%). Mean preoperative biological MELD score was 15. Median donor age was 
47 years and 58% of the donors were male. The mean DRI was 2.6. Mean duration 
of total DWIT and asystolic phase were respectively 32 minutes and 16 minutes. 
Average duration of the total agonal phase was also 16 minutes. Of note, a variety in 
dispersion of the DWIT-phases was observed (table 1): The SD and range in agonal 
phase were longer than in asystolic phase. SpO2 dropped already 2 minutes after 
WoT below 80%, while the SBP dropped below 50 mmHg after 9 minutes (figure 1), 
resulting in a longer SpO2-Agonal (13 minutes) than SBP-Agonal (6 minutes). Also, 
the dispersion of SpO2-Agonal was greater than SBP-Agonal, with larger SD and 
range. The mean time between the drop in SpO2 and SBP was 7 minutes. The mean 
duration of cold ischemia time and RWIT was 6.6 hours and 29 minutes, respectively.
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duration of ischemia periods and hepatic ischemia/reperfusion injury
More than half of the recipients developed EAD (60%) according to the Olthoff 
criteria (22), due to the relatively high peak AST levels (median 2287 U/L) in the first 
days after DCD liver transplantation. Therefore, this parameter was not considered 
suitable to quantify hepatic IRI. Instead, we used a cut off of 3000 U/L in peak AST in 
the first 72h after transplantation. The peak AST was >3000 U/L in 43% of the recipi-
ents. Univariable analysis of risk factors associated with severe hepatic IRI (table 2a) 
showed that duration of total agonal phase was significantly associated to a peak AST 
>3000 U/L (OR 1.08; 95%CI 1.01-1.14; p=0.01), but the correlation for SpO2-Agonal 
was even stronger (OR 1.11; 95%CI 1.01-1.20; p=0.004). No relation was observed 
for SBP-Agonal and severe hepatic IRI (p=0.41). Multivariable analysis of the same 
table 1 - baseline donor, recipient and surgical characteristics in DCD liver transplantation
donor total (n=93) donor warm ischemia (minutes) total (n=93)
Donor risk index 2.6 (0.46) Total donor warm ischemia time 32 (32; 12-60)
Age (years) 47 (39-53) Asystolic phase 16 (15; 7-28)
Male gender (%) 54 (58) Agonal phase
Body mass index 24.2 (22.0-26.0) Total agonal phase 16 (15; 4-39)
serum AST (U/L) 46 (29-89) SpO2-Agonal 13 (12; 2-38)
Graft steatosis SBP-Agonal 6 (5; 1-17)
None 53 (57%) Between SpO2 & SBP-Agonal 7 (6; 0-24)
1 - 10% 33 (36%) transplant procedure  
11 - 33% 4 (4%) Operation time (hours) 7.9 (7.7; 6-12)
>33% 3 (3%) Cold ischemia time (hours) 6.6 (6.4; 4-12)
Recipient   Recipient warm ischemia time (min) 29 (28; 17-61)
Age (years) 57 (49-63) Blood loss (liters) 4.1 (3.2-6.2)
Male gender (%) 65 (70) RBC transfusion (units) 3 (1-5)
Body mass index 26.5 (4.3) FFP transfusion (units) 3 (0-6)
Etiology of liver disease (%) Postreperfusion syndrome (%) 37 (40)
Biliary cirrhosis 16 (17) Dose norepinephrine end of surgery (ug/kg/min) 0.30 (0.12-0.50) 
Viral hepatitis 25 (27) postoperative  
Postalcoholic cirrhosis 20 (22) EAD 56 (60%)
Other 32 (34) Postoperative peak serum AST (U/L) 2287 (1305-4881)
Hepatocellular carcinoma (%) 31 (33) Peak serum AST in categories
LabMELD score 15 (7.8) 0 - 3000 U/L 53 (57)
Sodium (mmol/L) 138 (134-140) >3000 U/L 40 (43)
Medical history (%) AST = aspartate aminotransferase; EAD, early allograft dysfunction; 
FFP, fresh frozen plasma; MELD, model for end stage liver disease; 
RBC, red blood cells; SBP, systolic blood pressure. Continuous variables 
are displayed as mean (standard deviation) and median (IQR) where 
appropriate. Values of DWIT and intraoperative periods are displayed 
as follows: mean (median; range).
Hypertension 19 (20)
Coronary artery disease 2 (2)
Diabetes mellitus 29 (31)
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risk factors was used to correct for potential confounders in relation to severe hepatic 
IRI. Two multivariable analyses were performed, both with all factors of the univari-
able analysis and either with the SpO2-Agonal (table 2b) or SBP-Agonal (table 2c) 
period. In table 2B agonal phase was split into the time before and after the drop 
<80% in SpO2 and in table 2C agonal phase was equally split using the drop in SBP 
<50 mmHg. table 2b shows that only the SpO2-Agonal is related to severe hepatic 
IRI (p=0.006) and not the period before the drop in SpO2 (p=0.26). On the contrary, 
Table 2C shows that the duration of the SBP-Agonal period was not an independent 
factor (p=0.32), while the period between the drop in SpO2 and the drop in SBP was 
significantly related to severe hepatic IRI (hypoxic agonal phase) (p=0.003).
duration of spo2-agonal and clinically relevant outcome parameters
Early postoperative complications
table 3 displays the recipient outcome for duration of SpO2-Agonal. After visualiza-
tion of LOESS plots, the SpO2-Agonal was divided into two groups at the mean of 13 
minutes. Recipients with a long SpO2-Agonal had significantly more postoperative 
complications and a longer length of stay, for both ICU and hospital admission. The 
CCI was measured at hospital discharge, six months and one year after transplanta-
tion and at each moment the CCI was significantly higher in recipient with a long 
figure 1 – The course of SpO2-Agonal and SBP-Agonal after withdrawal of treatment of the liver 
organ donors.
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SpO2-Agonal. Also, recipients in the long SpO2-Agonal group experienced more 
90-day graft loss (26% versus 6%; p=0.01). Three recipients had postoperative PNF 
of the graft requiring retransplantation and all of them had a long SpO2-Agonal. 
Surprisingly, no correlation was observed between duration of SpO2-Agonal and 
development of biliary complications in the first year after transplantation.
Long term graft loss
The median follow up was 2.2 years. The estimated 2-year graft and patient survival 
was 79% and 86%, respectively. figure 2 shows the 2-year graft survival for recipi-
ents with a short and long SpO2-Agonal. Recipients with a long SpO2-Agonal had 
the worst survival rate (70% versus 87%; p=0.03). No difference was observed in 
table 3 - Duration of SpO2-Agonal and recipient outcomes after DCD liver transplantation.
length of spo2-agonal
<13 minutes 
(n=47)
≥13 minutes 
(n=46) total (n=93) p-value 
In-hospital  
≥ 1 Major postoperative complication* 10 (21%) 25 (54%) 35 (385) 0.001
Length of ICU admission (days) 2 (2-3) 3 (2-6) 2 (2-4) 0.02
Length of hospital admission (days) 16 (14-22) 22 (17-29) 18 (15-26) 0.009
Comprehensive Complication Index (median)  
In-hospital 32.0 43.0 38.1 0.002
Six months 46.0 58.4 48.2 0.006
One year 48.0 62.8 59.7 0.008
90-day graft loss 3 (6%) 12 (26%) 15 (16%) 0.01
Retransplantation - HAT 2 (4%) 3 (7%) 5 (5%)  
Retransplantation - PNF 0 3 (7%) 3 (3%)  
Retransplantation - ITBL 0 1 (2%) 1 (1%)  
Death 1 (2%) 5 (11%) 6 (6%)  
Biliary complications in first year  
Overall biliary complications** 17 (36%) 18 (39%) 35 (38%) 0.77
Anastomotic strictures*** 12 (26%) 12 (26%) 24 (26%) 0.95
ITBL 6 (13%) 5 (11%) 11 (11%) 0.78
Retransplantation for ITBL 1 (2%) 2 (4%) 3 (3%) 0.62
*Major postoperative complication was defined as a Clavien Dindo classification ≥3B: reoperation 
or ICU re-admittance.
** Including all biliary complications requiring at least medical treatment (i.e. antibiotics / ursode-
oxycholic acid).
*** Requiring at least endoscopic treatment.
HAT, hepatic artery thrombosis; ICU, intensive care unit; ITBL, ischemic-type biliary lesions; PNF, 
primary non function.
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two-year patient survival for recipients with a short (92%) and long (80%) SBP-Agonal 
(p=0.12). The Cox proportional hazard model (table 4) for graft loss in the first two 
years after transplantation showed that a long SpO2-Agonal leads to a three-fold 
increase in hazard ratio (HR) for graft loss (HR 3.30; 95% CI 1.15–9.48; p=0.03). 
Increasing recipient BMI was the other independent factor is this model (HR 1.13; 
95% CI 1.02–1.26; p=0.02).
discussion
This study provides new insight in the impact of vital parameters during the agonal 
phase on hepatic IRI in DCD liver transplantation. Our findings confirm the hypoth-
esis that ischemic hepatic injury is more closely related to the onset of hypoxia, 
rather than hypotension. Similarly, in regular medical practice we fear hypoxia for 
damaging a patient’s organs, while a short period of severe hypotension is tolerated 
SpO2-Agonal ≥13 min       70%
SpO2-Agonal <13 min        87%
P = 0.030
figure 2 - Kaplan Meier curve for duration of SpO2-Agonal and graft survival after DCD liver 
transplantation.
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much better. Therefore, we hypothesized hypoxia would be more detrimental to 
DCD donor livers than hypotension during the agonal phase and our results indicate 
that the drop in SpO2 to <80% is much more relevant to assess the potential severity 
of hepatic IRI. Moreover, a prolonged SpO2-Agonal is associated with more postop-
erative complications and long-term graft failure.
Previous studies have used many different definitions for DWIT and consequently, 
the duration of an acceptable DWIT in these studies ranges from 10 to 35 minutes 
(15,17,25–27). The study by Abt et al showed that a quick drop in SBP after WoT 
was associated with an improved graft survival (15). Hong et al identified a period of 
MAP <60 mmHg before circulatory arrest longer than 20 minutes increased the risk 
for graft loss (17). Of note, the course of SpO2 was not considered in these studies. 
In a study of Firl et al the trajectory of agonal phase was divided into three categories 
by the course of SpO2 and MAP; a quick decline, a slow gradual decline, and a 
relatively long stable phase with initial good vital parameters with a quick decline just 
before circulatory arrest (16). The authors were not able to form strong conclusions 
donors with the worst prognosis, but in donors with a slow decline, only the course 
table 4. Cox proportional hazard model for graft loss after DCD liver transplantation.
Recipient HR 95% ci p-value
Age 1.01 0.96 - 1.07 0.63
Body mass index 1.13 1.02 - 1.26 0.02
LabMELD 0.99 0.92 - 1.08 0.97
Hepatocellular carcinoma 0.28 0.07 - 1.15 0.08
donor      
Donor risk index 0.91 0.30 - 2.75 0.87
Graft steatosis  
None 1.00  
1-10% 1.84 0.70 - 4.79 0.21
>10% 4.11 0.77 - 22.01 0.09
ischemia periods      
DWIT - SpO2-Agonal  
<13 minutes 1.00  
≥13 minutes 3.30 1.15 - 9.48 0.03
DWIT - asystolic phase 1.06 0.94 - 1.20 0.33
Cold ischemia time 1.02 0.95 - 1.08 0.64
Recipient warm ischemia time 1.23 0.89 - 1.71 0.20
CI, confidence interval; DWIT, donor warm ischemia time; HR, hazard ratio;
MELD, model for end stage liver disease.
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of MAP was associated with graft loss. The course of SpO2 was not associated with 
graft loss, but is should be noted that pulse oximetry measurement of SpO2 is not 
reliable below a value of 80% (28–30). A more recent multicentre-study by Coffey 
et al investigated the relation between potential cut-offs of SpO2 and MAP and a 
composite endpoint consisting of early and late complications (31). Only the cut-off 
of SpO2 <60% was associated with postoperative complications, but these results 
were not confirmed in a multivariable analysis. Important pitfalls of this study are 
the low SpO2 cut-off of 60%, the uniform outcome that weakens potential effect on 
different complications and the lack of an analysis of the relation between DWIT and 
hepatic IRI.
In many countries, the cut-off for discarding a DCD liver is 30 minutes of functional 
DWIT (start of agonal phase at SBP<50 mm Hg until cold perfusion) and we also 
analysed these periods with this cut-offs for SBP. The cut-off for SpO2 was set at 80%, 
because the accuracy of pulse oximetry decreases significantly with arterial haemo-
globin saturation levels below 75-80%. Using these cut-offs, the onset of hypoxia was 
on average almost directly after WoT and seven minutes earlier than hypotension, 
leading to a much longer SpO2-Agonal than SBP-Agonal period. In the multivariable 
analysis, only duration of SpO2-Agonal was associated with severe hepatic IRI. More 
importantly, the period between the drop in SpO2 and SBP (hypoxic agonal phase) 
was actually the period related to severe hepatic IRI in this multivariable model, 
suggesting that an agonal phase starting with a long hypoxic period is the driving 
force of the extra hepatic IRI in DCD grafts. These results are supported by studies 
investigating shock livers suggesting that hypoxia is an important cause for hepatic 
injury, even without hemodynamic shock (32). The increased hepatic IRI with the 
use of DCD grafts has previously been linked to impaired outcomes (13,33,34). We 
found that recipients of a graft with a SpO2-Agonal period longer than 13 minutes 
had more major complications, a higher CCI and more graft loss in the first 90 days. 
Moreover, the three recipients with PNF all had a SpO2-Agonal of ≥13 minutes. 
Considering the sum of SpO2-Agonal (13 min) and asystolic phase (16 min) is 29 min, 
we would advise to set the new cut-off for functional DWIT at 30 minutes.
The severity of hepatic IRI and complications has a multifactorial origin. Steatotic 
grafts are more vulnerable to IRI and graft steatosis was a significant factor in our 
multivariable analysis as well (36,37). We also observed a trend for increased RWIT, 
a known factor to increase hepatic IRI (38). Remarkably, the duration of the asystolic 
phase was not significant, this might be caused by the relative narrow dispersion 
of this phase, reflecting the legal five minutes no-touch period, transport of the 
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donor and cannulation time of the dedicated organ retrieval team, thus almost 
standardizing this period in all donors. Cold ischemia was not a factor, which could 
be explained by the relatively short cold ischemia time (mean <6.5h). The molecular 
pathways that could potentially explain our results regarding the importance of 
hypoxia have been previously studied before in renal transplantation by Damman 
et al (39). In this human study, transcriptomics of donor biopsies during retrieval 
and transplantation followed by functional pathway analysis showed that pathways 
related to prolonged and worsening deprivation of oxygen were associated with 
delayed graft function in DCD grafts. These pathways were already upregulated 
before organ retrieval and included metabolic pathways related to hypoxia and the 
complement-and-coagulation cascades. After reperfusion, these pathways were 
related to delayed kidney graft function. Furthermore, an experimental study in a 
rat liver transplant model with simulated prolonged WIT by Zhang et al confirmed 
that these complement-associated pathways are an important factor in the severity 
of hepatic IRI (40). To our knowledge, such analyses of prolonged warm ischemia, 
have not yet been performed in human liver transplantation. However, these studies 
confirm that hypoxia is an important factor in the warm phase of IRI. Interestingly, the 
duration of SpO2-Agonal was not related to development of biliary complications in 
our study. It is known that the biliary tree responds differently to ischemia than he-
patocytes and previous experimental studies suggested that they are better resistant 
to hypoxia, but more susceptible to reoxygenation injury (41,42). Taner et al studied 
the impact of DWIT on ITBL and only observed a relation between the duration of 
asystolic phase and development of ITBL (10). This implicates that the biliary tree is 
less affected by hypoxia or hypotension during the agonal phase, compared to the 
full no-flow ischemia during the asystolic phase. Despite there was no relation be-
tween the duration of SpO2-Agonal and biliary complications, the 90-day outcomes 
and long-term survival rates were worse for grafts with a long SpO2-Agonal, due to 
an increased rate of HAT and PNF.
There are several limitations to this study. The retrospective design of this study 
means that recipient perioperative management varies, but our institution has a 
well-implemented liver transplant protocol and over 1000 liver transplants done. 
Donor data was retrieved from Eurotransplant, which has a well-organized database. 
However, in the first years of DCD organ retrieval, not all DWIT-data was available 
and we had to exclude eight cases. Peak serum AST levels are a surrogate marker 
for hepatic IRI, also depending on the weight of the donor liver. The only alternative 
option would be a histological assessment, but this would be subject to the inter-
pretation by different pathologists. We specifically not use the classic Olthoff-criteria 
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for EAD, as we have observed that the median peak AST levels is above 2000 U/L 
in the majority of the DCD recipients. This study is reflecting the practice in the 
Netherlands, which can be different from other countries.
We believe our study provides strong evidence that hypoxia, rather than hypoten-
sion, marks the beginning of hepatic tissue injury in DCD grafts. We advise transplant 
professionals to consider functional DWIT as the period between SpO2 <80% and 
start of cold perfusion, irrespective of blood pressure. Duration of hypoxia during the 
agonal phase over 13 min could identify potential poor-quality grafts and thereby 
enable the transplant surgeons to engage in application of graft-improving methods 
such as machine perfusion.
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summaRy
In this study, we provide a new prediction model for graft loss in DCD liver trans-
plantation. Using UK national DCD database, a risk analysis was performed in adult 
recipients of DCD liver grafts in UK between 2000 and 2015 (n=1153). A new risk 
score was calculated (UK DCD Risk Score) on the basis of regression analysis, and 
validated using the UNOS-database (n=1617) and our own DCD liver transplant da-
tabase (n=315). Finally, the new score was compared with two other available predic-
tion systems, the DCD risk scores from UCLA and Kings-College-Hospital, London. 
Seven strongest predictors of DCD graft survival were identifi ed: functional donor 
warm ischemia, cold ischemia, recipient MELD, recipient age, donor age, previous 
liver transplantation, and donor BMI. A combination of these risk factors (UK DCD 
Risk Score) stratifi ed best recipients in terms of graft survival in the entire UK DCD 
database as well as in the UNOS and in our own DCD population. Importantly, the UK 
DCD Risk Score signifi cantly predicted graft loss due to PNF or IC in the futile group 
(>10 score points). The new prediction model demonstrated a better C statistic of 
0,79, compared to the two other available systems (0,71 and 0,64; respectively). The 
UK DCD Risk Score is a reliable tool to detect high risk and futile combinations of 
donor and recipient factors in DCD liver transplantation. It is simple to use and offers 
a great potential to better decide which DCD graft should be rejected or may benefi t 
from functional assessment and further optimization by machine perfusion.
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intRoduction
Driven by organ scarcity and the need to decrease waiting list mortality, liver 
transplant professionals worldwide have expanded the donor organ pool (1). In this 
context, livers from DCD donors are increasingly used for transplantation and several 
countries implemented DCD programs (2–4). However, DCD organs may carry fur-
ther risk due to the additional donor warm ischemia leading potentially to a higher 
rate of severe complications, such as PNF and ITBL (5). Specific donor and recipient 
risk factors are therefore critically evaluated by transplant centres (6–9). For example, 
graft cold ischemia, donor age and donor BMI or recipient MELD score have all been 
reported to impact on graft survival (7). Careful selection of grafts and recipients 
appears therefore decisive for outcome. Data analysis from Kings College Hospital 
(KCH) underline this fact, showing excellent low rates of ITBL (2.5%), when the overall 
risk is low and WIT is kept short with an average of functional DWIT of 16 minutes 
(10,11). Such results stand in contrast to other European centres and to previous 
analyses of US data (12–14), which report longer donor warm ischemia times with 
higher incidence of ITBL and graft loss (15). The combination of too dangerous risk 
originating from three sources, e.g. donor, graft and recipient is however unclear.
The intention of this study was therefore to search for an easily applicable score 
system, based on a few independent donor and recipient key factors, with the high-
est possible accuracy in prediction of complications and graft loss after DCD liver 
transplantation.
metHods
study design and patients
After approval by the National Health Service (NHS) institutional review board in 
the UK, records of all adult (≥18 years) DCD recipients transplanted for chronic liver 
disease were extracted from an NHS Blood and Transplant (NHSBT) Analysis and Re-
search file from January 2000 through December 2015 (national UK cohort) (16). Two 
other DCD cohorts were used for validation. First, adult DCD cases were extracted 
from the United Network for UNOS database from December, 1987 through Septem-
ber, 2010, after approval by the University of Washington institutional review board 
(UNOS cohort). And second, we analysed our own institutional DCD database, which 
included patients transplanted from January 2005, to December 2015 (Birmingham 
cohort). To reduce confounding variables, paediatric and partial transplants (split 
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and living donor liver transplantation), DBD and combined liver transplants, were 
excluded. Recipients with lost follow up were excluded from the analysis. Patients 
with exception points (e.g., hepatocellular cancer within Milan criteria) were included 
in the analysis. Importantly, pretransplant MELD score was calculated without inclu-
sion of those exception points (laboratory MELD). The primary outcome measured 
for regression analysis was one-year graft survival (least missing entries). The final 
analysis included 1153 patients. The two validation cohorts, UNOS and Birmingham, 
consisted of 1861 and 315 DCD transplant cases. 0We defined ITBL in this analysis 
on the basis of radiological findings, e.g. intrahepatic or hilar biliary strictures and 
dilatations, occurring in the absence of hepatic artery stenosis (HAS) or thrombosis 
(HAT), portal vein thrombosis, chronic ductopenic rejection, or recurrent primary scle-
rosing cholangitis. Overall incidence of biliary complications, extrahepatic strictures, 
ITBL and bililary leakages for our DCD transplants from Birmingham are described in 
detail in Suppl. Table 5.
statistical analysis
To establish a clinically valid regression model, we choose parameters, which are 
easily available for surgeons at each DCD transplant centre worldwide. Our aim 
was, therefore, to combine donor, graft, and recipient factors in one practical score 
system on post-transplant graft survival. All factors should be easily available prior to 
transplantation. Accordingly, significant variables with impact on outcome after DCD 
liver transplantation (with a p-value<0.25) were considered further were selected (6 
metric, 1 dichotomous), for example, donor age, functional DWIT, cold ischemia, 
laboratory MELD score, recipient age and retransplantation (17–20). In an attempt 
to increase information on graft quality, donor BMI was also included as surrogate 
marker of steatosis and other metabolic disorders (21). Functional DWIT in UK is 
defined as time between SBP below 50 mmHg and cold aortic organ flush (22).
For candidate predictors with less than 60% missing values (e.g. recipient lab MELD 
score pre-transplant (32/1153; 2.8% missing), functional DWIT (464/1153; 40.2%) 
and cold ischemia of the graft (89/1153; 7.7% missing), we performed multiple 
imputation (MI) using multivariate normal regression, imputing a total of 20 datasets 
(n=24213) (23). This method assumes that the data are missing at random MAR, which 
appears as a less restrictive assumption than that required by complete case analysis 
and multivariate normal regression has been shown to be valid whether or not all 
imputed variables follow a normal distribution (24). In each of the imputed datasets 
we used a backward stepwise approach for the multivariable logistic regression with 
p-values ranging between <0.001 and >0.05 as inclusion and exclusion thresholds, 
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respectively. The strongest predictors for one-year graft survival after DCD liver 
transplantation, that were selected in 75% to 80% of the imputation models were 
included in the final multivariable model. Backward elimination is generally preferred 
as an automated predictor selection procedure because it takes correlations among 
predictors into calculation (23,25–31). The imputed data sets were combined and the 
point system was developed to enhance clinical applicability according to the Fram-
ingham risk scheme (table 2) (32). For each predictor, the median of all values below 
(Midpoint W1reference – W7reference) and above the threshold has been calculated. 
The Midpoint for the cohort below each threshold (W1-7reference) is subtracted 
from the midpoint of all values above the threshold. The factor β is multiplied with 
the difference (Wij-Wireference), separately for each factor (32).
performance and validation of the new prediction model
The performance of the prediction model in the derivation cohort was evaluated by 
examining measures of discrimination and calibration. Discrimination is the ability 
of the risk score to differentiate between patients who do and do not experience 
an event (in our case, the occurrence of graft loss after DCD liver transplantation). 
This measure was quantified by calculating the area under the curve (AUC) of the re-
ceiver operating characteristic statistic. Calibration reflects the agreement between 
predicted probabilities from the model and observed outcomes. We used the Hos-
mer–Lemeshow test to statistically determine the extent of agreement between the 
predicted and the observed probabilities. We performed an internal validation using 
a bootstrapping procedure. This approach uses the entire data in order to develop 
the prediction model and in addition accounts for model overfitting or uncertainty 
compensating for overoptimism in the final prediction model. The bootstrapping in 
the current study was performed using 500 bootstrap resamples, each time selecting 
variables and developing a model within the sample. The new prediction model 
was compared to available systems from UCLA (DCD risk score UCLA) (17) KCH 
named as DCD Risk Index (DCD-RI) (Suppl. Table 4) (33). Furthermore, the model 
was validated externally in the UNOS database and internally, in our own population 
from Birmingham, where we specifically evaluate the predictive value of our new 
score, excluding retransplantations. Statistical analysis was performed using IBM 
SPSS Statistics version 23 (IBM Corporation, Armonk, NY, USA).
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Results
are there differences between the 3 study populations from uk, unos 
and birmingham?
Following eligibility criteria, 1153 cases were available from the UK database, and 
1863 were selected from the UNOS database. Our institutional database included 
315 DCD transplants. Median follow-up accumulated to 865 days in the UK, as 
compared to 600 days in US and 936 days in our population. No differences were 
found between the three populations in terms of recipient age (median 55 vs. 54 
vs. 58 years), recipient BMI (27.0 vs. 27.4 vs. 27.0 kg/m2), donor BMI (median 25.0 
vs. 25.1 vs. 25 kg/m2) and cold ischemia time (median 7.1 vs. 7.0 vs. 7.0 hours). 
Major differences (UK data vs. UNOS vs. own data) were noted regarding donor age 
(median 49 vs. 34 vs. 51 years) and functional DWIT (median 17 vs. 14 vs. 17 min). 
In the UNOS cohort, centre dependent variations exist on the time of initiation of 
donor warm ischemia. Most US centres, however, define it also as functional DWIT, 
table 1 - Donor, graft, and recipient characteristics in the 3 DCD cohorts in the UK, UNOS, and 
in Birmingham.
donor & graft characteristics uk (n=1153) unos (n=1861) birmingham (n=315)
Age (years) 49 (35–59) 34 (21–47) 51 (36–62)
Body mass index (kg/m2) 25 (23–28) 25.1 (22.0–29.1) 25 (22.7–27.7)
Total donor warm ischaemia time (min) 27 (22–31) - 27 (22–32)
Functional warm ischaemia time (fDWIT) (min) 17 (14–20) 14 (9–21) 17 (14–21)
No. of donors with fDWIT >20 min 254 (22%) 364 (19.6) 82 (26)
No. of donors with fDWIT >30 min 40 (3.5%) 124 (6.7) 13 (4.1)
Asystolic warm ischaemia time (min) 13 (11–15) - 12 (10–14)
Cold ischaemia time (h) 7.1 (6–8.2) 7 (5.3–9) 7 (5.7–8.1)
No. of grafts with CIT >6 h 853 (74%) 1145 (61.5%) 222 (70.5%)
Recipient characteristics
Age (years) 55 (48–61) 54 (49–60) 58 (51–64)
Body-Mass-Index (kg/m2) 27 (24–30) 27.4 (23.8–31.2) 27 (24–30)
lab-MELD score 15 (11–19) 16.4 (10.8–23.5) 13 (9–17)
UKELD score 53 (50–57) - 53 (49–56)
BAR–Score 5 (3–8) 7 (3–10) 5 (3–7)
Follow-up (days) 865 (364–1704) 600 (160–1355) 936 (426–1602)
Data presented as median and IQR for continuous variables or as number and percent for categori-
cal variables.
BAR, Balance of Risk Score; BMI, Body-Mass-Index; CIT, cold ischaemia time; DCD, donation after 
circulatory death; fDWIT: IQR, interquartile range; MELD, model of end-stage liver disease; UKELD, 
United Kingdom model of end-stage liver disease; UNOS, United Network for Organ Sharing.
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initiated after a specified period of time during sustained hypotension (systolic blood 
pressure < 50mmHg)(14). The BAR-score at transplantation was slightly higher in 
UNOS compared to the other cohorts (median 5 vs. 7 vs. 5 points), corresponding 
to the slightly higher MELD score in UNOS regions when compared to the European 
population (median 15 vs. 16.4 vs. 13 points)(18). In addition, the percentage of 
retransplantations at the time of DCD transplant was comparable in UK and UNOS, 
while all candidates in our own population were primary transplants (11.3% vs. 11.3% 
vs. 0%, table 1).
Which are the key prediction factors for graft survival after dcd liver 
transplantation?
Initial calculations were performed in the large DCD database from UK and tested, 
in a next step, in the UNOS and our institutional DCD population. We evaluated 43 
table 2. Development of the new prediction score based on multivariate regression analysis.
parameter category
Regression 
coefficient ßi p-value
Reference value 
Wi (midpoint)
ßi x (Wij-
Wireference)
Risk 
score
Donor age ≤ 60 yr 0.084 0.001 46 (W1reference) 0 0
> 60 yr 66 1.688 2
Donor BMI £ 25 kg/m2 0.519 0.0001 23 (W2reference) 0 0
> 25 kg/m2     28 2.598 3
Functional DWIT ≤ 20 min 0.341 <0.0001 15 (W3reference) 0 0
21-30 min 24 3.069 3
> 30 min   32 5.797 6
Cold ischemia time no 0.791 0.001 5.5 (W4reference) 0 0
yes   7.7 1.74 2
Recipient age ≤ 6h 0.241 0.0001 52 (W5reference) 0 0
> 6h     64 2.892 3
Recipient lab MELD ≤ 25 0.109 0.0001 14 (W6reference) 0 0
> 25   30 1.744 2
Retransplantation No 8.571 <0.001 0 (W7reference) 0 0
Yes     1 8.571 9
total score points           0-27
The imputed data sets were combined and the point system was developed according to the Fram-
ingham risk scheme. For each predictor, the median of all values (Midpoint W1reference – W7refer-
ence) below and above the threshold has been calculated. The Midpoint for the cohort below each 
threshold (W1-7reference) is subtracted from the midpoint of all values above the threshold. The 
factor b is multiplied with the difference (Wij-Wireference), separately for each factor to develop 
the score points.32 BMI, body mass index; CIT, cold ischaemia time; fDWIT: functional donor warm 
ischaemia time; MELD, model of end-stage liver disease; yr, years; min, minutes; h, hours; b, regres-
sion coefficient.
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candidate predictors. The median number of missing values per candidate was 6 
(IQR 2.5-9.5). Five variables were excluded, due to more than 60% missing values, 
which involved AST, donor albumin, agonal donor phase, arterial donor pressure and 
recipient hospital status at transplant. Among the 38 remaining candidate variables 
28 had complete data and 10 contained <60% missingness and were subjected to 
the multiple imputation procedure. The full multivariable prediction model based 
on the backward stepwise approach and revealed seven parameters as significant 
predictors for graft loss: donor age and BMI, functional DWIT, cold ischemia time, 
recipient age, MELD score and previous liver transplantation (table 2).
Recipient BMI was not identified as independent predictor. Using the significant 
regression coefficients, the UK-DCD-Risk score was calculated with a range from 0 
to 27 points reflecting an exponential increase in one-year graft loss. The strongest 
predictor was retransplantation (0 or 9 points), followed by functional donor warm 
ischemia (0 or 3 or 6 points), recipient age (0 or 3 points), donor BMI (0 or 3 points), 
donor age (0 or 2 points), cold ischemia time (0 or 2 points), and lab MELD (0 or 
2 points; table 2). Internal validation yielded a c-statistic of 0.79 (95%CI: 0.744-
0.839) and the p-value for the Hosmer and Lemeshow goodness of fit test ranged 
from 0.143 to 0.506 in the 20 imputed data sets, corresponding to a well-calibrated 
model. Internal validation of the model using bootstrapping procedure revealed 
minimal optimism of 0.00005 (95%CI: 0.00574 to 0.064).
How does the newly developed risk score compare to other available 
prediction systems?
In an attempt to compare predictability of outcome, c-statistics of other score sys-
tems were assessed in the UK database referred to graft survival. For both available 
prediction models in DCD liver transplantation, the UCLA-DCDscore (17) and the 
KCH-DCD-RI from Kings College Hospital(33), the areas under the receiver operator 
characteristic curves (AUC) were 0.71 and 0.64, respectively (figure 1). These find-
ings were confirmed by a superior AUC for the new DCD model in our own cohort 
in Birmingham (AUC=0.754), compared to the UCLA-DCD score (AUC=0.639) and 
the KCH-DCD RI (AUC=0.583) (Suppl. Figure 3). Accordingly, the new UK-DCD-Risk 
score showed a more significant decrease in graft survival per increasing score cluster 
(0–5, 6–10, >10; figure 1), when compared to both other models. Of note, the BAR 
score was also inferior in prediction of graft survival after DCD liver transplantation in 
this dataset (Suppl. Figure 1). Additional analysis showed that cumulative 1-year graft 
survival per each single score point followed an exponential increase for the new 
score model above a certain threshold of approximately 10 points (figure 3). Both 
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other DCD scores failed to predict cumulative graft loss at each single score point 
(figure 3). Of note, UK DCD Score grouping at this threshold (≤10 vs. >10) splitted 
graft survival best as compared to the two other scores, that is, DCD Score from 
UCLA (≤4 vs. >4) and DCD-RI from KCH (≤4 vs. >4) (figure 3). The newly developed 
score showed a very good positive prediction value of 71% and 86.1% in UK and 
UNOS. The specificity was 0.95.
figure 1 - Five-year graft survival according to the UK DCD Risk Score and ROC curve analysis 
(UK cohort).
(A) Kaplan–Meier survival plots were developed for graft survival according to the three risk classes 
of the new score model. Comparisons between groups were made using the log-rank test. Discrimi-
nation is the ability of the risk score to differentiate between patients who do and do not experience 
graft loss. This measure was quantified by calculating the AUC statistic. (B) This is displayed in the 
ROC curve. (C) The table compares the AUC values of the new model with previously described 
DCD scores from UCLA and KCH. AUC, area under the receiver-operating-characteristic curve; 
DCD, donation after circulatory death; DCD-RI, donation-after-circulatory-death risk index; KCH, 
King’s College Hospital; ROC, receiver operating characteristic; SE, standard error; UCLA, University 
of California, Los Angeles.
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is the new prediction model valid in other dcd cohorts?
External validation in the UNOS database, confirmed the excellent discrimination be-
tween acceptable outcome below the threshold of 10 points and significantly lower 
graft survival in the futile group with more than 10 UK DCD Score points (figure 1&3). 
Of note, recipients in the futile group (>10 points) experienced a very high risk for 
graft loss of more than 60% in one year and > 80% in 5 years. In addition, candidates 
in the high-risk group (>5 to 10 score points) lost the graft in 18% and 40% in one and 
five years, compared to the lowest risk group (0-5 points), where 5% and 15% of DCD 
livers were lost in one and five years, respectively (figure 1&2). Importantly, UK DCD 
Score ranking was also useful in our own cohort, where the strongest predictor, re-
transplantation, was not available (p<0.0001; figure 2). Exclusion of cases with a UK 
DCD risk score of more than 10 points from a DCD liver transplant due to expected 
poor prognosis would refer to 13.4% of patients in the UK (93/689), to 14.7 % of cases 
in the US (237/1617) and to 11.4% of cases in our population (34/300) (figure 1&2).
figure 2 - Prediction of graft loss by the UK DCD Risk Score in all three cohorts, compared to 
other available DCD risk models.
(A) The positive predictive value and false omission rate are shown together with the specificity of 
three different score models. (B) Survival plots highlight the percentage of grafts, which are lost with 
increasing score points, for the new prediction model in three different cohorts (UK, UNOS, and 
Birmingham) compared to two existing models in the UK. DCD, donation after circulatory death; 
DCD-RI, donation-after-circulatory-death risk index; KCH, King’s College Hospital; UCLA, University 
of California, Los Angeles; UNOS, United Network for Organ Sharing.
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How does the new score correlate with post-transplant complications and 
morbidity?
While numerous risk factors have been described previously for DCD liver transplan-
tation, prediction of ischemic cholangiopathy (IC) or also primary non-function (PNF) 
remains unsolved. We were therefore particularly interested to identify a combination 
of key factors with significant impact on graft loss due to IC or PNF. Donor-recipient 
figure 3 - Validation of the UK DCD 
Risk Score in the UNOS region and Bir-
mingham. Kaplan–Meier survival plots 
for graft survival were developed to 
validate the new model in the UNOS 
DCD cohort.
Comparisons between groups were 
made using the log-rank test. (B) In ad-
dition, graft survival in our local DCD 
liver-transplant cohort in Birmingham is 
displayed. The AUC statistic, obtained 
from the UNOS cohort, parallels the val-
ues we received from the development 
cohort in the UK. (C) The table demon-
strates a similar AUC in the UNOS co-
hort, when compared to the UK cohort. 
AUC, area under the receiver-operat-
ing-characteristic curve; DCD, donation 
after circulatory death; ROC, receiver 
operating characteristic; UNOS, United 
Network for Organ Sharing.
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constellations with more than 10 score points (futile group) experienced significantly 
more graft loss due to PNFs and IC in both large DCD cohorts in UK and UNOS 
(p<0.0001; p=0.0001; table 4). In addition, recipients in the high risk and futile 
group developed significantly more often vascular complications, e.g. HAT, leading 
to graft failure in numerous cases in all cohorts (table 4). In order to evaluate liver 
function and other important post-transplant complications and general morbidity, 
we analysed our institutional DCD cohort in accordance with the three clusters of 
table 3. Potential combinations of additional key risk factors providing a UK DCD Risk Score ≤10 
or >10 points.
  potential combinations of risk factors
DCD Risk 
Score 
≤10 
points
No retransplantation [0] + recipient MELD ≤25 points [0] + recipient age ≤60 yr [0] + cold 
ischaemia time >6 h [2] + functional donor warm ischaemia >20 to ≤30 min [3] + donor age 
≤60 yr [0] + donor BMI ≤25 [0]
No retransplantation [0] + recipient MELD >25 points [2] + recipient age ≤60 yr [0] + cold 
ischaemia time ≤6 h [0] + functional donor warm ischaemia time >30 min [6] + donor age ≤60 
yr [0] + donor BMI ≤25 [0]
No retransplantation [0] + recipient MELD >25 points [2] + recipient age >60 yr [3] + cold 
ischaemia time >6 h [2] + any functional donor warm ischaemia >20 to ≤30 min [3] + donor 
age ≤60 yr [0] + donor BMI ≤25 [0]
No retransplantation [0]+ any functional donor warm ischaemia up to ≤30 min [0–6] + any 
donor age [0–2] + any recipient MELD [0–2]
No retransplantation [0]+ functional donor warm ischaemia >20 to ≤30 min [0–3] + any donor 
age [0–2] + any donor BMI [0–3] + any recipient MELD [0–2]
Retransplantation [9] + recipient MELD ≤25 points [0] + recipient age ≤60 yr [0] + cold 
ischaemia time ≤6 h [0] + functional donor warm ischaemia ≤20 min [0] + donor age ≤60 yr [0] 
+ donor BMI ≤25 [0]
DCD Risk 
Score > 
10 points
No retransplantation [0] + recipient MELD >25 points [2] + recipient age >60 yr [3] + cold 
ischaemia time >6 h [2] + functional donor warm ischaemia >20 to ≤30 min [3] + donor age 
>60 yr [2] + donor BMI ≤25 [0]
No retransplantation [0] + recipient MELD >25 points [2] + recipient age ≤60 yr [0] + cold 
ischaemia time >6 h [2] + functional donor warm ischaemia >30 min [6] + donor age >60 yr [2] 
+ donor BMI ≤25 [0]
No retransplantation [0] + recipient MELD >25 points [2] + recipient age >60 yr [3] + cold 
ischaemia time >6 h [2] + functional donor warm ischaemia >30 min [6] + donor age >60 yr [2] 
+ donor BMI ≤25 [0]
Retransplantation [9] + recipient MELD >25 points [2] + recipient age ≤60 yr [0] + cold 
ischaemia time ≤6 h [0] + functional donor warm ischaemia ≤20 min [0] + donor age ≤60 yr [0] 
+ donor BMI ≤25 [0]
Retransplantation [9] + recipient MELD >25 points [2] + recipient age ≤60 yr [0] + cold 
ischaemia time >6 h [2] + functional donor warm ischaemia >20 to ≤30 min [3] + donor age 
>60 yr [2] + donor BMI ≤25 [0]
BMI, body mass index; CIT, cold ischaemia time; DCD, donation after circulatory death; fDWIT, func-
tional donor warm ischaemia time; h, hours; MELD, Model of end stage; liver disease; min, minutes; 
UKELD, United Kingdom model of end-stage liver disease; yr, years.
*Numbers in parenthesis correspond to DCD Risk Score points.
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the new prediction model. Increasing risk is transmitted by increasing score points 
resulting in significantly impaired early liver function (INR day one: 1.5 vs. 1.7 vs. 2.0, 
p=0.0001, p=0.0005; Suppl. Figure 4) and higher liver enzyme release (median peak 
ALT during first week after transplant (787 vs. 1116 vs. 1906, p=0.0004; p=0.0002). In 
addition, ICU and hospital stay after DCD transplantation increased significantly from 
low risk to futile score group (Suppl. Figure 4). Overall post-transplant morbidity was 
summarized by the CCI (34), where the new DCD prediction score was associated 
with a significantly increased median CCI throughout the three risk groups (p<0.0001, 
p=0.0093; Suppl. Figure 4).
table 4. Aetiology of graft loss according to the UK DCD Risk Score in the UK, UNOS, and Bir-
mingham DCD cohorts.
outcome parameter overall
low risk High risk futile p value p value
(0-5 
points)
(6-10 
points)
(>10 
points)
low vs. 
high risk
high risk 
vs. futile
UK (n=) 689 396 200 93
Cause of graft failure
PNF 29 (4.2%) 2 (0.5%) 2 (1.0%) 25 (26.9%) 0.605 0.001
HAT 14 (2.0%) 1 (0.3%) 4 (2.0%) 9 (9.7%) 0.045 0.005
ITBL 26 (3.8%) 5 (1.3%) 6 (3.0%) 15 (16.2%) 0.194 0.001
One-year graft survival (%) 85% 96% 85% 37% <0.001 <0.001
UNOS (n=) 1617 925 455 237
Cause of graft failure
PNF 87 (5.4%) 21 (2.3%) 12 (2.6%) 54 (22.8%0 0.709 <0.001
HAT 32 (2.0%) 7 (0.7%) 2 (0.4%) 23 (9.7%) 0.726 <0.001
ITBL 58 (3.6%) 9 (1.0%) 4 (0.9%) 45 (19.0%) 1 <0.001
One-year graft survival (%) 75% 85% 80% 33% <0.001 <0.001
Birmingham (n=) 300 158 108 34
Cause of graft failure
PNF 9 (3.0%) 2 (1.3%) 2 (1.9%) 5 (14.7%) 1 0.009
HAT 17 (5.7%) 7 (4.4%) 6 (5.6%) 4 (11.8%) 0.775 0.133
ITBL 19 (6.3%) 5 (3.2%) 7 (6.5%) 7 (20.6%) 0.236 0.041
One-year graft survival (%) 85% 91% 85% 53% <0.001 <0.001
DCD, donation after circulatory death; HAT, hepatic artery thrombosis; IC, ischaemic cholangiopa-
thy; PNF, primary non-function; UNOS, United Network for Organ Sharing.
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discussion
Our search for a new score to optimize justice and utility for DCD liver allocation 
has led to several new findings. First, by combining a few major donor and recipient 
parameters, we developed a simple score system which best stratifies recipient graft 
loss after DCD liver transplantation, as compared to other recent developed predic-
tion concepts. Second, this score proved to be highly discriminatory for PNF and ITBL 
in both, the national UK (NHSBT) and US (UNOS) databases. Third, our calculations 
represent the largest analysis of DCD liver transplant recipients. Fourth, the new 
model correlates well with post-transplant morbidity throughout all three risk clusters.
Risk assessment in liver transplants has been repeatedly addressed by several studies 
but is usually limited to the main endpoints mortality or graft loss. In addition, it ap-
pears arbitrary which thresholds and which combinations of parameters in a critical ill 
patient predict outcome. Currently, the most convincing calculations of risk prediction 
in liver transplantation base on a relatively limited number of key parameters leading 
to varying score points according to their regression coefficients. The sum of such 
scores expresses the total risk up to a risk threshold (balance principle) (18,19,35). 
However, while risk scores have been implemented in DBD liver transplantation, their 
application in DCD liver transplants is limited, as the DCD population is by far smaller 
in most countries, and parameters depicting higher graft injury are less well defined. 
Importantly, graft loss due to PNF and ITBL is a major and much more relevant 
problem in DCD liver transplantation in contrast to DBD liver transplantation, and 
justifies from our point a new effort to find a formula of their prediction, based on a 
national analysis.
Minimizing the sum of risk is an old principle in surgery, and many transplant profes-
sionals automatically aim to allocate DCD livers to low MELD primary liver transplant 
candidates (10,22). This established approach has led to a significantly improved 
early patient survival after DCD grafting (12,22). However, the precise impact of 
different donor/recipient combinations on graft failure is unclear. Two groups have 
developed models to predict the likelihood of graft survival after DCD liver transplan-
tation (17,33). In one detailed analysis, Khorsandi et al identified six donor, graft and 
recipient factors to predict graft failure after transplantation by the DCD-RI, which 
combines functional DWIT, duration of donor hepatectomy, cold ischemia time, 
recipient MELD, underlying liver disease and retransplantation (33). DCD transplant 
cases are not equally distributed to the three risk clusters of this score from KCH. In 
contrast to the lowest risk group, which includes only a very small number of DCD 
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transplant cases (11.5%; 69/598), almost 40% are allocated to the highest risk group 
(235/598) and majority of DCD transplantations are classified into the “standard” risk 
group (50%; 294/598). Based on the number of score points allocated to each case 
at parameter cut-offs, the KCH DCD – RI showed inferior prediction in terms of graft 
loss. For example, one main risk factor in DCD liver transplantation, the functional 
DWIT, contributes to only 1 score point, when ranging above 25 minutes (53/677 
in UK DCD cohort, 7.8%). According to this score, majority of DCD livers receive 
zero points for an already prolonged functional DWIT of up to 25 minutes (624/677; 
92.2% of UK DCD cohort). A similar picture occurs from the parameter cold ischemia 
time, where the maximum of only 1 parameter point is distributed, when exceeding 
10 hours. In UK only, a few DCD grafts experience such long storage times (67/1153; 
5.8 %). In contrast, majority of points (three) are allocated to recipients with hepatitis 
C virus infection, alcohol related liver disease, cryptogenic liver cirrhosis or Budd-
Chiari syndrome as indication for liver transplantation. Such parameters, alone may 
not predict graft loss based on DCD-related complications (PNF and ITBL), but due 
to recurrence of the underlying disease. In addition, three score points are allocated 
to DCD liver recipients with an elevated lab MELD of >25 points, which appears 
only in a limited number of DCD transplantations in UK (59/691; 8.5%). Thus, the 
DCD-RI from KCH seems less suitable to stratify post-transplant graft survival when 
compared to the new UK DCD risk score.
Another risk model has been calculated to identify risk combinations, the UCLA-DCD 
Score, being a combination of 6 variables, e.g. donor HBV-core antibody positivity 
and functional warm ischemia (MAP <60mmHg to flush), cold storage time, recipient 
MELD, recipient BMI, retransplantation and underlying liver disease in the recipient 
(17). The highest predictive factor with 3 points was HCV positivity combined with 
HCC in this score, which may end up predicting graft loss due to HCV recurrence 
rather than PNF or ITBL. Secondly, the impact of Hepatitis C positivity will change 
in the near future due to the direct-acting antiviral medications (36). In addition, 
important predictors of early graft failure, e.g. functional DWIT contributed only with 
one score point. An additional score factor, selected by the authors of the UCLA-
DCDs core, published in 2011, was donor HBV-core antibody positivity, which is 
expressed in only very few cases in the UK DCD cohort (14/1153; 1.2%). Thus, the 
UCLA-DCD score was also inferior in predicting graft survival (Figure 3). To develop 
a meaningful prediction model, ideally this should base on clinically relevant score 
parameters, which are of great importance in all countries with DCD liver transplanta-
tion (35,37,38).
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In contrast to the above-mentioned calculations, our prediction model discriminated 
best in terms of graft survival below and above a cut-off of 10 (table 4; figure 1-4). 
Based on this, donor - recipient combinations with more than 10 points are exposed 
to a high risk of graft loss due to clinically relevant and DCD related complications, 
such as PNF or IC (table 4). In addition, the new model significantly correlates with 
post-transplant morbidity.
Our model has also shortcomings. First, we failed to include graft steatosis in our 
calculation due to limited donor liver biopsies in the UK. Nevertheless, a correlation 
of BMI and steatosis has been shown in a recent study (39), and we have been able 
to demonstrate donor BMI as independent predictor. Second, most DCD recipients 
in UK have a low MELD score at time of transplantation (median lab MELD 15 points), 
because DCD liver allocation is excluded from MELD allocation. Third, cut-off defini-
tions for higher risk based on graft survival deterioration with however further impact 
on complications. For example, candidates in the high-risk group (6 -10 score points) 
are exposed to significantly higher rate of graft loss due to IC. This high-risk group 
would therefore, benefit from a graft treatment prior to implantation (40). In this 
context, machine perfusion approaches such as hypothermic oxygenated perfusion 
(HOPE) have been previously shown to reduce reperfusion injury and intrahepatic 
biliary complications after transplantation of human DCD livers (41–43). In addition, 
ex-situ graft evaluation during normothermic or hypothermic machine liver perfusion 
might be a useful tool to test liver viability, though better markers of graft function 
during these approaches are urgently needed (44–46).
One of the advantages of UK DCD risk score is that it derives from objective factors, 
readily available at the time of an organ offer, with the exception of warm and cold 
ischemia. However, as the liver retrieval starts and the functional DWIT becomes 
available, the score can be recalculated with a fairly precise prediction of cold isch-
emia. At this stage, the score values may suggest a different decision regarding the 
use of the graft and/or the choice of a different local recipient. In the future, we will 
calculate the score system at organ offer. When donor/recipient combinations result 
in more than 10 points, we will either try to find a different recipient to decrease 
the overall risk and secondly perform graft treatment by machine perfusion prior to 
implantation. In addition, future models should also consider the amount of graft 
steatosis and the impact on the score threshold whether to accept a DCD liver for 
a certain recipient or not (47). Though more reliable methods of fat quantification 
are urgently needed, analysis of graft biopsies provide additional information on 
the amount of steatosis and therefore help to decide which DCD liver to accept or 
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how to adapt the preservation technique for a specific risk combination. Due to the 
fact that important risk parameters, e.g. WIT, are frequently missing or incomplete 
in nationwide databases, further multicentre cohort studies are required to refine 
existing and new scoring systems. More specifically, an outcome study including 
DCD transplants from multiple centres in Europe and US, has been initiated and 
will enable us to first provide another validation of our new model and second to 
demonstrate the effective relation between the number of risk points per DCD case 
and specific complications in the recipient.
In summary, we believe that the UK DCD Risk Score may be a very practical and new 
guidance for allocation of a specific organ to a recipient, and helps also to decide 
which DCD liver requires processing with a new preservation technology, including 
machine perfusion. This would potentially help to implement such expensive ap-
proaches more specifically.
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kidney pRoblems in liveR tRansplantation
Renal complications are an important issue after liver transplantation. Many patients 
with ESLD awaiting a liver transplant have renal impairment and they are at risk for 
short- and long-term renal problems afterwards. AKI is frequently observed in the 
early postoperative phase and is the result of several donor, recipient and surgical 
risk factors. A significant proportion of the recipients will be in need of peri-operative 
RRT and not all of them have a full recovery of kidney function and will develop 
CKD, and in some cases ESRD, requiring long-term RRT or kidney transplantation. 
Considering the growing pre-transplant renal problems due to the ‘sickest-first’ al-
location policy in many countries and the increased use of marginal grafts in liver 
transplantation, the rate of renal complications is likely to increase. In this chapter we 
will discuss the renal problems in patients with ESLD and risk factors for development 
of AKI and CKD after liver transplantation.
Renal failure in cirrhosis
Patients with ESLD will frequently present with AKI due to ascites with subsequent 
volume depletion or episodes of spontaneous bacterial peritonitis. On the other 
hand, some have a slower decrease in kidney function over the years of developing 
decompensated cirrhosis. The majority of kidney function in ESLD is thought to be 
functional (rather than damage) and related to hemodynamic disbalances (1). The 
portal hypertension in cirrhosis causes primary arterial vasodilatation in the splanch-
nic circulation, leading to a reduction in the systemic vascular resistance. Increased 
cardiac output can compensate for this reduction initially, but in advanced stages 
of cirrhosis the systemic vascular resistance will be so much reduced the cardiac 
compensation is not sufficient (figure 1). This will lead to hypovolemia and subse-
quent activation of vasoconstrictor systems will keep up the arterial blood pressure, 
but will impair the kidneys, leading to more ascites and renal vasoconstriction and 
hypoperfusion (2). There are four types of renal failure in ESLD: (I) the hepatorenal 
syndrome (HRS), (II) hypovolemia-induced renal failure, (III) parenchymal renal dis-
ease and (IV) drug-induced renal failure (1). HRS is the far most common form and 
can be divided into HRS-type 1 or HRS-AKI and HRS-type-2. HRS-type 1 classically 
presents like AKI within several days which usually responds well to medical therapy 
with vasoconstrictors (i.e. terlipressin), and is often related to a precipitating factor, 
such as spontaneous bacterial peritonitis, gastrointestinal haemorrhage or acute-on-
chronic liver failure (3). HRS-type 2 has a more gradual decrease in kidney function 
(>two weeks) and often severe ascites, resistant to diuretic therapies (4). The MELD-
score was developed in 2000 to predict mortality in patients undergoing transjugular 
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intrahepatic portosystemic shunt for refractory ascites and soon this prediction 
model was implemented in the US and many European countries to allocate grafts 
for liver transplantation (5–7). The MELD-score consists of three pillars: coagulopathy 
(INR), impaired bilirubin metabolism (serum bilirubin), and renal dysfunction (serum 
creatinine). A patient gets additional points, when he or she is in need of regular RRT, 
acknowledging the importance and predictive value of renal dysfunction in patients 
on the liver transplant waiting list. As a result, patients undergoing a liver transplant 
have more frequently severe renal dysfunction over the last years, increasing the risk 
for renal problems after the liver transplantation (8–10).
acute kidney injury after liver transplantation
Several centres have reported their experience with AKI after liver transplantation, 
with incidence rates ranging from 24% to 85% (11–24). This wide variance is partly 
figure 1 – Pathogenesis of circulatory abnormalities and renal failure in cirrhosis.
From Ginès et al, New Eng J Med, 2009 (1).
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used for AKI over the last years. Officially, AKI is defined by either an increase in 
serum creatinine levels or decrease or loss of urine output. However, since serum 
creatinine levels are most widely available and more accurately measured than urine 
output in the daily practice, almost all studies only use the creatinine levels to define 
AKI after liver transplantation. The Kidney Disease Improving Global Outcomes 
(KDIGO)-criteria are considered as the most up-to-date and is used in most of the 
recent literature.
Risk factors for acute kidney injury
Postoperative AKI is the result of the combination of donor, graft, recipient and 
surgical risk factors. Furthermore, the early use of nephrotoxic immunosuppression 
after the liver transplant increases the risk for AKI (15,17,22,28). The peri-operative 
practice in liver transplantation is very diverse worldwide and the numerous studies 
evaluating factors associated with AKI identified different risk factors. The literature 
(US National Library of Medicine - PubMed online database) since 2000 was screened 
for factors associated with development of AKI (acute kidney injury or acute renal 
failure) after liver transplantation. An overview of independent risk factors (using 
multivariable regression analysis) that were identified in at least two single-centre 
experiences were included, which is shown in table 2. The preoperative MELD-score 
was identified by most previous studies, other recipient factors included the serum 
creatinine, a raised BMI and history of DM. The use of DCD grafts and a longer 
recipient WIT during the transplant have an impact on AKI development as well. 
table 1 – Criteria based on serum creatinine levels to classify AKI after liver transplantation.
criteria stages year
RIFLE 
(25)
§ Risk: increased creatinine x 1.5 oR decreased GFR >25% from baseline
§ Injury: increased creatinine x 2.0 oR decreased GFR >50%
§  Failure: increased creatinine x 3.0 oR decreased GFR >75% oR creatinine level 
≥354 µmol/L with an acute rise of ≥ 44.2 µmol/L
§ Loss: complete loss of renal function for >4 weeks (renal replacement therapy)
§ End stage renal disease: no recovery of kidney function
2004
AKIN 
(26)
§ Stage 1: increased creatinine x 1.5 oR ≥26.4 µmol/L from baseline (within 48h)
§ Stage 2: increased creatinine x 2.0
§  Stage 3: increased creatinine x 3.0 oR creatinine level ≥354 µmol/L with an acute 
rise of ≥ 44.2 µmol/L oR requiring renal replacement therapy
2007
KDIGO 
(27)
§  Stage 1: increased creatinine x 1.5 (within 7 days) oR ≥26.4 µmol/L (within 48h) 
from baseline
§ Stage 2: increased creatinine x 2.0
§ Stage 3: increased creatinine x 3.0 oR creatinine level ≥354 µmol/L with an acute 
rise of ≥ 44.2 µmol/L oR requiring renal replacement therapy
2012
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Furthermore, blood loss with subsequent transfusion requirements and the use of 
vasopressors were identified by multiple centres. As expected, overexposure to 
calcineurin inhibitors was associated with AKI.
Graft quality and acute kidney injury
The Birmingham group showed a simultaneous increase in incidence of AKI after 
liver transplantation with the evolving use of marginal grafts, and especially with 
DCD grafts (21,29). In both studies, the postoperative release of transaminases was 
an independent factor associated with AKI, representing the severity of hepatic IRI as 
the link between graft quality and development of AKI. Interestingly, in a subgroup 
table 2 – Factors associated with development of AKI after liver transplantation
 Risk factor References
Donor / 
Graft
§ Use of a DCD graft Leithead 2012 (29), Doyle 2015 (30)
§ Duration of recipient warm ischemia 
time
Leithead 2014 (21), Barreto 2015 (14), Park 2015 (15), 
Zongyi 2017 (28)
Recipient § Preoperative serum creatinine Gallardo 2004 (11), Sanchez 2004 (31), O’Riordan 
2007 (12), Wadei 2016 (32), Zongyi 2017 (28)
§ Raised BMI Iglesias 2010 (17), Park 2015 (15), Hilmi 2015 (33)
§ Non-Caucasian race Contreras 2002 (34), Iglesias 2010 (17)
§ Diabetes mellitus Utsumi 2013 (22), Hilmi 2015 (33)
§ Viral hepatitis Barreto 2015 (14), Wadei 2016 (32)
§ APACHE-II-score Gallardo 2004 (11), Zhu 2010 (35)
§ MELD-score Sanchez 2004 (31), Zhu 2010 (35), Klaus 2011 (36), 
Utsumi 2013 (22), Romano 2013 (23), Kim 2014 (37), 
Park 2015 (15)
§ Child-Pugh-score Iglesias 2010 (17), Fonseca-Neto 2011 (20), Hilmi 
2015 (33)
§ Blood urea nitrogen Contreras 2002 (34), Sanchez 2004 (31)
§ Hypoalbuminemia Chen 2011 (19), Park 2015 (15), Cabezuelo (38)
Surgical § Operation time Park 2015 (15), Wadei 2016 (32)
§ Blood loss Utsumi 2013 (22), Hilmi 2015 (33), Park 2015 (15), 
Zongyi 2017 (28)
§ Red blood cell transfusion Contreras 2002 (34), Gallardo 2004 (11), Chen 2011 
(19), Park 2015 (15), Wadei 2016 (32)
§ Inotrope/vasopressor requirement Sanchez 2004 (31), Chen 2011 (19)
§ Postreperfusion syndrome Fonseca-Neto 2011 (20), Park 2015 (15)
Post-
operative
§ Calcineurin inhibitor (overexposure) Iglesias 2010 (17), Utsumi 2013 (22), Park 2015 (15), 
Zongyi 2017 (28)
§ Transaminase peak Contreras 2002 (34), Leithead 2014 (21), Rahman 
2017 (39), Jochmans 2017 (40)
§ Prolonged dopamine use Cabezuelo (38), Zongyi 2017 (28)
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analysis of DBD grafts, these peak transaminase levels were also higher in recipients 
with post-transplant AKI (41). Several factors impact on graft quality. Grafts from older 
donors, steatotic graft and DCD grafts are known to be more susceptible to hepatic 
IRI, as are grafts who experience longer cold and warm ischemia times (42–47). It is 
known that hepatic IRI induces a systemic inflammatory response similar as seen in 
sepsis (48). The subsequent release of pro-inflammatory cytokines and reactive oxy-
gen species causes renal injury (figure 2) (49). Although the pathogenesis between 
hepatic IRI and development of AKI is not fully understood yet, there is evidence that 
the release of these cytokines (including TNF-α) leads to dysregulation of endothelial 
adhesion molecules and renal endothelial cell apoptosis, which promotes leukocyte 
recruitment in the interstitial space, causing renal injury (50–52). The reactive oxygen 
species released by activated neutrophils cause direct renal damage and recruitment 
of leukocytes like monocytes and macrophages further aggravate the oxidative injury 
in the kidney (53).
figure 2 – overview of the mechanism causing AKI after hepatic ischemia/reperfusion injury
From Nastos et al, Oxidative Medicine and Cellular Longevity, 2014 (49).
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Acute kidney injury biomarkers
Over the last years, several serum and urine biomarkers for the prediction for AKI 
after liver transplantation have been identified. The most common cause of AKI 
in this setting is acute tubular necrosis. Therefore, markers of acute tubular injury, 
including kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin 
(NGAL), and interleukin-18 (IL-18) are the main subject of interest (54). In a recent 
study evaluating the relationship between postreperfusion gene expression, serum 
mediator and development of postoperative AKI revealed that a combination of 
endothelin-1 (ET-1) and IL-18 expression was highly predictive for AKI (55).
Acute kidney injury in relation to other outcomes after liver transplantation
Development of AKI after liver transplantation does not stand on its own. Due to the 
intense relation with hepatic IRI, recipients developing (severe) AKI are also likely to 
experience other complications, including infections and the need for a reoperation 
in the first days after liver transplantation with an prolonged admission in intensive 
care and in the hospital (11,19,34,39). Postoperative AKI in general is related with 
increased use of hospital resources and costs and previous studies have also linked 
AKI to an increased risk for graft loss (19,28,56,57). Furthermore, there is a clear rela-
tion between AKI and recipient mortality on the short and long-term, especially in 
recipients that require RRT in the early postoperative phase (12,14,34–36). Although 
most recipients recover from the direct renal damage in the following months after 
liver transplantation, Ojo et al already reported in 2003, that postoperative AKI 
requiring RRT is a risk factors for development of CKD, which was later confirmed by 
several single-centre experiences (29,32,33,58).
development of chronic kidney disease after liver transplantation
In the US nationwide study from Ojo and colleagues including 69.321 recipients of 
non-renal organs, the 5-year cumulative incidence of severe CKD (eGFR <30 ml/
min/1.73 m2) was 18% for liver transplantation recipients (58). This is relatively high, 
compared to recipients of heart (11%) and lung (16%) transplants, even though liver 
transplant recipients require less nephrotoxic immunosuppression. Other studies 
reported observed overall CKD (eGFR <30 ml/min/1.73 m2) in 39% up to 78% of the 
recipients (16,33,59,60). Severe CKD and ESRD incidence rates reached from 6% to 
18% and 1% to 12%, respectively (16,32,33,60–63). figure 3 shows the course of 
renal function over 25 years after liver transplantation in a US large cohort with more 
than 1.000 recipients (60). This study (and several others) has shown that recipients 
who develop CKD after liver transplantation have an increased mortality-risk, espe-
cially when the eGFR drops <30 ml/min/1.73 m2 (58,64,65).
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Risk factors for CKD
Similar to AKI after liver transplantation, CKD has a multifactorial origin. Sharma 
et al introduced the three-hit model with risk factors contributing to the develop-
ment of post-transplant CKD (figure 4) (66). The first hit is the combination of 
pre-transplant renal impairment due to HRS, glomerulonephritis, comorbidities such 
figure 3 – Course of renal function after liver transplantation
From Allen et al, Journal of Hepatology, 2014 (60).
figure 4 – the three-hit model of risk factors for development of CKD after liver transplantation
From Sharma et al, Advances in Chronic Kidney Disease, 2015 (66).
Chapter 6
104
as hypertension and DM, and additional acute tubular necrosis due to episodes of 
sepsis (1,58,59,67–70). The second hit happens peri-operatively: blood loss and 
hypotensive episodes during the transplant procedure and postoperative complica-
tions such as infections, bleeding and biliary complications further impact on kidney 
function. As described above, the use of marginal grafts increase the severity of 
hepatic IRI with subsequent AKI, potentially increasing the risk for renal impairment 
on the long-term. The third hit is the result of immunosuppression that not only has 
direct nephrotoxic consequences, but long-term use of calcineurin inhibitors and 
steroids also increase the risk for post-transplant metabolic syndrome. This syndrome 
and its individual components DM and hypertension have a further negative impact 
on kidney function (66,71,72).
Recovery of renal function after liver transplantation
Up to one fourth of the recipients with AKI require RRT in the first weeks after liver 
transplantation (12,21,37,73). This group is a mix of those who have with pre-trans-
plant renal failure, those who have a difficult transplant procedure and/or postopera-
tive complications. Recovery of renal function ranges from 70% to 98%, which mostly 
depends on the duration of RRT prior to liver transplantation (62,64,69,74–76). Other 
risk factors for non-recovery of kidney function include recipient age, MELD-score 
and pre-existing DM (69,74–76). In a study with 155 patients requiring post-transplant 
RRT the average duration until recovery was 33 days and after one year 83% was not 
dialysis dependent anymore (74). It should be noted that in most countries there is 
a thorough and careful selection of patients who are likely to not recover from their 
renal failure and they are offered a simultaneous liver and kidney transplant (68,77).
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summaRy
AKI is frequently observed after DBD liver transplantation and associated with im-
paired recipient survival and chronic kidney disease. Hepatic IRI is suggested to be 
an important factor in this process. PRS is the fi rst manifestation of severe hepatic 
IRI directly after reperfusion. We performed a retrospective study on the relation 
between hepatic IRI and PRS and their impact on AKI in 155 DBD liver transplant 
recipients. Severity of hepatic IRI was measured by peak postoperative AST levels 
and PRS was defi ned as >30% decrease in MAP ≥1 minute <5 minutes after reperfu-
sion. AKI was observed in 39% of the recipients. AKI was signifi cantly more observed 
in recipients with PRS (53 vs. 32%; p=0.013). Median peak AST level was higher in 
recipients with PRS (1388 vs. 771U/L; p<0.001). Decrease in MAP after reperfusion 
correlated well with both severity of AKI (p=0.012) and hepatic IRI (p<0.001). Multiple 
logistic regression identifi ed PRS as an independent factor for postoperative AKI 
(OR 2.28; 95% CI 1.06-4.99; p=0.035). In conclusion, PRS refl ects severe hepatic IRI 
and predicts AKI after DBD liver transplantation. PRS immediately after reperfusion 
is an early warning sign and creates opportunities to preserve postoperative renal 
function.
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intRoduction
AKI is a common complication after liver transplantation with a reported incidence 
of 20 to 78% (1–6). Recipients developing AKI have an impaired short- and long-
term survival and an increased risk to CKD (3–8). Furthermore, it is associated with 
an increased length of hospital stay, utilization of resources and costs of care (9). 
The etiology of AKI after liver transplantation is multifactorial and not completely 
understood. Besides pre-operative renal function, known risk factors include sever-
ity of liver disease (MELD score), recipient age and co-morbidities such as DM and 
hypertension (3,7,10). After liver transplantation calcineurin inhibitor nephrotoxicity 
is considered to be a major risk factor for renal failure (11–13). Next to these classic 
risk factors, graft characteristics are increasingly being recognized as contributors 
to the development of AKI after liver transplantation(14). A comparative study by 
Leithead et al. showed that AKI was more frequent when DCD grafts were used 
(54%) compared to DBD grafts (32%) (1). The obligatory extra DWIT in DCD liver 
transplantation appears to be responsible for this higher incidence of AKI. However, 
the majority of liver transplantations with deceased donors are still performed using 
DBD grafts (15,16). With AKI developing in one third of DBD recipients, it remains 
an important complication after DBD liver transplantation. Hepatic IRI, giving rise to 
a systemic inflammatory response similar as seen in sepsis and multi-organ failure, is 
the predominant factor associated with postoperative AKI after DBD liver transplan-
tation (2,17–20).
Currently, graft biopsies at reperfusion and peak serum AST levels until 72 hours 
after liver transplantation are being used to quantify the severity of hepatic IRI 
(21–23). These diagnostic modalities do not allow early recognition nor quantifica-
tion of hepatic IRI at reperfusion during the operation. However, early identification 
of severe hepatic IRI is pivotal to facilitate possible preventive measures to preserve 
renal function. An early indicator of severe hepatic IRI in liver transplantation is PRS. 
PRS is characterized by a decrease in systemic vascular resistance, hypotension, im-
paired cardiac output and an increased pulmonary vascular resistance directly after 
reperfusion (24). This hemodynamic phenomenon has an incidence between 12% 
and 55% and is associated with higher in-hospital mortality (25–29). Knowing hepatic 
IRI is a risk factor for development of postoperative AKI and PRS is a manifestation 
of severe hepatic IRI, recognition of PRS could allow early identification of recipients 
at risk for AKI after DBD liver transplantation. Paugam-Burtz et al. has demonstrated 
in a retrospective study about the consequences of PRS that this phenomenon is 
associated with an increase of postoperative severe renal dysfunction (eGFR < 30ml/
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min) (25). However, this relatively small study did not focus on postoperative renal 
injury and did not investigate a linear correlation between hemodynamic instability 
after reperfusion and the severity of postoperative renal injury.
The aim of our study was first to analyze the effect of PRS on the development of 
postoperative AKI and second to explore the relation between hemodynamic insta-
bility after reperfusion and the severity of hepatic IRI in DBD liver transplantation.
metHods
This retrospective study was performed with approval of the Erasmus University Medi-
cal Center Rotterdam Institutional Review Board (MEC-2014-670). All consecutive 
patients who underwent first DBD liver transplantation in our center from July 2008 
until October 2014 were included. Exclusion criteria were liver transplantation for 
acute liver failure, urgent retransplantation in the first week of follow up, living-donor 
liver transplantation, combined liver-kidney transplantation and AKI diagnosed in the 
week prior to liver transplantation.
Recipient baseline characteristics at time of admission (age, gender, etiology of liver 
disease, HCC, serum sodium, creatinine, bilirubin, and INR) were collected. The 
estimated glomerular filtration rate (eGFR) was calculated using the Modification 
of Diet in Renal Disease Study 4-variable equation: 186 x (serum creatinine (umol/L) 
/ 88,4)- 1,154 x age (in years)- 0,203 x 0,742 (if woman) x 1,212 (if black), as was MELD 
score (30). Relevant medical history (hypertension, insulin dependent diabetes mel-
litus (IDDM) and coronary artery disease) was recorded. Presence of ascites, either 
diuretic controlled or refractory, was evaluated by historic evidence of ascites by 
CT-scan (31). The DRI, was calculated to assess graft quality (32). During surgery re-
cipient’ hemodynamics were monitored using an intra-arterial and pulmonary artery 
catheter. Continuous infusion of norepinephrine was adjusted to target a MAP of 70 
mmHg. Hypotension after reperfusion was treated with single-dose administration 
of epinephrine. Infusion of norepinephrine was registered throughout surgery. The 
regular fluid regimen during surgery consisted of the combined use of crystalloids, 
hydroxyethyl starches, transfusions of RBC, FFP and platelets. Albumin 20% (200cc) 
was administered to every recipient at the end of surgery. Standard surgical tech-
nique included piggyback cavocaval anastomosis without the use of a portocaval 
shunt or veno-venous bypass. Reperfusion was induced after portal anastomosis 
before completion of arterial and biliary anastomosis. Length of cold ischemia time 
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and WIT, intraoperative blood loss with subsequent transfusion were recorded. MAP 
was documented at start of the surgical procedure, prior to reperfusion, lowest 
MAP in the first 5 minutes following reperfusion and then 15, 30, 45 and 60 minutes 
after reperfusion. PRS was defined as a decrease of >30% in MAP lasting at least 
one minute within the first five minutes after reperfusion (24). The peak serum AST 
level in the first 72 postoperative hours was used as a marker for hepatic IRI. This 
parameter has previously been used to describe the effect of hepatic IRI on AKI in 
liver transplantation by Leithead et al and is used as a marker for EAD as well (33–35). 
Postoperative serum creatinine levels were collected daily in the first week after liver 
transplantation. AKI was defined according to AKIN criteria (36): stage 1; ≥1.5 times 
baseline serum creatinine level or an increase of 26.5 umol/L above baseline, stage 
2; >2 times baseline level, and stage 3; >3 times baseline level or requirement of RRT 
all within 48 hours. Postoperative AKI was divided into mild AKI (AKIN stage 1) and 
severe AKI (AKIN stage 2&3).
The postoperative immunosuppression regimen changed during the study period. 
In the first 3.5 years the regimen included tacrolimus from postoperative day 0 
(target trough serum concentration (C0) of 8-12 ug/L), prednisolone for 3 months 
and intravenous basiliximab (20mg) on postoperative day 0 and 4. In the last three 
years tacrolimus introduction was delayed until day 5 and MMF was added from 
day 0 and withdrawn after adequate concentrations of tacrolimus were reached. The 
immunosuppression was adjusted in case of impaired renal function or infection. As 
a surrogate marker for potential tacrolimus nephrotoxicity, the highest trough serum 
tacrolimus level (C0) in the first postoperative week was recorded. Length of hospital 
and ICU stay, recipient and graft survival up to one year were documented. All major 
postoperative complications during hospitalization were documented where major 
postoperative complications were defined as grade ≥ 3a by the Clavien Dindo clas-
sification (37).
statistical analysis
Data were analyzed using IBM SPSS Statistics version 21 (IBM Corporation, Armonk, 
NY, USA). Continuous variables were tested for normality with the Shapiro-Wilk test. 
The student’s t test and the one-way analysis of variance (ANOVA) were used to com-
pare normally distributed continuous variables. Nonparametric continuous variables 
were compared using the Mann-Whitney U test. To compare categorical variables the 
Chi-square test or the Fisher’s exact test were used. P-values < 0.05 were considered 
statistically significant. Continuous variables were expressed as mean with standard 
deviation (SD) or median and interquartile range (IQR), where appropriate. Long-
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term survival rates were estimated using Kaplan-Meier methods. Recipient, donor 
and peri-operative variables with a p-value <0.1 in univariable analysis were included 
in a multiple logistic regression model to identify predictors for postoperative AKI.
Results
During the study period 206 patients underwent first DBD liver transplantation of 
which 155 were included. Forty-eight recipients were excluded: 36 for acute liver 
failure, three with retransplantation within the first week of follow up, three living do-
nor liver transplants, four combined liver-kidney transplantations and two recipients 
who developed AKI prior to liver transplantation. Additionally three recipients were 
excluded because of incomplete intraoperative data.
Recipient, graft, and surgical characteristics
table 1 shows the preoperative recipient and graft characteristics. Two third (68%) of 
the recipients were men and median age was 54 years. The majority of etiology of 
liver diseases could be divided into three groups: biliary cirrhosis (39%), viral hepatitis 
(19%), and post-alcoholic cirrhosis (15%). Median lab MELD score was 16 and median 
preoperative recipient’ creatinine levels were 72 umol/L. Surgical characteristics are 
displayed in table 2. Median length of cold ischemia and WIT was respectively 6.2 
hours and 28 minutes. Median blood loss during surgery was 4.0 liters. PRS was ob-
served in 53 (34%) of the recipients and the mean decrease in MAP post-reperfusion 
was 14 mmHg. Median average dose of continuous norepinephrine infusion was 0.17 
ug/kg/min. The peak postoperative serum AST level was 930 U/L. The induction of 
tacrolimus therapy was in 65 (42%) of the recipients before the fifth postoperative 
day. The median highest peak C0 in this group was 6.4 ug/L.
postoperative acute kidney injury
Sixty-one recipients (39%) developed AKI in the first week, of whom 71% developed 
AKI within the first two days. Of this 61 recipients, 47 recipients (77%) developed 
mild AKI (AKIN stage 1) and 14 recipients (23%) developed severe AKI (AKIN stage 
2: 8 recipients; AKIN stage 3: 6 recipients). RRT was required in 5 of the 61 recipients 
(8%) during their hospital stay. To identify factors associated with postoperative AKI 
an univariable and subsequent multiple logistic regression analysis was performed. 
Preoperative serum creatinine and eGFR, length of cold ischemia and WIT, RBC 
transfusion, occurrence of PRS and average dose of norepinephrine infusion during 
surgery were associated with the development of postoperative AKI as shown in 
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table 3. These factors were subsequently included in the multiple logistic regres-
sion analysis, shown in the right section of table 3. Duration of cold ischemia (OR 
1.302; 95% CI 1.067-1.590; p=0.009), length of WIT (OR 1.064; 95% CI 1.002-1.130; 
p=0.030), and the occurrence of PRS (OR 2.283; 95% CI 1.061-4.915; p=0.035) were 
significantly associated with the development of postoperative AKI.
table 1 - Preoperative graft and patient characteristics in liver transplantation
characteristics n = 155
graft
 Donor risk index 1.81 (0.36)
Recipient
 Age (years) 54 (43-60)
 Male gender (%) 105 (68)
 Etiology of liver disease (%)
 Viral hepatitis 30 (19)
 Biliary cirrhosis 61 (39)
 Postalcoholic cirrhosis 23 (15)
 Other 41 (27)
 Hepatocellular carcinoma (%) 40 (26)
 LabMELD score 16 (10-21)
 Creatinine (umol/L) 72 (59-91)
 eGFR (ml/min/1.73m2) 89 (66-117)
 Sodium (mmol/L) 138 (134-141)
 Ascites (%)
 None 69 (45)
 Diuretic controlled 47 (30)
 Refractory ascites 39 (25)
 Medical history (%)
 Hypertension 16 (10)
 Coronary artery disease 9 (6)
 Hepatorenal syndrome 12 (8)
 Diabetes mellitus
 None 119 (77)
 None insulin dependent 10 (7)
 Insulin dependent 26 (17)
eGFR = estimated glomerular filtration rate; MELD = model for end stage liver disease. Continu-
ous variables are displayed as mean (standard deviation) and median (interquartile range) where 
appropriate.
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impact of postreperfusion syndrome and hepatic iRi on development of aki
Postoperative AKI was significantly more observed in recipients with PRS: 28 (53%), 
compared to 33 (32%) in recipients without PRS (p=0.013). The mean decrease in 
MAP after reperfusion was 14 (SD 21) mmHg and significantly more pronounced 
in recipients with AKI (19 (SD 23) vs. 10 (SD 19) mmHg; p=0.007). In addition, a 
significant larger decline in MAP was observed with increasing AKI severity (p=0.012) 
(figure 1). To assess the relation between PRS and hepatic IRI, postoperative peak 
serum AST levels were compared between recipients with and without PRS. Recipi-
ents experiencing PRS had higher peak AST levels (median 1388 U/L; IQR 785-3027) 
compared to recipients without PRS (median 771 U/L ; IQR 601-1362) (p<0.001). 
Furthermore, in recipients with PRS the postoperative peak AST levels increased with 
severity of AKI (p=0.009) whereas there was no relation between severity of hepatic 
IRI and AKI in recipients without PRS (p=0.814). After stratification of the postopera-
tive peak AST levels (figure 1), there was also a significant correlation between the 
decrease of MAP at reperfusion and the severity of hepatic IRI (p<0.001).
table 2 – Intra- and postoperative characteristics for patients undergoing liver transplantation
characteristics n = 155
intraoperative
 Cold ischemia time (hours) 6.2 (5.3-7.5)
 Warm ischemia time (min) 28 (25-33)
 Blood loss (liters) 4.0 (2.5-6.0)
 RBC transfusion (units) 3 (1-6)
 Hemodynamics
 MAP start operation (mmHg) 89 (16)
 MAP decrease at reperfusion (mmHg) 14 (21)
 Postreperfusion syndrome (%) 53 (34)
 MAP hour 1 postreperfusion (mmHg) 68 (8)
 Inotropics- norepinephrine
 Average dose in surgery (ug/kg/min) 0.17 (0.10-0.25)
postoperative
 Postoperative peak serum AST (U/L) 930 (637-1752)
 Postoperative tacrolimus use
 Highest C0 in first week (ug/L) 3.5 (<1.4-7.3)
 Start before day 5 postoperative (%) 65 (42)
 Highest C0 if start < day 5 (n=65) (ug/L) 6.4 (4.1-11.1)
AST = aspartate aminotransferase; MAP = mean arterial pressure; RBC = red blood cells . Continu-
ous variables are displayed as mean (standard deviation) and median (interquartile range) where 
appropriate.
119
The Postreperfusion Syndrome and Acute Kidney Injury
C
ha
pt
er
 7
Pa
rt 
II
table 3 - Univariable and multiple logistic regression analysis of variables associated with acute 
kidney injury
 
univariable analysis  
 
multiple logistic regression 
analysis
odds ratio 95% ci p-value odds ratio 95% ci p-value
Recipient
 Age 0.990 0.962 - 1.018 0.462 . . .
 Male gender 0.627 0.309 - 1.275 0.197 . . .
 Etiology of liver disease
 Viral hepatitis 1.000 . . .
 Biliary cirrhosis 0.976 0.386 - 2.469 0.958 . . .
 Postalcoholic cirrhosis 1.538 0.502 - 4.718 0.451 . . .
 Other 2.100 0.972 - 5.569 0.136 . . .
 LabMELD score 1.030 0.990 - 1.072 0.138 . . .
 Serum creatinine 1.008 1.000 - 1.016 0.047 1.004 0.995 - 1.014 0.348
 eGFR 0.992 0.993 - 1.001 0.082 . . .
 Sodium 1.008 0.948 - 1.072 0.806 . . .
 Medical history
 Refractory ascites 1.360 0.610 - 3.030 0.452 . . .
 Hypertension 1.623 0.575 - 4.582 0.361 . . .
 Coronary artery disease 1.249 0.322 - 4.848 0.748 . . .
 Hepatorenal syndrome 2.307 0.697 - 7.633 0.171 . . .
 IDDM 1.191 0.816 - 4.513 0.135 . . .
graft
 Donor risk index 1.093 0.440 - 2.713 0.849 . . .
intraoperative
 Cold ischemia time 1.244 1.035 - 1.494 0.020 1.302 1.067 - 1.590 0.009
 Warm ischemia time 1.083 1.027 - 1.142 0.003 1.064 1.002 - 1.130 0.030
 RBC transfusion 1.134 1.045 - 1.230 0.003 1.090 0.988 - 1.203 0.085
 Hemodynamics
 MAP start operation 0.985 0.965 - 1.006 0.161 . . .
 Postreperfusion syndrome 2.342 1.186 - 4.624 0.014 2.283 1.061 - 4.915 0.035
 MAP hour 1 postreperfusion 1.012 0.978 - 1.047 0.500 . . .
 Average dose norepinephrine
 ≤ 0.17 ug/kg/min 1.000 . . .
 > 0.17 ug/kg/min 1.783 0.928-3.424 0.082 1.137 0.541 - 2.392 0.735
postoperative tacrolimus use
 Highest C0 level in first week 0.959 0.896 - 1.026 0.221 . . .
 Start < postoperative day 5 0.749 0.388 - 1.448 0.749 . . .
CI = confidence interval; eGFR = estimated glomerular filtration rate; IDDM = insulin dependent 
diabetes mellitus; MAP = mean arterial pressure; MELD = model for end stage liver disease; RBC 
= red blood cells.
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consequences of aki
Median length of ICU stay was 3 (IQR 2-5) days in recipients with AKI, compared to 2 
(IQR 2-3) days in the control group (p=0.003). Furthermore, median length of hospital 
stay was one week longer in recipients with AKI with 24 (IQR 19-35) days, compared 
to 17 (IQR 14-27) days in the control group (p < 0.001). In-hospital morbidity cor-
related well with AKI severity: the occurrence of at least one major postoperative 
complication increased with severity of AKI: 30 (32%) of recipients without AKI had a 
major complication, compared to 31 (66%) for recipients with mild AKI and 12 (86%) 
with severe AKI (p<0.001). In-hospital mortality increased with severity of AKI as well: 
two (2%) of the recipients without AKI died during hospital stay, compared to five 
(11%) and four (29%) recipients with respectively mild and severe postoperative AKI 
(p<0.001). The impact of AKI on recipient survival continued until one year postop-
erative, which is displayed in figure 2. Overall estimated one-year recipient survival 
was 88% and decreased with AKI severity (overall log-rank p<0.001). Moreover, the 
mild AKI group had a significantly lower survival compared to the control group 
(log rank p=0.026). The overall estimated one-year graft survival was 84% with no 
difference in graft survival observed between recipients with no AKI (91%) and mild 
AKI (80%) (p=0.072).
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figure 1 - Decrease in mean arterial pressure after reperfusion for severity of acute kidney injury 
(left) and hepatic ischemia reperfusion injury (right)
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discussion
In this study we observed AKI in 39% of DBD graft recipients, which is in line with 
earlier published studies (1–6). Confirming our hypothesis, AKI was more frequently 
observed in recipients who experienced PRS during liver transplantation. We also 
showed that the decrease in MAP immediately after reperfusion correlated well with 
severity of AKI. Multivariable analysis identified PRS as an independent risk factor for 
AKI: if recipients experienced PRS, the odds of developing AKI showed a more than 
two-fold increase. The other subject of our hypothesis was the relation between the 
figure 2 - Kaplan-Meier survival table for recipient survival, divided in groups of severity of acute 
kidney injury
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severity of hepatic IRI and the extent of hemodynamic instability after reperfusion 
and that PRS is an early manifestation of severe hepatic IRI. Our results confirm this 
hypothesis: the decrease in MAP directly after reperfusion correlated well with post-
operative peak AST levels and recipients with PRS had significant higher peak AST 
levels as well. Leithead et al. previously observed a relationship between hepatic IRI 
and AKI when DBD grafts are used (35). Our results do not only confirm this theory, 
but also provide new insight in this process. The extent of hepatic IRI is displayed by 
the amount of hemodynamic instability after reperfusion and severe hepatic IRI with 
subsequent occurrence of PRS can be predictive for the development of postopera-
tive AKI.
AKI after liver transplantation has previously been related to the use of marginal 
organs, such as DCD grafts (1,14). Paugam-Burtz et al was the first to describe a rela-
tion between PRS and postoperative renal failure (25). Fonseca-Neto et al described 
a positive correlation between PRS and AKI in liver transplantation performed using 
conventional surgical technique without veno-venous bypass (38). In a cohort of 
living-donor liver transplant recipients Park et al. correlated the occurrence of PRS 
with postoperative AKI as well (39). However, we are the first to describe a dose-
effect relationship between the extent of hemodynamic instability and the severity 
of renal injury. In our cohort, the decrease in MAP correlated well with the severity 
of postoperative AKI (figure 1). Ekser et al. demonstrated in patients requiring com-
bined liver-kidney transplantation, that delaying the kidney transplantation beyond 
48 hours after liver transplantation, yielded significantly better renal outcomes than 
simultaneous kidney (40). This contributes to our hypothesis that renal function is 
especially vulnerable in the first hours after reperfusion, a phase characterized by 
hemodynamic instability and the release of pro-inflammatory cytokines caused by 
hepatic IRI.
AKI after liver transplantation is multifactorial of origin and in our study PRS occurred 
in 46% of recipients with postoperative AKI. So others factors are likely to contribute 
to development of AKI as well. Therefore, we performed a multiple logistic regres-
sion analysis. PRS was an independent factor associated with AKI in this model with 
an odds ratio of 2.3. In previous studies numerous preoperative factors are ascribed 
to influence development of AKI, such as age, female sex, severity of liver disease 
and renal function (3,7,10). The preoperative creatinine levels were significantly 
higher in the AKI group in the univariate analysis. However, this factor was not a 
significant contributor to the development of AKI in the multiple logistic model, 
which is in line with numerous previous studies (7,35,41). Next to PRS, several factors 
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related to the transplant procedure were identified. We described that increase of 
both cold and warm ischemia periods contributes to postoperative AKI when DBD 
grafts are used. These ischemia periods are both known factors to worsen hepatic 
IRI , but only WIT has earlier been linked to development of AKI (21,42–44). To 
our knowledge, duration of cold ischemia has not been related to AKI before. Liver 
transplantation is high risk surgery with substantial blood loss which increases the risk 
for periods of hypotension, a classical risk factor for AKI after major surgery (45,46). In 
our univariable logistic regression the influence of blood loss during surgery on AKI is 
illustrated by the requirement of RBC transfusion, but in the multiple logistic regres-
sion model with other factors, RBC transfusion requirement was not contributing to 
AKI. Tacrolimus has an important role in the immunosuppression after liver transplan-
tation and is known for its nephrotoxicity (11–13). Over two third of the recipients 
developed AKI within the first two postoperative days, but in the majority of patients 
(58%) the introduction of tacrolimus was delayed until day 5. Of the recipients who 
received tacrolimus before day 5, the highest trough levels (C0) were relatively low 
and comparable in recipients with and without AKI. This could explain why exposure 
to tacrolimus did not influence AKI development in our model. Furthermore, the fluid 
regimen during surgery might also contribute to the development of AKI. The usage 
of HES during liver transplantation has been linked with postoperative AKI. However 
this effect was only seen when it was not combined with albumin (45). Although HES 
is regularly used in our perioperative regimen, we consider its effect on AKI limited 
since all patients routinely received intravenous albumin.
This study has several limitations; the retrospective design has its inherent short-
comings. One third of the recipients were excluded, but our strict exclusion criteria 
yielded a more homogenous population where preoperative renal injury was 
minimal. The majority of the excluded recipients were transplantations for acute liver 
failure and retransplantations. The retransplantation rate in our cohort is relatively 
high, due to the increased use of DCD grafts. The retrospective design of this study 
could have given rise to varying perioperative management, but our institution has a 
well-implemented transplant protocol. Opposed to earlier studies, we assessed renal 
injury using serum creatinine levels only during the first week. This shorter and fixed 
period prevents confounders such as surgical and infectious complications that occur 
beyond the first postoperative week. Moreover, we strictly followed AKIN-criteria, 
being the most sensitive AKI definition at present. To our knowledge our study is the 
first to link PRS to the development of AKI after DBD liver transplantation using these 
strict AKIN criteria.
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The importance of inclusion of recipients with relatively mild AKI (AKIN stage 1) 
is underlined by the observed morbidity and increased mortality. Recipients who 
developed mild AKI did experience more major complications and hospital mortality 
was higher compared to the control group. This effect carried on as reflected in the 
impaired one-year survival in recipients with mild AKI. Given the impact of AKI on 
recipient outcomes in our study, there is an obvious need to prevent renal injury. Pro-
tection against hemodynamic instability after reperfusion using vasopressor agents 
could be a feasible preventive intervention. Ryu et al. studied the effect of vasopres-
sor therapy before reperfusion on the occurrence of PRS (47). Occurrence of PRS 
decreased with vasopressor pretreatment, being either phenylephrine or epineph-
rine, compared to placebo. However, this relatively small study did not investigate 
postoperative renal injury and no difference in-hospital mortality or hospital length 
of stay was observed. These results raise the question whether PRS, or hepatic IRI 
in general should be the focus of an intervention to preserve postoperative renal 
function. Other effects of hepatic IRI associated with renal injury – such as the release 
of pro-inflammatory cytokines – are not reflected by PRS (20,48,49). The exact ef-
fects of hepatic IRI on the kidney are complex, but experimental murine studies 
showed renal injury characterized by renal tubular necrosis, inflammatory changes 
and interstitial capillary endothelial apoptosis (50). These inflammatory responses of 
the kidney to hepatic IRI suggest that solely preventing the hemodynamic instabil-
ity after reperfusion might not be enough to preserve renal function. Other ways 
to reduce hepatic IRI are surgical techniques such as initial arterial reperfusion or 
stepwise portal reperfusion are suggested to improve hemodynamic stability after 
reperfusion. This could also prevent the sudden release of cold components and 
pro-inflammatory cytokines in the systemic circulation and perhaps limit hepatic IRI. 
Other emerging strategies to minimalize hepatic IRI are hypothermic or normother-
mic oxygenated perfusion of the graft. These preservation methods have already 
shown in animal models to reduce postoperative biliary injury and immune response 
in DCD liver transplantation (51–54). In this setting the occurrence of PRS could also 
be used as an early measurement of hepatic IRI. Furthermore, the occurrence of 
PRS allows early identification -within minutes after reperfusion- of recipients at risk 
for AKI and enables early preventive measures to minimize additional renal injury 
after reperfusion. This could trigger adjustment of postoperative fluid management, 
delayed introduction of calcineurin inhibitors and other nephrotoxic medication.
In conclusion, our study confirmed that AKI is an important complication after DBD 
liver transplantation as even mild postoperative AKI has a substantial impact on 
recipient outcomes including survival. Hepatic IRI is a known factor to influence 
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development of AKI and the severity of hepatic IRI correlates with the extent of 
hemodynamic instability after reperfusion during transplantation. PRS, as a reflection 
of severe hepatic IRI, is predictive for development of AKI and allows early identifica-
tion of patients at risk and could create opportunities to limit postoperative renal 
injury.
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summaRy
AKI is a common complication after liver transplantation and more frequently ob-
served when high-risk grafts, such as DCD grafts are used. Our aim was to investigate 
the impact of the ischemia periods on development of AKI in DCD liver transplanta-
tion. We performed a two-center retrospective study with 368 DCD graft-recipients. 
DWIT was divided into agonal phase (withdrawal of life-support – cardiac arrest) and 
asystolic phase (cardiac arrest – start cold perfusion). We introduced a new period of 
warm ischemia: the combined warm ischemia time (combined WIT), that was defi ned 
as the sum of DWIT and recipient WIT. AKI was observed in 65% of the recipients 
and severe AKI in 41% (KDIGO stage 2/3). The length of combined WIT increased 
signifi cantly with AKI severity: 61 minutes in recipients without AKI up to 69 minutes 
in recipients with the most severe form of AKI (p<0.001). On multivariable analysis, 
increasing duration of the combined WIT was associated with an increased risk of de-
veloping severe AKI (OR 1.032 per every extra minute; 95% CI 1.014-1.051; p<0.001). 
No relation was observed between length of cold ischemia time and severe AKI. In 
conclusion, combined WIT is a newly defi ned period of warm ischemia in DCD liver 
transplantation. Length of combined WIT is associated with severity of postoperative 
AKI and should ideally not exceed 60 minutes.
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intRoduction
DCD grafts are increasingly used to overcome the donor shortage in liver trans-
plantation (1,2). However, the use of these marginal grafts is associated with more 
PNF, EAD and ischemic cholangiopathy with subsequent impaired graft survival 
rates (3–10). These complications are the result of the additional DWIT, leading to an 
increase in hepatic IRI (11). The kidney is an organ known to suffer from hepatic IRI, 
and acute kidney injury (AKI) is also more frequently observed when DCD grafts are 
used (12–15). Overall, AKI affects up to 75% of the liver graft recipients and is related 
to CKD and impaired survival rates (13,15–20).
The additional DWIT of DCD livers can be divided into two periods: the agonal 
phase (withdrawal of life support - circulatory arrest) and the asystolic phase (circula-
tory arrest – start cold perfusion). Various factors impact on the length of DWIT: 
the course of vital parameters and length of agonal phase differs widely between 
donors and length of asystolic phase depends on institutional and national protocols 
(e.g. location of withdrawal of life support and the ‘no touch’ time after circulatory 
arrest). Both length of agonal and asystolic phase have been linked to postoperative 
development of ischemic cholangiopathy and graft survival rates (21–24). figure 1 
shows an overview of the combined WIT in DCD liver transplantation: a new defined 
period that is the sum of agonal phase and asystolic phase during organ procure-
ment and recipient warm ischemia time before reperfusion (recipient WIT). These 
periods have their own biological profile, where the blood and oxygen supply gradu-
ally decreases within agonal phase, followed by warm ischemia without any flow and 
oxygen distribution during asystolic phase. After cold storage, livers are exposed to 
another type of warm ischemia in the recipient, where a gradual rewarming occurs 
during reconstruction of the vascular anastomoses. Little is known about the impact 
of such different types of WIT on hepatic IRI and development of AKI. Furthermore, 
2. Asystolic phase 
Cold storage 
Withdrawal of 
life support 
Liver  
out of ice 
Circulatory 
arrest Start cold     
perfusion 
1. Agonal phase 
   1 + 2 + 3 = Combined warm ischemia time 
Reperfusion 
3. Recipient WIT 
 
figure 1 - Definition of combined warm ischemia time in DCD liver transplantation
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the length of the separate phases varies in every transplant and they have not been 
assessed together before.
The negative impact of AKI on long term outcomes necessitates further research on 
this subject. Our aim was therefore to investigate the impact of such different periods 
of warm ischemia on development of postoperative AKI in DCD liver transplantation.
metHods
This retrospective study was performed in two liver transplant centers: the Queen 
Elizabeth Hospital, NHS Foundation Trust, Birmingham, UK and the Erasmus MC 
University Medical Center, Rotterdam, the Netherlands. The study was approved 
by both institutional review boards (Birmingham, CARMS-13009; Rotterdam, MEC-
2014-670). All consecutive adult patients, who underwent orthotopic DCD liver 
transplantation in both centers between July 2008 and July 2016 were included. 
Exclusion criteria were transplantation for acute liver failure, re-transplantation, AKI 
in the week prior to transplantation (but not pre-existent renal impairment) and 
machine perfusion of the graft.
The collected donor characteristics are displayed in table 1, including the DRI (25). 
The most recent European classification for definitions and terminology in DCD do-
nation was used to assess the different phases of DWIT (26). In the UK, all donor data 
are collected via the UK Transplant Registry. Rotterdam is part of the Eurotransplant 
allocation system. The recipient characteristics collected at admission are shown in 
table 1: Clinical characteristics of DCD liver transplantation recipients
donor characteristics
birmingham 
(n = 279)
Rotterdam 
(n = 89)
total 
(n=368) p-value
Age (years) 53 (39-64) 47 (40-53) 51 (39-61) <0.001
Male gender (%) 192 (69) 64 (72) 256 (70) 0.581
Body mass index 24.8 (22.8-28.0) 24.2 (22.0-25.6) 24.7 (22.5-27.4) 0.022
Donor risk index 2.7 (2.2-3.1) 2.6 (2.2-2.9) 2.7 (2.2-3.1) 0.164
Donor ɣGT (U/L) (n=264) 40 (21-80) 37 (21-75) 39 (21-80) 0.895
Donor cause of death (%) 0.004
Hypoxia 72 (26) 14 (16) 86 (23)
Trauma 34 (12) 18 (20) 52 (14)
CVA 142 (51) 55 (62) 197 (54)
Other 31 (31) 2 (2) 33 (9)
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table 1: Clinical characteristics of DCD liver transplantation recipients (continued)
birmingham 
(n = 279)
Rotterdam 
(n = 89)
total 
(n=368) p-value
donor warm ischemia time (min)              
Total DWIT 28.4 (8.7) 31.3 (8.4) 29.1 (8.7) 0.005
Agonal phase 15.8 (8.3) 15.3 (7.2) 15.7 (8.1) 0.632
Asystolic phase 12.6 (3.7) 16.0 (4.3) 13.4 (4.1) <0.001
Recipient        
Age (years) 58 (51-65) 57 (50-63) 58 (51-64) 0.089
Male gender (%) 192 (69) 64 (72) 256 (70) 0.581
Body mass index 26.6 (24.0-29.9) 25.8 (23.5-29.5) 26.5 (23.9-29.8) 0.369
Etiology of liver disease (%) 0.010
Viral hepatitis 88 (32) 26 (29) 114 (31)
Cholestatic disease 69 (25) 16 (18) 85 (23)
Postalcoholic cirrhosis 81 (29) 19 (19) 100 (27)
NASH 17 (6) 13 (15) 30 (8)
Other 24 (9) 15 (17) 39 (11)
Hepatocellular carcinoma (%) 109 (39) 31 (35) 140 (38) 0.473
LabMELD score <0.001
< 15 170 (61) 44 (49) 214 (58)
15 - 20 77 (28) 18 (20) 95 (26)
> 20 32 (12) 27 (30) 59 (16)
eGFR (ml/min/1.73m2) 0.057
> 90 142 (51) 35 (39) 177 (48)
≤ 90 137 (49) 54 (61) 191 (52)
Ascites (%) 0.056
Diuretic controlled 82 (29) 35 (39) 117 (32)
Refractory ascites 53 (19) 21 (24) 74 (20)
Medical history (%)
Hypertension 44 (16) 18 (20) 62 (17) 0.328
Diabetes mellitus 50 (18) 28 (32) 79 (21) 0.007
surgery              
Cold ischemia time (hours) 7 (6.1-8.1) 6.4 (5.8-7.2) 6.9 (5.9-7.9) 0.001
Recipient warm ischemia time (min) 37 (31-43) 27 (23-33) 35 (28-42) <0.001
RBC transfusion (units) 2 (0-4) 2 (1-5) 2 (0-4) 0.020
FFP transfusion (units) 6 (2-11) 3 (0-7) 6 (2-10) <0.001
Platelet transfusion (units) 2 (0-10) 5 (0-10) 2 (0-10) 0.891
postoperative              
Peak ALT (U/L) (n=274) 1775 (1029-2630) 1603 (817-2834) 1718 (981-2656) 0.595
Tacrolimus peak trough level (ug/L) 9.2 (6.4-12.4) <1.5 (<1.5-3.7) 7.5 (4.0-11.5) <0.001
ALT, alanine transaminase; DWIT, donor warm ischemia time; eGFR, estimated glomerular filtration 
rate; FFP, fresh frozen plasma; ɣGT, gamma-glutamyltransferase; MELD, model for end-stage liver 
disease; NASH, non alcoholic steatohepatitis; Continuous variables are displayed as mean (standard 
deviation) and median (interquartile range) where appropriate.
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table 1. The eGFR was calculated using the MDRD-4 equation and the severity of 
liver disease was calculated using the preoperative MELD score (27–29). Duration of 
cold ischemia time and RWIT and the transfusion requirements were recorded.
In the UK, the donor WoT takes place either in ICU or in the anesthetic room next 
to theatres, while the withdrawal is always in ICU in the Netherlands. Both coun-
tries keep a maximum length of agonal phase at 60 minutes to proceed with organ 
retrieval and the ‘no-touch’ period after circulatory arrest is five minutes in both 
countries (30,31). In both countries, heparin is not administered to the donor prior to 
WoT. During the organ retrieval process, in Birmingham the preferred preservation 
fluid for procurement is heparinized UW solution (5-6 L) under 200 mm HG pressure 
via the aorta and 1 L under gravity via the portal vein. In Rotterdam, heparinized UW 
is used as well, 6-8 L via the aorta only. Additional back-table flushed is performed 
in both centers and the biliary tract is flushed in both centers as well. The standard 
surgical technique in both centers includes piggyback caval anastomosis (classical 
or side-to-side cavocavostomy) without the use of veno-venous bypass and only a 
portocaval shunt in selected cases.
The peak serum alanine aminotransferase (ALT) level in the first 48 hours was used 
as a surrogate marker for hepatic IRI. Postoperative creatinine levels were collected 
in the first week after liver transplantation. AKI was defined according to KDIGO 
criteria (32): an increase in serum creatinine by ≥26.5 umol/L within 48 hours or an 
increase in creatinine to ≥ 1.5 times baseline within the first 7 postoperative days. 
AKI was classified into 3 stages: stage 1, increase ≥26.5 umol/L or increase of 1.5-
1.9 fold from baseline; stage 2, increase of 2-2.9 fold; stage 3, increase >3-fold or 
increase in serum creatinine to ≥354 umol/L or initiation of RRT. In both centers, 
patients received triple-therapy immunosuppression after transplant. In Birmingham, 
the regimen consisted of tacrolimus, azathioprine or MMF, and prednisolone, which 
were all introduced at day 0. Prednisolone therapy was generally discontinued after 
three months. In Rotterdam, the immunosuppression regimen was modified during 
the study period. From 2012, induction of tacrolimus was delayed until day 5, MMF 
was added from day 0 and basiliximab was given on day 0 and 4. The attending 
physicians adjusted the immunosuppression in case of impaired renal function or 
infection. Target peak trough levels for tacrolimus were 8-10 ug/L during the first 
month in both centers. To detect tacrolimus nephrotoxicity, the peak trough levels in 
the first week were recorded.
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statistical analysis
Data were analyzed with IBM SPSS Statistics version 24 (IBM Corporation, Armonk, 
New York, USA). Continuous variables were tested for normality with the Shapiro-Wilk 
test. The student’s t test and the one-way analysis of variance were used to compare 
normally distributed continuous variables. Nonparametric continuous variables were 
compared using the Mann-Whitney U test. To compare categorical variables, the 
Chi-square test or the Fisher’s exact test were used. P-values < 0.05 were considered 
statistically significant. Continuous variables were expressed as mean with standard 
deviation (SD) or median and IQR, where appropriate. Categorical variables were 
expressed in quantities and percentages. To relate donor-, recipient-, and peri-
operative factors to the development of severe AKI after DCD liver transplantation, 
a multiple logistic regression analysis was performed with all clinical relevant factors. 
Long-term survival rates were estimated using Kaplan-Meier methods, with compari-
sons between groups performed using log-rank tests.
Results
During the study period 422 patients received a DCD liver graft; 317 in Birmingham 
and 105 in Rotterdam. The following 26 patients were excluded: one for acute liver 
failure, 1 re-transplantation, 5 patients with AKI in the week prior to transplantation, 
and 18 patients because of end-ischemic machine perfusion. One patient was ex-
cluded because of intra-operative death. Another 27 cases were excluded because 
of incomplete data (DWIT and intra-operative data). This resulted in an inclusion of 
368 patients; 279 in Birmingham and 89 in Rotterdam
Recipient, donor, and perioperative characteristics in both centers
The baseline characteristics for both centers are displayed in table 1. Median donor 
age was 53 years in Birmingham, compared to 47 years in Rotterdam (p<0.001). 
Donor BMI was also higher in Birmingham (median: 24.8 versus 24.2; p=0.022). The 
mean total DWIT was longer in Rotterdam (31 versus 28 min; p=0.005), because 
of a longer asystolic phase in this center (16 versus 13 min; p<0.001). The mean 
agonal phase length was 16 minutes in the entire cohort and comparable between 
centers. In Birmingham, livers were exposed to a longer period of cold ischemia 
(median 7.0 versus 6.4 hours; p=0.001) and RWIT was also longer in Birmingham 
(37 versus 27 min; p<0.001). Median recipient age (58 years) and BMI (26.5m2/kg) 
were comparable in both centers. The labMELD score was higher in Rotterdam, were 
30% of the recipients had a score of 20 or higher, compared to 12% in Birmingham 
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(p<0.001). The preoperative kidney function (eGFR) was below 90 ml/min/1.73m2 in 
61% of the recipients in Rotterdam and 49% in Birmingham (p=0.057). Due to the 
delayed introduction of tacrolimus in Rotterdam, the median peak tacrolimus trough 
level in the first week was lower in this center (<1.5 versus 9.2 ug/L; p<0.001).
development of acute kidney injury
The incidence of postoperative AKI is displayed in table 2. A total of 239 (65%) 
recipients developed any form of AKI; 67% in Birmingham and 57% in Rotterdam 
(p=0.083). Of these 239 recipients, 37%, 18%, and 45% respectively developed AKI 
stage 1,2, and 3. More recipients in Birmingham required postoperative RRT (30% 
versus 6%; p<0.001). Correspondingly, the peak creatinine levels in the first week 
after transplant were higher in Birmingham (140 versus 119 umol/L; p=0.026). In 
the recipients who received RRT (n=89), the serum creatinine at the start of RRT was 
lower in Birmingham, (276 vs. 429 umol/L), suggesting a lower threshold to use RRT 
in this center. Recipients from the entire cohort were divided into three groups: no 
AKI, mild AKI (KDIGO stage 1), and severe AKI (KDIGO stage 2/3). Donor, recipient 
and surgical characteristics for the three AKI groups are displayed in table 3. No sig-
nificant differences were observed in the evaluated donor characteristics in relation 
to postoperative development of AKI. BMI was the only recipient factor increasing 
with severity of AKI (p=0.006). Transfusion requirements during surgery all increased 
with the extent of postoperative renal injury. The peak tacrolimus trough level was 
comparable for all AKI groups. The incidence of the postreperfusion syndrome was 
33% and no relation was observed between the incidence of this phenomenon and 
the severity of AKI (p=0.987).
table 2: Incidence and severity of acute kidney injury after DCD liver transplantation
  birmingham Rotterdam total p-value
Total recipients 279 (100%) 89 (100%) 368 (100%) .
Peak serum creatinine (umol/L) 140 (98-235) 119 (89-184) 133 (95-218) 0.026
AKI total* 188 (67%) 51 (57%) 239 (65%) 0.083
Stage 1 56 (30%) 32 (63%) 88 (37%) .
Stage 2 32 (17%) 12 (24%) 44 (18%) .
Stage 3 100 (53%) 7 (14%) 107 (45%) .
Severe AKI (KDIGO stage 2/3) 132 (47%) 19 (21%) 151 (41%) <0.001
Renal replacement therapy (RRT) 84 (30%) 5 (6%) 89 (24%) <0.001
Serum creatinine at start RRT (umol/L) 276 (201-423) 429 (216-470) 279 (205-429) 0.345
AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes.
*All the percentages in Italic are the percentage of all recipients that developed AKI.
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table 3: Donor, recipient characteristics and surgical parameters and mild and severe acute kidney 
injury in DCD liver transplantation
donor no aki (n=129) mild aki (n=88)
severe aki 
(n=151) p-value
Age 50 (39-64) 52 (37-59) 51 (42-61) 0.710
Male gender (%) 87 (67) 66 (75) 103 (68) 0.442
Body mass index 24.5 (22.5-26.7) 24.5 (22.5-26.2) 25.1 (22.8-28.4) 0.093
Donor risk index 2.7 (2.2-3.1) 2.7 (2.2-3.02) 2.7 (2.3-3.0) 0.852
Donor ɣGT (U/L) (n=264) 38 (19-66) 36 (20-94) 41 (23-86) 0.228
Recipient
Age (years) 57 (51-64) 58 (51-65) 59 (52-64) 0.832
Male gender (%) 87 (67) 66 (75) 103 (68) 0.442
Body mass index 25.4 (22.9-29.4) 25.9 (23.8-29.5) 27.3 (24.6-30.8) 0.006
Etiology of liver disease (%) 0.715
Viral hepatitis 37 (29) 23 (26) 54 (36)
Biliary cirrhosis 32 (25) 24 (27) 29 (19)
Postalcoholic cirrhosis 33 (26) 25 (28) 42 (28)
NASH 10 (8) 8 (9) 12 (8)
Other 17 (13) 8 (9) 14 (9)
Hepatocellular carcinoma (%) 47 (36) 29 (33) 64 (42) 0.314
LabMELD score 0.160
< 15 74 (57) 44 (50) 96 (64)
15 - 20 33 (26) 24 (27) 38 (25)
> 20 22 (17) 20 (23) 17 (11)
eGFR (ml/min/1.73m2) 0.139
> 90 69 (54) 35 (40) 73 (48)
≤ 90 60 (47) 53 (60) 78 (52)
Sodium (mmol/L) 138 (135-141) 138 (134-140) 138 (136-141) 0.082
Ascites (%) 0.341
Diuretic controlled 35 (27) 28 (32) 54 (36)
Refractory ascites 27 (21) 22 (25) 25 (17)
Medical history (%)
Hypertension 19 (15) 12 (14) 31 (21) 0.283
Diabetes mellitus 21 (16) 21 (24) 36 (24) 0.238
peri-operative
RBC transfusion (units) 1 (0-3) 2 (1-5) 3 (1-6) <0.001
FFP transfusion (units) 4 (0-6) 6 (1-10) 8 (4-12) <0.001
Platelet transfusion (units) 0 (0-5) 1 (0-5) 4 (0-10) 0.003
Postreperfusion syndrome (n=117) 16 (34) 12 (33) 11 (32) 0.987
Tacrolimus peak trough level (ug/L) 7.5 (4.0-11.5) 6.3 (0.8-11.7) 4.8 (7.7-11.5) 0.293
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; ɣGT, 
gamma-glutamyltransferase; MELD, model end-stage liver disease; NASH, non alcoholic steato 
hepatitis; RBC, red blood cells. Continuous variables are displayed as mean (standard deviation) and 
median (IQR) where appropriate.
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Warm ischemia time and acute kidney injury
table 4 shows the length of ischemia periods for all AKI stages. Interestingly, length 
of asystolic phase was not found to be significantly associated with severity of AKI 
in either center. The duration of agonal phase was associated with renal injury in 
Rotterdam (p=0.042), but not in Birmingham (p=0.935). In contrast, in Birmingham 
severity of AKI increased with length of RWIT (p=0.007), while no significant associa-
tion was observed in Rotterdam (p=0.136). To explore the impact of the total amount 
of warm ischemia (combined WIT), duration of the donor agonal and asystolic phase 
were added to the secondary warm ischemia of the graft in the recipient (RWIT). 
figure 2 demonstrates the relation of combined WIT to the different AKI stages in 
both centers and the total cohort. Duration of combined WIT was longer in recipients 
with an increased severity of AKI in both centers. In the total cohort, the combined 
WIT was 61 minutes in recipients without AKI and increased up to 69 minutes in re-
cipients with the most severe form of AKI (stage 3, p<0.001). Cold ischemia time was 
not found to be associated with the development of AKI in both centers. A further 
analysis confirmed that severe AKI was not more frequently observed in recipients 
with a prolonged cold ischemia time (incidence severe AKI: <6 hours 40%; 6-8 hours 
40%; 8-10 hours 45%; >10 hours 45%; p=0.901).
table 4: Length of ischemia periods and severity of acute kidney injury after DCD liver transplan-
tation.
birmingham
no aki 
(n=91)
aki stage 
1 (n=56)
aki stage 2 
(n=32)
aki stage 3 
(n=100) p-value
Donor warm ischemia time (min)
Agonal phase 15 (±7.4) 16 (±8.8) 16 (±8.3) 16 (±9.0) 0.915
Asystolic phase 13 (±3.2) 12 (±3.9) 12 (±2.2) 13 (±4.3) 0.207
Total 28 (±7.5) 28 (±9.6) 28 (±9.0) 29 (±9.2) 0.726
Cold ischemia time (hours) 7.1 (±1.6) 7.1 (±1.5) 6.9 (±1.7) 7.1 (±1.5) 0.911
Recipient warm ischemia time (min) 35 (±8.5) 38 (±8.6) 40 (±13.2) 40 (±11.8) 0.007
Rotterdam
no aki 
(n=38)
aki stage 
1 (n=32)
aki stage 2 
(n=12)
aki stage 3 
(n=7) p-value
Donor warm ischemia time (min)
Agonal phase 14 (±6.0) 15 (±5.9) 17 (±10.7) 22 (±8.7) 0.042
Asystolic phase 17 (±4.0) 15 (±4.9) 15 (±3.8) 16 (±3.9) 0.548
Total 31 (±6.8) 30 (±7.6) 32 (±12.3) 38 (±10.4) 0.128
Cold ischemia time (hours) 6.3 (±1.1) 6.7 (±1.2) 6.7 (±1.2) 6.7 (±1.0) 0.431
Recipient warm ischemia time (min) 28 (±5.9) 29 (±8.3) 34 (±9.6) 28 (±8.8) 0.136
AKI, acute kidney injury. Values are demonstrated as mean and standard deviation.
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figure 2 - Mean length of total warm ischemia time and severity of acute kidney injury after DCD 
liver transplantation
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multivariable analysis for development of severe acute kidney injury
Multiple binary logistic regression was used to identify donor, graft, recipient and 
surgical factors associated with development of severe AKI (table 5). Independent 
predictors were an increased recipient BMI (OR 1.09 per kg/m2; 95%CI 1.03-1.15; 
p=0.003), transfusion of RBC during liver transplant (OR 1.10 per unit; 95%CI 1.03-
1.18; p=0.004) and the length of combined WIT (OR 1.03 per one extra minute; 
95% CI 1.01-1.05; p<0.001). Duration of old ischemia time (CIT) was not found to be 
significantly associated with development of severe AKI (OR 0.98; 95%CI 0.84-1.15; 
p=0.822).
table 5 - Univariable and multivariable analysis of factors associated with development of severe 
acute kidney after DCD liver transplantation
  unvariable analysis  
 
multivariable analysis
Donor oR 95% ci p-value oR 95% ci p-value
Age (years) 1.008 0.995 1.021 0.238 1.005 0.989 1.021 0.574
Female gender 0.967 0.633 1.477 0.875 0.943 0.570 1.559 0.819
Body mass index 1.069 1.014 1.128 0.014 1.050 0.986 1.118 0.127
Recipient                  
Age (years) 1.000 0.999 1.001 0.947 0.999 0.998 1.001 0.420
Female gender 1.114 0.710 1.747 0.002 1.764 0.981 3.173 0.058
Body mass index 1.074 1.026 1.123 0.002 1.086 1.028 1.148 0.003
Diagnosis liver disease
Viral hepatitis 1.000 1.000
Biliary cirrhosis 0.575 0.322 1.028 0.062 0.808 0.386 1.692 0.808
Alcohol related cirrhosis 0.805 0.468 1.382 0.432 0.817 0.433 1.541 0.817
NASH 0.741 0.327 1.678 0.472 0.713 0.279 1.820 0.713
Other 0.622 0.294 1.318 0.215 0.867 0.372 2.021 0.867
Hepatocellular carcinoma 1.365 0.891 2.091 0.617 1.001 0.552 1.815 0.998
labMELD 0.957 0.920 0.995 0.029 0.955 0.907 1.006 0.081
eGFR preoperative (ml/min/1.73m2) 1.005 0.998 1.011 0.154 1.007 0.999 1.015 0.075
Graft                  
Cold ischemia time (hours) 1.046 0.910 1.203 0.526 0.982 0.842 1.147 0.822
Combined WIT (minutes) 1.035 1.018 1.052 <0.001 1.032 1.014 1.051 <0.001
RBC transfusion (units) 1.080 1.020 1.143 0.008 1.101 1.031 1.175 0.004
Postoperative                  
Tacrolimus peak level week 1 (ug/L) 1.016 0.981 1.052 0.006   1.016 0.975 1.058 0.447
CI, confidence interval; eGFR, estimated glomerular filtration rate; MELD, model for end stage 
liver disease; NASH, non alcoholic steatohepatitis; OR, odds ratio; RBC, red blood cells; WIT, warm 
ischemia time.
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Hepatic iRi, graft-related outcomes and acute kidney injury
The median peak serum ALT level in the first 48 hours, a surrogate marker for hepatic 
IRI, was comparable in both centers (1775 U/L in Birmingham vs. 1603 U/L in Rot-
terdam; p=0.595). figure 3 shows the relation between peak serum ALT levels and 
severity of AKI. In both centers, peak ALT levels were associated with severity of AKI. 
Short term outcomes after transplant in relation to the development of postoperative 
AKI are shown in table 6. EAD was more frequently observed in recipients with AKI 
in both centers In addition, graft loss in the first six months after transplantation was 
6% in recipients without AKI and increased up to 10% and 20% in recipients with 
mild and severe AKI, respectively (p=0.002). figure 4 displays the KM-curves for the 
3-year graft survival (A) and recipient survival (B) for the entire cohort. The overall 
figure 3 - hepatic IRI and acute kidney injury after DCD liver transplantation
figure 4 - Acute kidney injury and estimated 3-year graft (left) and recipient (right) survival and 
severity of acute kidney injury after DCD liver transplantation
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3-year estimated graft survival was 76% and decreased significantly with severity of 
AKI (p=0.019). Recipients without AKI and mild AKI had comparable survival rates 
(80% and 79%; p=0.491), while the 3-year graft survival decreased significantly for 
recipients with severe AKI, compared to recipients with no or mild AKI (70% versus 
80%; p=0.008). The 3-year overall estimated recipient survival was 81%, but was not 
significantly associated with AKI stages (p=0.341).
table 6: severity of acute kidney injury and in-hospital and 90 days outcome parameters after DCD 
liver transplantation
total cohort no aki (n=129) mild aki (n=88) severe aki (n=151) p-value
EAD (%) 42 (33) 34 (39) 88 (58) <0.001
Length of stay ICU 2 (1-3) 3 (2-4) 5 (3-9) <0.001
Length of stay hospital 9 (7-15) 12 (8-18) 16 (10-24) <0.001
6 month graft loss 8 (6) 9 (10) 30 (20) 0.002
Death (%) 2 (2) 4 (5) 12 (8)
Retransplantation - PNF (%) 2 (2) 2 (2) 7 (5)
Retransplantation - HAT (%) 2 (2) 2 (2) 9 (6)
Retransplantation - ITBL (%) 3 (1) 1 (1) 2 (1)
birmingham no aki (n=91) mild aki (n=56) severe aki (n=132)  
EAD (%) 23 (25) 16 (29) 72 (55) <0.001
Length of stay ICU 2 (1-3) 3 (2-4) 5 (3-9) <0.001
Length of stay hospital 8 (7-11) 9 (7-12) 16 (9-23) <0.001
6 month graft loss 7 (8) 4 (7) 23 (17) 0.040
Death (%) 1 (1) 2 (4) 6 (5)
Retransplantation - PNF (%) 1 (1) 1 (2) 7 (5)
Retransplantation - HAT (%) 3 (2) 0 1 (1)
Retransplantation - ITBL (%) 2 (3) 1 (2) 9 (7)
Rotterdam no aki (n=38) mild aki (n=32) severe aki (n=19)  
EAD (%) 19 (50) 18 (56) 16 (84) 0.041
Length of stay ICU 2 (1-3) 3 (2-4) 6 (2-10) 0.001
Length of stay hospital 15 (14-23) 20 (17-29) 21 (16-29) 0.002
6 month graft loss (%) 1 (3) 5 (16) 7 (37) 0.003
Death (%) 0 3 (9) 3 (16)
Retransplantation - PNF (%) 0 0 1 (5)
Retransplantation - HAT (%) 1 (3) 1 (3) 2 (11)
Retransplantation - ITBL (%) 0 1 (3) 1 (3)
AKI, acute kidney injury; EAD, early allograft dysfunction; ICU, intensive care unit; LOS, length of 
stay. Continuous variables are displayed as mean (standard deviation) and median (interquartile 
range) where appropriate.
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discussion
AKI has been shown to be an important complication after transplantation of marginal 
liver grafts and with this study we provide new insight regarding its etiology in the 
context of DCD liver transplantation (12–14). First, we combined two main European 
cohorts of DCD liver transplantation and found a significant lower graft survival in 
recipients with the severe form of AKI. Second, we introduce the combined WIT as an 
important factor related to the development of AKI in recipients who receive a DCD 
liver graft, especially the severe form of AKI.
The general definition and consecutive impact of warm ischemia on outcome after 
DCD liver transplantation is differently interpreted amongst transplant professionals. 
Here we introduced combined WIT, the period that combines all warm ischemia of 
a DCD graft, and our results indicate that this period is associated with the develop-
ment and severity of postoperative AKI. Postoperative AKI in surgery in general is 
known for its impact on length of stay, costs, and development of CKD (20,33,34). 
Additionally, severe AKI is associated with higher complication rates, longer ICU and 
hospital stay and consecutively inferior survival rates (35,36). Therefore, we chose to 
evaluate mild and severe AKI separately and the results confirm our hypothesis that 
the severity of AKI impacts recipient outcomes: severe AKI correlated with both early 
postoperative outcomes and long term graft survival.
This is the first study investigating post-transplant AKI in more than one center. In 
our analysis, almost two out of three recipients developed AKI. In general, more 
recipients in Birmingham required RRT, which is started generally at a lower peak 
creatinine threshold in this center. Despite the similar retrieval and surgical technique 
in both centers, a few donor and recipient parameters were different. For example, 
the higher donor age in Birmingham is explained by the maximum age limit of 60 
years for DCD liver donors in the Netherlands, while transplant centers in the UK also 
accept older donors (30,37). The duration of total DWIT was significantly longer in 
Rotterdam due to a three-minute longer asystolic phase. This is probably the result 
of the different location of WoT the donor: in the Netherlands, the withdrawal mainly 
takes place on ICU, while in the UK some withdrawals are performed in the anes-
thetic room. The association between location of treatment withdrawal and impaired 
recipient outcome has been previously shown, because prolonged donor transport 
time from ICU to theatre may impact negatively (38). However, in our study this 
additional time is already included in the asystolic phase. The allocation system for 
liver transplantation in the Netherlands follows the MELD principle. In the UK, the 
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allocation of designated liver grafts is decided by the recipient institution. This cre-
ates a window of opportunity for the transplant surgeons to match DCD grafts with a 
higher risk to recipients with a relatively low labMELD score. In this context, the pre-
operative labMELD score was lower in Birmingham and these recipients had a better 
pre-transplant kidney function. As expected, the peak trough tacrolimus levels were 
higher in Birmingham, due to the earlier introduction of this immunosuppressant. Our 
multivariable analysis identified an increased recipient BMI and transfusion require-
ment during surgery as independent factors associated with development of severe 
AKI. Recipient BMI has previously been linked to post-transplant AKI and transfusion 
requirements represent the amount of blood loss and hypotensive periods during 
surgery, which are also factors known to damage the kidney (16,17,20,39–41). The 
last factor identified by our model was the length of combined WIT. Warm ischemia 
is not only well known to significantly aggravate hepatic IRI, previous studies also 
showed a link to the development of AKI after liver transplantation (13,15,42). In our 
cohort, we used the peak serum ALT levels as a surrogate marker for hepatic IRI and 
these levels correlated well with the extent of AKI in both centers.
Hepatic IRI during DCD liver transplantation is the result of four consecutive periods 
of warm and cold ischemia. The exact impact of each period on development of AKI 
remains unclear. Interestingly, the duration of the asystolic phase and cold ischemia 
time were not found to be significantly associated with AKI. Longer asystolic phase 
has previously been related to impaired graft survival, but only when it exceeds 25 or 
30 minutes (8,43). This could explain why our relatively short asystolic phase (mean of 
13 minutes) was not associated with hepatic IRI or AKI. Also, in contrast to the agonal 
phase, the range of length of asystolic phase is relatively small, as the retrieval pro-
cedure is a standardized surgical procedure in these two centers with experience in 
DCD retrievals. Previous studies have not identified cold ischemia as an influencing 
factor for AKI or graft survival in DCD liver transplantation and, with a mean of only 7 
hours, the cold ischemia duration was relatively limited in our cohort (13,44). Due to 
the lack of transplant cases with a prolonged cold ischemia in our study, larger cohort 
studies with a wider range of cold ischemia would be of interest to further support 
this result. RWIT has been related to AKI before, but this is the first analysis of the 
relation between DWIT and postoperative AKI (40,45). Several studies have shown a 
relation between DWIT and postoperative outcomes: a prolonged course of agonal 
phase with a slow decrease of vital parameters has been related to impaired graft 
survival, while a longer asystolic phase is associated with ischemic cholangiopathy 
and impaired graft survival (8,21,23,24,43). In our cohort, the structure of combined 
WIT and severity of AKI varied between the two centers. Length of agonal phase was 
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significantly associated with postoperative AKI in Rotterdam, but not in Birmingham. 
On the contrary, length of RWIT was longer in Birmingham and increased signifi-
cantly with severity of AKI, whilst there was no significant relation between RWIT and 
AKI in Rotterdam. In donors with prolonged WIT, the transplant surgeon could limit 
the combined WIT by choosing a technically easier transplant candidate with quicker 
graft implantation, to further reduce the risk of severe AKI. In contrast, when DWIT is 
short, there is more time left for graft implantation. Both scenarios could be of inter-
est in the context of technically challenging recipients or teaching scenarios. One 
advantage of the combined WIT is, that the overall WIT is included in one parameter, 
where our analysis showed that a prolonged combined WIT significantly predicts the 
development of more severe AKI in both centers.
This study has several limitations. The retrospective design of this study has its 
inherent shortcomings. A total of 27 cases were excluded because of missing data, 
17 of them due to missing information on DWIT. This is a known problem in DCD 
liver transplantation, because in the early years of this study not all DWIT data 
were registered. The two-center study design has several advantages, but several 
potential confounders should be addressed: comparisons of the two cohorts in this 
study confirmed that there are differences in daily practice and protocols between 
transplant programs that influence postoperative development of AKI. For example, 
in Birmingham tacrolimus is introduced at day 0 after transplant, while in Rotterdam 
most of the recipients received tacrolimus from day 5. However, in the multivariable 
analysis, the peak tacrolimus trough level was not found to be significantly associated 
with development of severe AKI, probably because recipients who are suspected to 
experience renal injury receive a low-dose or late introduction of tacrolimus. Also, 
the treatment of recipients with severe AKI was more aggressive in Birmingham, as 
shown in the lower median serum creatinine level at start of RRT. This could result 
in a relatively larger proportion of recipients in the AKI stage 3 group in this center, 
that would not receive RRT in Rotterdam and be assigned to the AKI stage 2 group. 
Therefore, we bundled the recipients with AKI stage 2 and 3 into one group as severe 
AKI.
The potential amount and impact of ischemic graft injury varies during the different 
types of warm ischemia in DCD grafts. The injury, conveyed through a slow decrease 
of oxygen and graft cooling in the donor might be in contrast to the rewarming injury 
during graft implantation prior to reperfusion. Unfortunately, retrospective studies 
are not ideal for this purpose and in order to separately assess the impact of donor or 
recipient WIT with and without remaining blood in the liver, experimental transplant 
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studies might be of further benefit. However, this study is the first step into large 
multicenter cohort studies on the etiology of AKI after DCD liver transplantation. 
The results of this study help to earlier anticipate a high risk for later kidney injury 
and to implement kidney protective strategies to prevent additional injury during or 
after transplantation. For example, a long agonal phase could be used as a threshold 
to use novel preservation techniques, such as machine perfusion after or instead of 
cold storage, and to limit the duration of RWIT through a quick implantation of the 
DCD graft by an experienced surgeon (46,47). When combined WIT exceeds 60 
minutes, preventive management can be undertaken to limit further AKI, such as ad-
justment of the immunosuppression regimen with delayed introduction of calcineurin 
inhibitors. Combined WIT is a new concept and its relation to other postoperative 
complications in DCD liver transplantation should be investigated as well.
In conclusion, this study provides new insight in the impact of warm ischemia during 
DCD liver transplantation and the development of post-transplant AKI. We intro-
duced combined WIT as a new variable to explore the impact of the total burden 
of warm ischemia. Although the structure of warm ischemia varies, the duration of 
the combined WIT is important in the development of severe postoperative AKI and 
should ideally not exceed 60 minutes.
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summaRy, discussion and futuRe peRspectives
The number of liver transplantations performed globally keeps increasing every year 
(1). However, due to expansion of the donor pool with grafts from older donors, 
steatotic grafts, and DCD grafts, the quality of the average liver allograft is at risk. 
Therefore, transplant surgeons worldwide are trying to find thresholds to use these 
marginal grafts depending on their risk of postoperative complications, need for 
retransplantation and recipient mortality. In this thesis we have focused (I) on the 
additional morbidity and risk assessment in DCD liver transplantation and (II) the 
increasing development of renal complications due to the use of such DCD and other 
marginal grafts.
comparing outcomes & risk assessment in dcd liver transplantation
chapter 2 provides a summary on the evolving use of (Maastricht type III) DCD liver 
grafts. Due to the additional warm ischemia in the donor, these grafts experience 
more hepatic IRI (2). Hence, DCD grafts are retrieved with a ‘super rapid’ surgical 
technique, speeding up the process to get the liver into the ice box for transport to 
the recipient (3). Nonetheless, the use of DCD grafts is associated with an increased 
incidence of specific complications, such as PNF, ITBL and AKI (4–6). This leads to 
impaired graft and patient survival rates, with previous studies showing mixed results 
in comparison to DBD grafts (7–11). To limit the risk, most centres have adopted 
selection criteria for the donors and recipients of DCD grafts, such as a maximum 
for age and BMI for the donor and relatively low recipient MELD-scores. Several 
centres have reported their DCD experience using propensity score matching. When 
DCD grafts were matched to their DBD counterparts by the donor and recipient risk 
factors, the outcomes of the DCD grafts proved worse compared to the unmatched 
studies (12–15). The results of these studies reveals the ‘real’ additional risk of DCD 
grafts and highlights the importance of careful donor and recipient selection when 
DCD grafts are used.
Previous studies evaluating the outcomes in DCD liver transplantation mainly as-
sessed patient and graft survival or the development of specific complications, such 
as ITBL. However, the experience of the patient depends on the sum of all postop-
erative complications. Until recently, there has not been a method to comprehend 
all these events and therefore Clavien and colleagues from the Zurich University 
Hospital have developed the Comprehensive Complication Index (16,17). This novel 
tool combines all postoperative complications according to their Clavien-Dindo 
into one number, which can be used for comparison of outcomes between groups 
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(18). In chapter 3 we present our comparison study of recipient outcomes after 
liver transplantation with DCD and DBD grafts using the CCI. Interestingly, the CCI 
was comparable for recipients in both groups during hospital admission. Yet, after 
six months DCD recipients had a significantly higher CCI. Recipients of DCD grafts 
also required more retransplantations in the first six months, but long-term patient 
survival was comparable for both groups. Recipient BMI, duration of recipient WIT 
and DCD grafts were identified as risk factors for a complicated postoperative course 
(CCI >60 after six months). Our CCI >60 threshold has recently been tested in a 
Canadian transplant cohort of DCD, DBD and living donor grafts (19). Similar to our 
results, recipients of DCD grafts did not have a higher CCI after hospital discharge, 
but unfortunately the comparison was not repeated after six months in their study. 
Benchmarking is the next attempt to improve risk assessment in liver transplantation 
by the Zurich team. In a multicentre outcome analysis with >2000 low-risk cases, 
they defined a benchmark for liver transplantation recipients (20). The authors set 
the Benchmark cut-off for the CCI after six months at 37.2 points, clearly lower than 
in our DCD cohort (53.4 points). Bearing in mind, this benchmark study consists of 
recipients with the lowest estimated risks and we feel that it is essential to develop 
such a benchmark for DCD liver transplantation separately, to determine the best 
achievable results in this particular group of recipients.
In this context, we aimed to identify the specific period of DWIT that is responsible 
for the additional hepatic IRI in DCD grafts. Therefore, we analysed the course of the 
agonal phase during DWIT in chapter 4. There is a wide variance in the duration 
of the hypoxic and hypotensive agonal phase between donors. In most countries, 
hypotension (SBP <50 mm Hg) is considered as the start of functional DWIT (21,22). 
However, based on clinical experience, we hypothesized hypoxia (SpO2 <80%) plays 
a more important role in the onset of warm ischemia in DCD donors. Our results 
showed that SpO2 dropped below the threshold after two minutes, compared to 
nine minutes for blood pressure, resulting in a longer hypoxic agonal phase. Only the 
length of this hypoxic phase was associated with severity of hepatic IRI, displayed by 
the peak transaminase levels after the transplant. Furthermore, recipients receiving a 
DCD graft with a hypoxic agonal phase of more than 13 minutes had more complica-
tions assessed with the CCI and 90-day and long-term graft loss. With this study, 
we are the first highlighting the importance of the early-onset hypoxia during DWIT. 
There is not much known about the exact pathophysiology of the hepatocyte injury 
during the agonal phase, but the pathophysiology of hypoxic hepatitis has a similar 
pattern. Up to 10% of the critically ill patients in ICU with cardiac/respiratory failure or 
septic shock have clinical signs of hypoxic hepatitis (23). Previously, hypotension was 
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considered the major contributor to the hepatic injury, but recent studies suggest 
that hemodynamic mechanisms of hypoxia, such as hypoxemia, dysoxia and hepatic 
congestion play a more important role, while shock is only present in half of the 
patients with hypoxic hepatitis (24). It will likely require intensive animal studies with 
a specific hypoxic and hypotensive agonal phase models to fully understand the 
pathogenesis of ischemia during this period in DCD donation.
To assist the transplant surgeons in matching the appropriate DCD donor and recipi-
ent, we have developed a new prediction model for graft loss in chapter 5: the UK 
DCD Risk Score. Using the UK national database with more than 1000 DCD liver 
transplants we calculated this score that consists of the seven strongest predictors 
(functional DWIT, cold ischemia time, MELD-score, recipient and donor age, donor 
BMI and retransplantation). The UK DCD risk score had a better predictive value 
(C-statistic of 0.79) than the known DCD prediction scores from UCLA and King’s 
College Hospital and the new score was validated in a large UNOS-database cohort 
and the local DCD population in of the Queen Elizabeth Hospital in Birmingham 
(25,26). The score was divided into three classes: low risk (0-5 points), high risk (6-10 
points), and futile (11-27 points) and the new score significantly predicted graft loss 
caused by PNF or ITBL. The UK DCD Risk Score is easily calculated at the time of 
liver acceptance and therefore has a great potential to improve the decision making 
in DCD liver transplantation. Furthermore, by stratifying the risk into three groups, 
we suggest which donor/recipient combinations will not require additional graft 
treatment with machine perfusion (low risk), when graft treatment is recommended 
(high risk), and when the graft should be declined (futile), if no adequate machine 
perfusion is available.
Balance of Risk & machine perfusion for DCD grafts
There is a substantial difference in the approach to DCD liver transplantation be-
tween the US and European countries, like the UK and the Netherlands. The percent-
age DCD grafts of the total deceased donor liver transplants increased significantly 
to 24% and 30% in 2016 in the UK and the Netherlands, respectively (27,28). In 
contrast, the total DCD liver transplants in US only increased from 5% in 2006 to 6% 
in 2016 (29). This is likely the result of the use of more extended criteria DCD donors 
(older / higher BMI) in the two European countries (21). Furthermore, the UK has 
a centre allocation for DCD grafts, which enables the transplant surgeon to match 
DCD grafts to the appropriate recipient (30). Recently, there have been more efforts 
in US to balance the risk between donor and recipient, so more DCD grafts can be 
considered for transplantation (31).
Chapter 11
194
Due to the marginality of DCD grafts, these organs are one of the main targets 
of machine perfusion in liver transplantation. Several machine perfusion techniques 
have been developed over the last years and three are currently tested in the clinical 
setting (figure 1): (I) normothermic regional perfusion (NRP) in the donor, (II) and the 
ex-vivo techniques normothermic machine perfusion (NMP), and (III) hypothermic 
oxygenated machine perfusion (HOPE) (32). During NRP in Maastricht type III do-
nors, an abdominal regional circuit is set up for perfusion through cannulation of the 
aorta/iliac artery and cross-clamp of the thoracic aorta with the regular super-rapid 
technique. An additional venous catheter for return of the fluid is inserted in the 
inferior vena cava. In-situ perfusion follows with donor blood, approximately for 2-3 
hours (33). NRP was first introduced in Spain in uncontrolled (Maastricht type II) DCD 
donors to resuscitate the liver after the cardiac arrest prior to procurement (34). In 
the series from Barcelona, the one-year graft survival was satisfactory with 73%, but 
the utilisation of these grafts was only 12% (35). The first reports of NRP in Maastricht 
type III donors from Spain and the UK showed better results with 80-90% one-year 
graft survival rates (33,36). However, only 40-50% of the NRP grafts in these series 
were transplanted, so the assessment of graft function during NRP needs refine-
ment to improve utilisation of these grafts without increasing the risk. In the first 
figure 1 – Mechanism of protection and injury through the three machine perfusion techniques
From Schlegel et al, Minerva Anestesiologica, 2018 (32).
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report of NMP in humans (n=20), the grafts were connected to the machine directly 
after procurement, reducing the period of cold storage to a minimum, where after 
the grafts are perfused for 10-15 hours (37). The perfused grafts (of whom 4 DCDs) 
showed lower peak serum transaminase levels compared to matched cold-stored 
grafts, but no comparable graft survival rates after one-year. A similar Canadian study 
in a combined DBD/DCD cohort confirmed safety and feasibility of this technique, 
but did no clear benefit compared to static cold storage (38). Recently, the Con-
sortium for Organ Preservation in Europe presented the results of their randomized 
controlled trial (39). The most noteworthy outcome of this trial is the lower discard 
rate of the machine perfused grafts, probably due to surgeon bias of a working organ 
on a machine, compared to simple cold storage, making a more confident call to 
use the organ. Also in this study, the peak serum transaminase levels were lower in 
the perfused group with subsequent lower EAD rates. However, the incidence of the 
more clinically significant biliary complications and graft and patient survival were 
similar in the machine perfused and non-machine perfused grafts. To date, there are 
no reports evaluating the outcomes of NMP-perfused DCD grafts separately.
Both NRP and NMP preservation techniques are relatively labour intensive and logis-
tically challenging, as they require transport of additional equipment and staff to join 
the organ retrieval team. The end-ischemic HOPE technique is less demanding as 
the organ can be retrieved in the regular way and will be connected to the machine 
in the recipient transplant centre and perfused with oxygenated perfusion fluid for 
2-3 hours. The Zurich University hospital has the largest experience with DCD grafts 
using HOPE, as a 10-minute ‘no touch’ period in DCD donation is imposed by the 
Swiss national law. This group has shown that the early outcomes of liver function 
of HOPE-perfused DCD grafts were comparable or better than their matched DBD 
counterparts from the same centre (40). Furthermore, HOPE has shown to be effec-
tive in reducing ITBL, compared to a matched cohort of unperfused DCD grafts from 
two other European centres, including Erasmus MC (41). The transplant group from 
Groningen published their initial experience with HOPE last year and the first results 
from this centre also indicate that HOPE is successful in reducing biliary strictures in 
DCD grafts (42,43). A multicentre trial comparing the outcomes of HOPE perfused 
DCD grafts with static cold storage has therefore been initiated in the Netherlands 
and is currently recruiting patients (NCT02584283).
the kidneys at risk after liver transplantation
Renal complications after liver transplantation have become a more serious issue 
over the last years due to (I) the ‘sickest first’ allocation of patients on the waiting list, 
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favouring patients with renal failure and (II) the expanding use of marginal grafts that 
have more severe hepatic IRI causing additional kidney damage in the early postop-
erative period (44–46). In chapter 6 we summarized the donor, recipient and surgical 
risk factors for AKI with a focus on the pathogenesis of the impact of graft quality 
on this complication. Postoperative AKI is associated with increased use of hospital 
resources and costs, graft loss and mortality (47–50) and recipients with AKI are at 
risk for developing CKD, especially when they require temporary RRT (51). Similar to 
AKI, post-transplant CKD has a multifactorial origin and is explained by the three-hit 
model (52). The first hit for the kidney is subsequent to the liver disease in patients 
with cirrhosis. Peri-operative events, such as extensive blood loss and reperfusion 
during the transplant procedure and postoperative complications are responsible for 
the second hit and finally, the third hit is a chronic process after liver transplant, due 
to the use of nephrotoxic immunosuppression and new-onset diseases, such as DM.
In chapter 7 we analysed the impact of the postreperfusion syndrome on develop-
ment and severity of AKI after liver transplantation. PRS is the first manifestation of 
severe hepatic IRI after reperfusion and has previously been linked to severe renal 
failure with RRT and an increased mortality risk (53). Our findings show that the de-
crease in blood pressure after reperfusion has a linear relation with both the severity 
of hepatic IRI and postoperative AKI. Furthermore, if recipients experienced PRS, 
the odds of developing AKI showed a more than two-fold increase and long-term 
patient survival decreased significantly with the severity of AKI. Our results were 
recently confirmed in a large living-donor liver transplantation cohort from Korea 
(54,55). PRS can be used as an early warning sign for other problems in the early 
postoperative course and it is being used in the assessment of early graft function in 
machine perfusion as well (33,39). In addition, biomarkers that are expressed in case 
of severe reperfusion injury have been linked to postoperative AKI, highlighting the 
significance of PRS in the development of renal problems after liver transplantation 
(56,57).
To further explore the comprehensive impact of all the warm ischemia periods in 
DCD liver transplantation, we introduced a new period of warm ischemia time in 
chapter 8; the combined WIT. This is the sum of the agonal phase and asystolic 
phase during DWIT and the recipient WIT. We evaluated the length of this combined 
WIT and the incidence of severity of AKI after DCD liver transplantation in the two 
cohort of the Erasmus MC, Rotterdam and the Queen Elizabeth Hospital in Birming-
ham. In both centres, the duration of combined WIT was associated with severity of 
AKI and recipients receiving a graft with more than one hour of combined WIT had 
197
Summary, discussion and future perspectives
C
ha
pt
er
 1
1
Pa
rt 
II
a more than two-fold increase in the risk of developing severe AKI. In addition, our 
results confirmed that recipients with the most severe form of AKI had the worst 
postoperative outcomes with longer hospital admission and higher retransplantation 
and mortality rates. The newly defined period of combined WIT could be useful in 
assessing the risk for other postoperative complications with the use of DCD grafts, 
such as PNF and ITBL.
Early identification of recipients at risk for post-transplant AKI is required for preven-
tion of this serious complication and we aimed to develop a new prediction model 
for severe AKI. We choose severe AKI as the endpoint for this score, as this has the 
strongest relation with other recipient outcomes, described in our previous studies. 
We feel that the score is of most clinical use if it is available directly at the end of the 
transplant, so that preventive strategies can be undertaken to minimize further renal 
damage. The new AKI Prediction Score is presented in chapter 9. Using the well-
known Framingham Risk Scheme, we developed an easy-to-use prediction model, 
consisting of five donor, graft and recipient factors: Donor and recipient BMI, use of a 
DCD graft, FFP transfusion requirements during the transplant and the duration graft 
implantation. We identified three risk groups, to stratify the recipients with a low, in-
termediate and high risk for postoperative severe AKI. In case of an intermediate risk, 
we suggest a renal sparing immunosuppression protocol is considered (58,59). Early 
initiation of RRT has been proven to be effective in critically ill patients and therefore 
we would consider early RRT in high-risk recipients, according to the AKI Prediction 
Score (60). These potential helpful clinical applications make the new score unique. 
This is not the first prediction model for post-transplant AKI, but the previous scores 
did all use postoperative risk factors, including the use of nephrotoxic immunosup-
pression and postoperative inotrope requirements (61,62).
A logical consequence of the pre-transplant kidney problems in patients with ESLD 
and AKI in the peri-operative period is development of long-term renal impairment. 
On average, after 5 years 2% of the recipients is either RRT dependent or has re-
ceived a kidney transplant. This number can increase up to 11% of the recipients 
who are still alive after 25 years (63). The evolving use of marginal grafts over the last 
years and the increasing burden of post-transplant AKI encouraged us to evaluate 
the impact of marginal grafts and development of CKD (46). In chapter 10 we show 
that recipients of marginal grafts (DCD grafts and marginal DBD grafts [long cold 
storage, higher BMI, older donors]) do not have an increased risk to develop CKD 
per se and the incidence of CKD is around 40% for recipients of standard, marginal 
DBD, and DCD grafts. However, those who experience severe AKI after the trans-
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plant and require RRT have a significantly impaired long-term kidney function. Our 
results showed that recipients with RRT that had an additional complication requiring 
a reoperation in the early postoperative period were less like to have a full recovery 
of kidney function on the long-term.
general conclusion
In part i of this thesis we present the extra morbidity for recipients of DCD grafts with 
the novel CCI, identify prolonged hypoxia during DCD donation as the driving force 
of hepatic ischemia and present a new risk score to assist the transplant surgeon in 
making the decision for the best DCD graft and recipient combination and to help 
in deciding which graft will require additional therapy, e.g. machine perfusion. The 
results presented in part ii of this thesis highlight the impact of DCD grafts and other 
marginal grafts on postoperative AKI. Although no direct correlation was observed 
between these grafts and long-term kidney function, development of severe AKI 
with RRT-requirement should be avoided at all costs, as those recipients have an 
increased risk for CKD. Our new AKI Prediction Score could be useful to limit the risk 
for severe AKI and subsequent development of chronic renal impairment.
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afkoRtingen
anf Acuut nierfalen
bmi Body mass index
cci Comprehensive Complication Index
cnf Chronisch nierfalen
dbd Donation after brain death; donatie na hersendood
dcd Donation after circulatory death; donatie na circulatoire dood
dWit Donor warme ischemietijd
Hope Hypotherme geoxygeneerde machineperfusie
ic Ischemische cholangiopathy
iRs Ischemie / reperfusie schade
meld Model for end-stage liver disease; model voor eind stadium leverfalen
nmp Normotherme machineperfusie
nRp Normotherme regionale perfusie
pnf Primaire non-functie
pRs Postreperfusiesyndroom
unos United network for organ sharing
Wit Warme ischemietijd
207
Nederlandse Samenvatting
C
ha
pt
er
 1
2
Pa
rt 
II
samenvatting, discussie en toekomstpeRspectieven
Wereldwijd worden er jaarlijks meer levertransplantaties verricht (1). Desalniettemin, 
door de uitbreiding van de donor pool met veelal grafts van oudere donoren, steato-
tische grafts en “donation after circulatory death” (DCD) grafts, is de kwaliteit van de 
gemiddelde donorlever niet gegarandeerd. Daarom zoeken transplantatiechirurgen 
en hepatologen wereldwijd naar de limieten om deze organen te gebruiken, aan de 
hand van hun risico op postoperatieve complicaties, retransplantatie en mortaliteit. 
In dit proefschrift hebben wij de focus gelegd op (I) de extra morbiditeit en risico-
inschatting in DCD levertransplantatie en (II) de toename in renale complicaties door 
het gebruik van deze DCD en andere marginale donorlevers.
Risicoanalyse in dcd levertransplantatie
Hoofdstuk 2 dienst als samenvatting over het toenemende gebruik van (Maastricht 
type III) DCD donorlevers. Door de extra warme ischemietijd in de donor, hebben 
deze organen meer last van lever ischemie/reperfusie schade (IRS) (2). DCD grafts 
worden daarom uitgenomen met de ‘super-rapid’ chirurgische techniek, om de lever 
sneller naar de ontvanger te kunnen transporteren (3). Desondanks is het gebruik 
van DCD levers geassocieerd met een hogere incidentie van specifieke complicaties, 
zoals primaire non-functie (PNF), ischemische cholangiopathie (IC) en acuut nierfalen 
(ANF) (4–6). Dit leidt tot een slechtere overleving van de graft en de patiënt. Eerdere 
studies die de resultaten van DCD en ‘donation after brain death’ (DBD) grafts 
onderzochten hebben uiteenlopende resultaten laten zien (7–11). Om het risico 
te minimaliseren, hanteren de meeste centra selectiecriteria voor de donoren en 
ontvangers van DCD grafts, zoals een maximum voor de leeftijd en body mass index 
(BMI) voor de donor en relatief lage Model for End-stage Liver Disease (MELD)-
scores van de ontvanger. Enkele centra hebben hun uitkomsten gerapporteerd door 
middel van ‘propensity score matching’. Na het matchen van DCD grafts met hun 
DBD tegenhangers aan de hand van donor en ontvanger risicofactoren, lijken de 
uitkomsten van DCD grafts slechter dan in studies zonder matching (12–15). Deze 
studies brengen echter wel het ‘echte’ additionele risico van deze grafts aan het licht 
en benadrukken het belang van selectie van donor en ontvanger met het gebruik 
van deze organen.
Eerdere studies naar de uitkomsten van DCD levertransplantatie hebben met name 
overleving en specifieke complicaties zoals IC, geanalyseerd. Voor de patiënt zijn 
echter alle postoperatieve problemen en complicaties van belang. Daarom hebben 
Clavien et al van het Zurich Universiteitsziekenhuis een nieuwe methode ontwikkeld 
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om alle postoperatieve complicaties samen te voegen: De Comprehensive Compli-
cation Index (CCI) (16,17). Dit nieuwe instrument combineert alle complicaties (aan 
de hand van de Clavien-Dindo classification) tot één getal, wat gemakkelijk gebruikt 
kan worden om de uitkomsten tussen groepen te vergelijken (18). In Hoofdstuk 3 
presenteren wij een vergelijke studie naar de uitkomsten van de patiënten na le-
vertransplantatie met DCD en DBD organen, aan de hand van de CCI. De eerste 
meting aan het einde van de ziekenhuisopname liet vergelijkbare resultaten zien 
in beide groepen. Echter, tegenovergestelde uitkomsten werden geobserveerd na 
een half jaar, waar DCD ontvangers een significant hogere CCI hadden. Zij hadden 
ook een vaker behoefte aan een retransplantatie, maar de lange termijn overleving 
voor deze patiënten was gelijk aan DBD ontvangers. Daarnaast waren de BMI van 
de ontvanger, de duur van de warme ischemietijd én het gebruik van een DCD graft 
geassocieerd met een gecompliceerd postoperatief beloop (CCI >60 na 6 maan-
den). Deze CCI >60 grens is recentelijk ook getest in een groot Canadees cohort van 
DCD, DBD en levende-donor levertransplantatie, waarbij de resultaten gedurende 
ziekenhuisopname ook geen verschillen liet zien (19). Helaas is dezelfde analyse 
in deze studie niet herhaald na zes maanden. De volgende stap die het team in 
Zürich om risico-inschatting in lever transplantatie te verbeteren is “benchmarking”. 
Door middel van een multicenter-uitkomstanalyse van meer dan 2.000 laag-risico 
patiënten, hebben zij een nieuwe benchmark geformuleerd voor patiënten die een 
levertransplantatie hebben ondergaan (20). De auteurs hebben de benchmark cut-
off na zes maanden gezet op een CCI van 37.2, wat aanzienlijk lager is dan in ons 
DCD cohort (53.4 punten). Daarbij moet worden benadrukt dat deze benchmark 
studie bestaat uit patiënten met het laagst ingeschatte risico. Wij denken dat het 
essentieel is om zo’n benchmark te ontwikkelen voor DCD levertransplantatie, om de 
best mogelijke resultaten te voorspellen in deze specifieke groep patiënten.
De extra periode van warme ischemie; de donor warme ischemietijd (DWIT) is ve-
rantwoordelijk voor de additionele lever IRS in DCD grafts. Daarom hebben wij de 
duur en het verloop van de eerste periode van DWIT onderzocht in Hoofdstuk 4. 
Deze agonale fase is de periode tussen het stoppen van de behandeling van de 
donor en zijn of haar overlijden. Er is een wijde variantie in de duur van hypoxie en 
hypotensie gedurende deze periode tussen donoren. In de meeste landen wordt 
hypotensie (systolische bloeddruk <50 mm Hg) gezien als het begin van de functio-
nele DWIT (de periode waarin de ischemie daadwerkelijk aanwezig is) (21,22). Echter, 
op basis van klinische ervaring, is onze hypothese dat hypoxie (SpO2 <80%) een 
belangrijkere rol speelt in de aanvang van warme ischemie in DCD donoren. Onze 
resultaten laten zien dat SpO2 passeerde de grens van 80% al twee minuten na het 
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stoppen van de behandeling, in vergelijking met negen minuten voor de grens van 
hypotensie, resulterend in een langere hypoxische agonale fase. Alleen de duur van 
deze hypoxische periode was geassocieerd met de ernst van de lever IRS, gemeten 
aan de hand van de peak transaminasen na levertransplantatie. Daarnaast hadden 
ontvangers van een DCD grafts waarbij de agonale fase langer was dan 13 minuten 
meer postoperatieve complicaties en een hogere kans op verlies van de graft binnen 
90-dagen en op de lange termijn. Dit is de eerste studie waarin het belang van 
vroege en langdurige hypoxie gedurende de agonale fase wordt aangetoond. Er 
is maar weinig kennis over de exacte pathofysiologie van de hepatocytenschade 
gedurende de agonale fase, maar de pathofysiologie van hypoxische hepatitis kent 
eenzelfde patroon. Tot wel 10% van de ernstig zieke patiënten opgenomen op de 
intensive care met cardiogene/respiratoir falen of septische shock hebben klinische 
tekenen van hypoxische hepatitis (23). Tot op heden werd gedacht dat hypotensie 
de voornaamste factor is in hepatische schade, maar recente studies laten zien dat 
mechanismen van hypoxie, zoals hypoxemie, dysoxie en congestie van de lever een 
nog belangrijkere rol spelen, terwijl shock maar werd geobserveerd in de helft van 
de patiënten (24). Waarschijnlijk zijn intensieve observationele proefdier studies 
met specifieke hypoxische and hypotensieve agonale fase modellen nodig om de 
pathogenese van ischemie gedurende deze periode in DCD donatie te begrijpen.
In Hoofdstuk 5 wordt een nieuw predictiemodel gepresenteerd dat is ontwikkeld 
om de transplantatiechirurgen te assisteren in het matchen van DCD donoren 
en ontvangers: de UK DCD Risk Score. De nationale database van het Verenigd 
Koninkrijk met meer dan 1000 DCD levertransplantaties is gebruikt om dit model te 
ontwikkelen, dat bestaat uit de zeven sterkste voorspellers voor het verlies van de 
graft (duur van functionele DWIT en koude ischemietijd, MELD-score, leeftijd van 
de donor en ontvanger, donor BMI en retransplantatie). Onze nieuwe score heeft 
een betere predicatieve waarde (C-statistiek van 0.79) dan de eerder gepubliceerde 
scores van de University of California in Los Angeles en King’s College Hospital in 
Londen (25,26). De score is ook gevalideerd in een groot nationaal cohort uit de 
Verenigde Staten (UNOS) en de lokale DCD populatie in Birmingham. Mogelijke 
donor/ontvanger combinaties worden ingedeeld in drie categorieën: laag risico (0-5 
punten), hoog risico (6-10 punten) en futiel (>10 punten) en het aantal punten in de 
score is ook voorspellend voor het verlies van de graft door PNF of IC. De score is 
snel en gemakkelijk te berekenen tijdens de beoordeling van een orgaanaanbod en 
heeft daarbij een grote potentie om het beslissingsproces in DCD levertransplantatie 
te verbeteren. Daarnaast kan met behulp van de drie risicogroepen worden bepaald 
of de graft waarschijnlijk geen behandeling met machineperfusie nodig heeft (laag 
Chapter 12
210
risico), machineperfusie wordt aangeraden (hoog risico) of de graft moet worden 
afgewezen als er geen adequate machineperfusie beschikbaar is (futiel).
Risicoverdeling en machineperfusie voor DCD grafts
Er is een substantieel verschil in de benadering van DCD levertransplantatie tussen 
de Verenigde Staten en de Europese landen, zoals het Verenigd Koninkrijk en Neder-
land. Het percentage DCD grafts van de totale levertransplantaties met postmortale 
donoren is de laatste jaren toegenomen tot 24% in het Verenigd Koninkrijk en 30% 
in Nederland in 2016 (27,28). Daarentegen, in de Verenigde Staten is het aantal 
DCD levertransplantaties gelijk gebleven op een laag niveau van 5% in 2006 tot 6% 
in 2016 (29). Dit is waarschijnlijk het resultaat van het gebruik van meer extended 
criteria DCD donoren (hogere leeftijd / hoger BMI) in de Europese landen (21). In het 
Verenigd Koninkrijk heeft men daarnaast ook nog de zogenoemde centrumallocatie 
voor DCD grafts, wat de chirurgen de mogelijkheid geeft om DCD grafts te matchen 
met een geschikte ontvanger (30). Recentelijk zijn er ook in de Verenigde Staten 
inspanningen gedaan om het risico tussen de donor en ontvanger te verdelen, zodat 
meer DCD grafts gebruikt kunnen worden voor transplantatie (31).
DCD grafts zijn één van de belangrijkste doelwitten voor machineperfusie in le-
vertransplantatie en verschillende technieken zijn over de laatste jaren ontwikkeld, 
waarvan er momenteel drie in de klinische praktijk worden gebruikt (figuur 1): (I) 
normotherme regionale perfusie (NRP) in de donor en de ex-vivo technieken (II) nor-
motherme machine perfusie (NMP) en hypotherme geoxygeneerde machineperfusie 
(HOPE) (32). Gedurende NRP in Maastricht type III donoren wordt een abdominaal 
regionaal circuit aangelegd voor perfusie door cannulatie van de aorta/arteria iliaca 
communis en cross-clamping van de thoracale aorta met de reguliere super-rapid 
uitnametechniek. Daarnaast wordt een extra katheter ingebracht in de vena cava 
inferior voor de teruggave van bloed, gevolgd door 2-3 uur in-situ perfusie (33). 
NRP werd als eerste geïntroduceerd in Spanje in ongecontroleerde (Maastricht 
type II) DCD donoren om de organen te resusciteren na de hartstilstand voor de 
uitname van de organen (34). De uitkomsten van de eerste serie uit Barcelona waren 
bevredigend met een één jaars-overleving van de DCD grafts van 73%. Dit was 
wel met een zéér strenge selectie, want maar 12% van de geperfundeerde grafts 
werd gebruikt (35). De eerste resultaten van NRP in Maastricht type III donoren 
vanuit Spanje en het Verenigd Koninkrijk lieten betere resultaten zien met 80-90% 
één jaars-graftoverleving (33,36). Maar ook hier werd maar 40-50% van de grafts 
gebruikt, dus het is noodzakelijk dat de beoordeling van graftfunctie tijdens NRP 
wordt verfijnd om de utilisatie van DCD grafts te uit te breiden zonder het risico voor 
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de patiënt te vergroten. In de eerste studie met NMP in mensen (n=20) werden de 
grafts direct na de uitname aan de machine verbonden, zodat de koude ischemietijd 
wordt gereduceerd tot een minimum, waarna de grafts voor 10-15 uur worden 
geperfundeerd (37). De grafts die machineperfusie ondergingen (waarvan 4 DCD’s) 
hadden een lagere piek serum transaminase, in vergelijking met grafts die op ijs 
werden getransporteerd. Er werd geen verschil geobserveerd in graftsoverleving na 
één jaar. Een vergelijkbare Canadese studie in een gecombineerd DCD/DBD cohort 
bevestigde de haalbaarheid en veiligheid van deze techniek, maar wederom werd 
geen duidelijk voordeel gevonden ten opzichte van opslag van de lever op ijs (38). 
Het Consortium for Organ Preservation in Europe heeft onlangs de resultaten van 
zijn gerandomiseerde studie gepubliceerd (39). De meest opmerkelijke uitkomst 
van deze studie was het lagere afwijzingspercentage in de machine groep, wat 
mogelijk het resultaat is van chirurg-gerelateerde bias van een ‘werkend’ orgaan op 
de machine, in vergelijking met simpele opslag op ijs, om een meer zekere besliss-
ing te nemen het orgaan te gebruiken. Ook in deze studie was de postoperatieve 
transaminase piek lager in de machineperfusie groep, net als de incidentie van early 
allograft dysfunction, maar ook hier werd geen verschil gezien in de overleving van 
figuur 1 – schade en protectiemechanismen in de drie machine perfusietechnieken
Uit Schlegel et al, Minerva Anestesiologica, 2018 (32).
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graft en patiënt op de lange termijn. Tot op heden zijn er geen studies die het effect 
van NMP specifiek in DCD grafts hebben geanalyseerd.
NRP en NMP zijn beiden arbeidsintensieve en logistiek veeleisende preserva-
tietechnieken, omdat extra spullen en personeel nodig zijn voor de uitname. De 
eind-ischemische HOPE techniek is minder veeleisend, omdat de graft volgens de 
normale procedure kan worden uitgenomen en getransporteerd en pas bij aankomst 
in het transplantatiecentrum wordt aangesloten op de machine voor 2-3 uur perfusie. 
Het Zürich Universiteitsziekenhuis heeft de meeste ervaring met HOPE voor DCD 
grafts, omdat er een langere no-touch periode is van 10 minuten, opgelegd bij door 
de Zwitserse wet. De eerste HOPE-DCD grafts hadden vergelijkbare of zelfs betere 
graftfunctie als vergelijkbare DBD grafts van hun centrum (40). Daarnaast zijn er ook 
aanwijzingen dat HOPE effectief is tegen de ontwikkeling van IC in een studie met 
vergelijkbare niet geperfundeerde DCD grafts van twee andere Europese centra, 
waaronder het Erasmus MC (41). De transplantatiegroep uit Groningen heeft hun 
eerste ervaring met HOPE (specifiek D-HOPE, waarbij de lever wordt geperfundeerde 
door de vena portae en de arteria hepatica) en hun eerste resultaten zijn ook posi-
tief over de potentie van deze perfusietechniek om biliaire stricturen te reduceren 
(42,43). Daaropvolgend is een multi-centrum gerandomiseerde studie geïnitieerd 
in Nederland, waarin de uitkomsten van HOPE worden vergeleken met standaard 
opslag op ijs voor DCD grafts en de D-HOPE studie is momenteel patiënten aan het 
rekruteren (NCT02584283).
Het risico voor de nieren na levertransplantatie
Renale complicaties na levertransplantatie komen steeds meer voor door (I) de ziek-
ste eerst allocatie van patiënten op de wachtlijst voor een levertransplantatie, waarbij 
patiënten met nierfalen prioriteit krijgen en (II) het de uitbreiding van het gebruik 
van marginale grafts met meer lever IRS leidend tot extra nier schade in de vroege 
postoperatieve fase (44,45). Hoofdstuk 6 dienst als samenvatting van de donor, ont-
vanger en chirurgische risicofactoren voor ANF na levertransplantatie met een focus 
op de impact van graftkwaliteit op het ontstaan van deze complicatie. Postoperatief 
ANF is geassocieerd met een toename in het gebruik van ziekenhuismiddelen en 
kosten, retransplantatie en mortaliteit (46–49). Patiënten met ANF hebben daarnaast 
ook een ook verhoogd risico op het ontwikkelen van chronisch nierfalen (CNF), 
met name als zij dialyse-behoeftig zijn in de eerste periode na levertransplantatie 
(50). CNF na levertransplantatie is het resultaat van verschillende risicofactoren en 
wordt vaak geanalyseerd volgens het drie-factoren model (51). De eerste schade 
aan de nieren vindt al plaats voor de transplantatie, aangezien veel patiënten met 
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gedecompenseerde cirrose ook nierfalen hebben. Peri-operatieve gebeurtenissen, 
zoals extensief bloedverlies en reperfusieschade gedurende de transplantatie en 
postoperatieve complicaties zijn verantwoordelijk voor de tweede hit aan de nieren. 
De laatste schade komt door langdurige blootstelling aan nefrotoxische immunosup-
pressie en het ontstaan van nieuwe chronische ziektes, zoals diabetes mellitus.
In Hoofdstuk 7 hebben wij de impact geanalyseerd van het postreperfusiesyndroom 
(PRS) op de ontwikkeling en ernst van ANF na levertransplantatie. PRS is het eerste 
teken van ernstige lever IRS na reperfusie en is in het verleden al geassocieerd met 
postoperatieve dialysebehoefte en een verhoogd mortaliteitsrisico (52). Onze bevin-
dingen laten zien dat de mate van bloeddrukdaling na reperfusie een lineaire relatie 
heeft met de ernst van lever IRS en postoperatief ANF. Bovendien, patiënten met 
PRS hadden meer dan twee keer zoveel kans om ANF te ontwikkelen en de patiënt 
overleving was ook slechter voor patiënten met ernstig ANF. Onze resultaten zijn 
recentelijk bevestigd in een groot levende donor cohort uit Zuid-Korea (53,54). PRS 
kan worden gebruikt als vroeg waarschuwingssignaal voor andere potentiele proble-
men na de transplantatie en PRS wordt ook regelmatig gebruikt in de beoordeling 
van vroege graftfunctie in machineperfusie (33,39). In aanvulling hierop, biomarkers 
die tot uiting komen bij ernstige lever IRS zijn geassocieerd met postoperatief ANF 
en benadrukken hiermee het belang van PRS in de ontwikkeling van renale complica-
ties na levertransplantatie (55,56).
In Hoofdstuk 8 wordt een nieuwe periode van warme ischemietijd in DCD lever-
transplantatie gepresenteerd om de invloed van alle warme ischemieperiodes te 
analyseren: de gecombineerde warme ischemietijd (gecombineerde WIT). Dit is de 
som van de agonale and asystolische fase gedurende DWIT en de implantatie warme 
ischemietijd. We hebben de duur van deze gecombineerde WIT en de ernst van ANF 
na DCD levertransplantatie geëvalueerd in de twee cohorten van het Erasmus MC in 
Rotterdam en het Queen Elizabeth ziekenhuis in Birmingham. In beide centra was de 
duur van gecombineerde WIT gerelateerd aan de ernst van ANF en patiënten waarbij 
deze periode langer dan 60 minuten duurde hadden vaker ANF. Daarnaast bevestig-
den onze resultaten ook dat patiënten met ernstig ANF (KDIGO criteria graad 2/3) 
slechtere postoperatieve uitkomsten hadden, zoals een langere opnameduur en een 
hoger retransplantatie- en mortaliteitsrisico. De nieuwe gecombineerde WIT zou ook 
gebruikt kunnen worden om het risico voor andere complicaties van DCD grafts te 
evalueren, zoals PNF en IC.
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Vroege identificatie van patiënten met een verhoogd risico op post-transplantatie 
ANF is essentieel om deze complicatie te voorkomen. Dit motiveerde ons om een 
predictiemodel te ontwikkelen om het risico voor ANF voor iedere patiënt te voor-
spellen. We hebben ernstig ANF gekozen als uitkomstmaat, omdat deze de sterkste 
relatie heeft met andere postoperatieve uitkomsten in eerdere studies. De score 
heeft de meeste klinische waarde als hij direct beschikbaar is aan het einde van de 
transplantatieprocedure, zodat preventieve maatregelen kunnen worden genomen 
om verdere schade aan de nieren te voorkomen. De ontwikkeling van deze nieuwe 
AKI Prediction Score wordt gepresenteerd in Hoofdstuk 9. Met gebruik van de 
welbekende Framingham risicomodellen hebben we een gemakkelijk te gebruiken 
model ontwikkeld met vijf risicofactoren: BMI van de donor en ontvanger, transplan-
tatie met een DCD graft, transfusie met plasma gedurende de procedure en de duur 
van de implantatie. Drie risicogroepen zijn geïdentificeerd om patiënten in te delen 
met een laag, gemiddeld en hoog risico op ANF. Bij een gemiddeld risico adviseren 
wij een niersparend immunosuppressie protocol waarbij calcineurin inhibitoren in de 
eerste dagen na levertransplantatie wordt gemeden (57,58). Daarbij is vroege dialyse 
effectief gebleken in het verminderen van de mortaliteit in ernstig zieke patiënten 
op de IC en daarom zou vroege dialyse overwogen kunnen worden in patiënten 
met een hoog risico, aan de hand van de AKI Prediction Score (59). Deze potentieel 
nuttige toepassingen van de score maken de AKI Prediction Score uniek. Het is niet 
de eerste predictiemodel voor AKI, maar eerdere scores maakten allen gebruik van 
postoperatieve risicofactoren, waaronder het gebruik van immunosuppressie (60,61).
Een logische consequentie van pre-transplantatie nierproblemen en ANF in de peri-
operatieve periode is de ontwikkeling van CNF. Vijf jaar na de levertransplantatie zijn 
gemiddeld 2% van de patiënten dialysebehoeftig of hebben een niertransplantatie 
ondergaan. Dit getal loopt op tot 11% van de patiënten die nog in leven zijn 25 jaar 
na transplantatie (62). Het toenemende gebruik van marginale grafts gedurende de 
laatste jaren met meer postoperatief ANF als gevolg, was voor ons de reden om de 
invloed van deze grafts op CNF te onderzoeken (63). In Hoofdstuk 10 tonen wij dat 
patiënten die een marginale graft ontvangen (DCD grafts en DBD grafts van oudere 
of obese donoren of een lange koude ischemietijd), niet direct een verhoogd risico 
hebben op CNF en de incidentie van CNF na vijf jaar was 40% voor ontvangers van 
standaard, marginale DBD en DCD grafts. Echter, patiënten die ernstig ANF met di-
alysebehoefte hadden na de transplantatie hadden wel een significant verminderde 
nierfunctie op de lange termijn. Met name patiënten met dialyse na de transplantatie 
die nog een andere complicatie krijgen, hebben een groter risico om geen volledig 
herstel van hun nierfunctie te krijgen op de lange termijn.
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algemene conclusie
In deel i van dit manuscript wordt de extra morbiditeit voor patiënten die een 
DCD graft ontvangen geanalyseerd met de nieuwe CCI, langdurige hypoxie ge-
durende DCD donatie geïdentificeerd als de drijvende kracht voor lever ischemie 
en introduceren wij een nieuwe score om de transplantatiechirurg te assisteren in 
het beslissingsproces voor de beste combinatie van DCD donor en ontvanger. De 
bevindingen gepresenteerd in deel ii benadrukken de invloed van DCD en andere 
marginale grafts op de ontwikkeling van postoperatief ANF. Ondanks dat er geen 
directe relatie werd geobserveerd tussen deze levers en lange termijn nierfunctie, 
ernstig ANF met dialysebehoefte zou ten allen tijden voorkomen moeten worden, 
omdat deze patiënten een verhoogd risico hebben op nierfunctiestoornissen op de 
lange termijn. Onze nieuwe AKI Prediction Score kan nuttig zijn in het identificeren 
en limiteren van ernstig ANF en bijkomende ontwikkeling van CNF.
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